var title_f29_62_30688="Saethre-Chotzen syndrome";
var content_f29_62_30688=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Saethre-Chotzen syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Craniosynostosis (mild). Ptosis with facial asymmetry and septal deviation. Low-set hairline and simple syndactyly of index and middle finger.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_62_30688=[""].join("\n");
var outline_f29_62_30688=null;
var title_f29_62_30689="Cavum septum pellucidum";
var content_f29_62_30689=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cavum septum pellucidum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial view of the fetal head at the level used to measure the biparietal diameter and head circumference. The cavum septum pellucidum (large arrow) and slit-like third ventricle (short arrow) are indicated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andrew P MacKenzie, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_62_30689=[""].join("\n");
var outline_f29_62_30689=null;
var title_f29_62_30690="Balanced salt solution: Drug information";
var content_f29_62_30690=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Balanced salt solution: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/2/1060?source=see_link\">",
"    see \"Balanced salt solution: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AquaLase&reg;;",
"     </li>",
"     <li>",
"      BSS Plus&reg;;",
"     </li>",
"     <li>",
"      BSS&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F138973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      BSS Plus&reg;;",
"     </li>",
"     <li>",
"      BSS&reg;;",
"     </li>",
"     <li>",
"      Eye-Stream&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F138981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Irrigating Solution;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F138974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Irrigation:",
"     </b>",
"     Based on standard for each surgical procedure",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9468277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F138975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15673261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15673262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F138965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [irrigation; preservative free]: Sodium chloride 0.64%, potassium chloride 0.075%, calcium chloride 0.048%, magnesium chloride 0.03%, sodium acetate 0.39%, sodium citrate 0.17% (18 mL, 500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AquaLase&reg;: Sodium chloride 0.64%, potassium chloride 0.075%, calcium chloride 0.048%, magnesium chloride 0.03%, sodium acetate 0.39%, sodium citrate 0.17% (90 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BSS&reg;: Sodium chloride 0.64%, potassium chloride 0.075%, calcium chloride 0.048%, magnesium chloride 0.03%, sodium acetate 0.39%, sodium citrate 0.17% (15 mL, 30 mL, 250 mL, 500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BSS Plus&reg;: Sodium chloride 0.71%, potassium chloride 0.038%, calcium chloride 0.015%, magnesium chloride 0.02%, sodium phosphate 0.042%, sodium bicarbonate 0.21%, dextrose 0.092%, glutathione 0.018% (250 mL, 500 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F138955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9468278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not for injection or I.V. infusion. Do not use if discolored or contains a precipitate. Solution should be used when between 15&deg;C to 25&deg;C (59&deg;C to 77&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F138966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Irrigation solution for ophthalmic surgery:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AquaLase&reg;, BSS&reg;: Intraocular or extraocular irrigating solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BSS Plus&reg;: Intraocular irrigating solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Irrigation solution for eyes, ears, nose, or throat",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F138979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Ocular: Intraocular pressure increased (11% to 12%), cataract (7% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Discomfort (3% to 5%), dry eyes (3% to 5%), macular edema (4%), conjunctival hyperemia (3% to 4%), posterior capsule opacification (2% to 3%), iritis (1% to 3%), retinal hemorrhage (1% to 3%), blurred vision (1% to 2%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3401662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injection or I.V. infusion; use during electrosurgical procedures",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F138958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; intraoperative lens changes have been observed when undergoing vitrectomy procedure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For use during surgical procedures with an expected duration &le;60 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F138968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Balanced Salt Solution (DK, FI, GB, NZ)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8800 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-213.131.41.98-64F77B4D5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_62_30690=[""].join("\n");
var outline_f29_62_30690=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138972\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138973\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138981\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138974\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9468277\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138975\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673261\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673262\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138965\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138955\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9468278\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138966\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138979\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401662\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138958\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298811\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218227\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138968\">",
"      International Brand Names",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8800\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8800|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/2/1060?source=related_link\">",
"      Balanced salt solution: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_62_30691="Flunisolide (nasal): Drug information";
var content_f29_62_30691=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Flunisolide (nasal): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/30/4580?source=see_link\">",
"    see \"Flunisolide (nasal): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/24/22915?source=see_link\">",
"    see \"Flunisolide (nasal): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8097134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Flunisolide&reg;;",
"     </li>",
"     <li>",
"      Nasalide&reg;;",
"     </li>",
"     <li>",
"      Rhinalar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8097142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Nasal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8097264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Seasonal allergic rhinitis:",
"     </b>",
"     Intranasal: 2 sprays each nostril twice daily (morning and evening); may increase to 2 sprays 3 times daily; maximum dose: 8 sprays/day in each nostril (400 mcg/day)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8097263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/24/22915?source=see_link\">",
"      see \"Flunisolide (nasal): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Seasonal allergic rhinitis:",
"     </b>",
"     Intranasal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-14 years: 1 spray each nostril 3 times daily",
"     <b>",
"      or",
"     </b>",
"     2 sprays in each nostril twice daily; not to exceed 4 sprays/day in each nostril",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;15 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8097265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15881456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15881457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8097304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [spray]: 25 mcg/actuation (25 mL); 29 mcg/actuation (25 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8097135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8097287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Before first use, prime by pressing pump 5-6 times or until a fine spray appears. Repeat priming if &ge;5 days between use, or if dissembled for cleaning. Administer at regular intervals. Blow nose to clear nostrils. Insert applicator into nostril, keeping bottle upright, and close off the other nostril. Breathe in through nose. While inhaling, press pump to release spray.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8097161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Seasonal or perennial rhinitis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14225178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to antibiotics in empiric treatment of acute bacterial rhinosinusitis (ABRS) (Chow, 2012)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8097076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flunisolide may be confused with Flumadine&reg;, fluocinonide",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8097217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Respiratory: Nasal congestion (15%), nasal burning/stinging (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasal dryness, nasal irritation, rhinitis, sneezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Loss of smell",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1%: Nasal ulcer",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8097185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to flunisolide or any component of the formulation; infections of the nasal mucosa",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8097186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	Delayed wound healing: Avoid nasal corticosteroid use in patients with recent nasal septal ulcers, nasal surgery or nasal trauma until healing has occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Intranasal corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range 0.3-1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of intranasal corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8097223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8097162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8097163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in animal studies. A decrease in fetal growth has not been observed with inhaled corticosteroid use during pregnancy. Inhaled corticosteroids are recommended for the treatment of allergic rhinitis during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8097184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9770303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Other corticosteroids have been found in breast milk. It is not known if sufficient quantities of flunisolide are absorbed following inhalation to produce detectable amounts in breast milk. The use of inhaled corticosteroids is not considered a contraindication to breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8097306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Flunisolide Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025% (25 mL): $68.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     29 MCG/ACT (0.025%) (25 mL): $54.96",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8097229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability; does not depress hypothalamus",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8097255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: ~50%",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(8):e72-112.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/62/30691/abstract-text/22438350/pubmed\" id=\"22438350\" target=\"_blank\">",
"        22438350",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      NAEPP Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9125 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-1A4E1675F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_62_30691=[""].join("\n");
var outline_f29_62_30691=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097134\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097142\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097264\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097263\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097265\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881456\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881457\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097304\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097135\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097287\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097161\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14225178\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097076\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097217\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097185\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097186\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299346\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097223\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097162\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097163\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097184\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770303\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097306\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097229\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097255\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9125\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9125|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/30/4580?source=related_link\">",
"      Flunisolide (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/24/22915?source=related_link\">",
"      Flunisolide (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/34/9766?source=related_link\">",
"      Flunisolide (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/49/34581?source=related_link\">",
"      Flunisolide (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_62_30692="Cetuximab: Patient drug information";
var content_f29_62_30692=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cetuximab: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     see \"Cetuximab: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F149013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Erbitux&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F1995494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Erbitux&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10012229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700525",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Some patients have very bad side effects during the infusion. Tell your doctor if you have any bad effects during the infusion.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700318",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Heart attack and death are rare in people taking this drug and getting radiation or other chemo.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701760",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cetuximab or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701035",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to mouse proteins, talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects from the sun while taking this drug and for at least 2 months after care ends.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698085",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. Mild pain drugs may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F14789919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11234 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-118.97.94.19-A006EFEBA2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_62_30692=[""].join("\n");
var outline_f29_62_30692=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149013\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1995494\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012229\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012231\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012230\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012235\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012236\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14789919\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012233\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012240\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=related_link\">",
"      Cetuximab: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_62_30693="Multiple atypical nevi";
var content_f29_62_30693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple atypical nevi",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple atypical nevi on the posterior trunk of an adolescent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_62_30693=[""].join("\n");
var outline_f29_62_30693=null;
var title_f29_62_30694="Breast MRI documenting response to neoadjuvant chemotherapy";
var content_f29_62_30694=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F63203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F63203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Breast MRI documenting response to neoadjuvant chemotherapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 484px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHkAgIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5Uoor6VvPg78O9A+EujeM/E2o+J/9Ms7SZ4LKWAs8syKxWNWj6DJPLdFPJNAHzVRX0V47+D3gix+CU/jzwrqOvT7oYJreO8lhKjzJkjZXVYxyNzDhuo7ivnWgAor1Gz+C2uXkehpb6tobalrenjUrDTzLMs00WzeQCYvLDAdi/Y1xEvhTxDFYG+k0HVksRG0puTZyCPYpAZt2MYBIBOcZNAGLRWtqPhvXNM0+G/1HRtTtLGbHlXNxavHHJnptYjB/CtT4c+BdX+IGuSaXoQiWaOFp3kn3iNVXsSqsQSeBxyaAOVoroV8E+K3aRV8M64zRymBwLCX5ZAu4ofl4bbzjrjmqieGtdk0U6xHouptpIyTei1kMAwcH95jb+tAGTRW5ceEfEltpK6pc+H9Yh0xkWVbySykWEowyGDlduCCCDmug8TfCjxdoFvocs2k3V3/a8CTQpaW00jRswLCFxsGJQASUGehoA4OiuhHgnxUZbeIeGdcMtxu8lPsEuZNv3to284746VU0nw1rus3VxbaRoup39xbcTxWtrJK8XOPmCgleQRzQBk0Vuad4S8R6lEZdO8P6vdxCY25eCykkAlAyUyF+8B261t+Hfhf4o8QeGtd1nTdPmdNImS3mtfJlNxLIWAZI0CHJTILAkEA5oA4iiut+GfgPVPiJ4ifRtEnsoLpLdrktduyptUqCMqrHPzDtWra/CXxJP4W8Ta9L9ktrTw/PJbXSTs6yPJHjeIwFIOMjqRQB57RXqr/BHXRfQadFrGhS6xPpg1aHT0knEskBzyGaIR7uDwX7enNYFn8Pri6+Hdx4yXW9HTTLeU20kLfaPOE+0MIsCIruIK4O7bzyw5wAcTRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfcln4G1Xxr4U+EbLqMVjoOk6Za3s3l4a4e4FugiKq8bRkKf72fvHjpXw3RQB9geP/BuqeA/2b/HGh313b3elx30U2mOjHzEge7iOyQbVUNnJ+XIyx6V8f0UUAe7eJ/i5aaXpHgWTwcmn3OuaboCWE19NBP5tjJsCusYZljJ6/Ntb2NVPEXxNtk8FfDPT9L1a8uF01XOuafG0saTjzY2CSZAWTID/wB4DJ9a8UooA+hPiP8AE3SNRs/Fsnh/UNAktdca3nNtcWN7LevLGybQ4lY2y7cHlcggAbfTlvg/8RbXTfiLZaj4rNhZWCW1xbmew0mC3CGRMAutvGpcZA7EjPHU15JRQB7JD42tPDXwPufDXh7xRIuvf24Z/M077RAJbYxAEh2RDjcACpweOmOa6u8+KmgzWFhe6NdaJp83/CP/ANjXlpf2l9LOqhTmOFY2FuyscYLbSO/pXzhRQB9K6N44+HekeHtTtdIu9MsbO98LyWT2n9mTG8lv2XDebN5ZBXoAA+3JJIHBrP03x14UbxF8Jtbm1yKBfD+nR6fqFq9tOZY2WNl3grGVZc46NnkcdcfPVFAH0Pp/xI8NRaFpFvJq7CeHx4NZlXyJeLPexMmdvPXO373PSrl18T/Cl5B4ms7S402G7bxJ/bdjd6lBeC2uVGNpP2bEodSMgOpXgcZ6fNlFAH0hrHxS0G+8NvHPrNs+rP4uttVk+x2U8MTQosQaVQwYgZQnBO44zgZxVPXvHXhPXZPi3pya5FZw+IprObT7ye2nMT+UVLBgqF1PHda+e6KAPTPgH4p0rwl4p1e91u9NnFNpFzbQyCN3JlbZtHyAkdDz0967y4+N1l4n8DeLtP1tI9KurjSooLaCMPKLy6LMZpSVTCFvk4bpjqa8M0CwS+nk81S0SLz16/hWvLo1ooby7csR/tN+fWgD3W8+LPg++12LTLjUFh0i88LxabJrVtZMl1YXK7yyhwglZD8uVGVzjHVjXn1nqvh21+AOseFj4m099Zm1Y6jFEtvdYdERVC7jDgM2zIyQMMMkc48luwi3MixABAcDGf61DQAUVLKoQR8clcmoqACiiigAooooAKKKKACiiigAooooAKKKKACilUZNKwGeKAG0VJ8oXG05z19qTaueCaAGUU4DJwMknoMVduLM2lrGbiMrNL8ygnlV9xQBQop+AOoINWJrYR2MUpHzO36UAVKK1dKtIZ4GaVNzBsZyR2FXf7OtP+eX/jx/xoA52iuh/s61/wCeX/jx/wAaDp1r/wA8v/Hj/jQBz1FdB/Z9r/zy/wDHj/jR/Z9r/wA8v/Hj/jQBz9FdB/Z9r/zy/wDHj/jSf2fa/wDPL/x4/wCNAGBRXQf2fa5/1X/jx/xp40u2Ay0XHsx/xoA5yiukOl2oYjyjwP7x6/nTP7NtskeV06/Mf8aAOeoroRp1pgZjOc8/MeKDp9qP+WX0+Y8/rQBz1FdENMgfAjt2Y/7JY1pReFJGAMlmYVIyGmk8sEfiaAOLorr5NE06IgSzRk5wRFub9c1G+n6aYSsFsxcHmSSQjj6A0AcpRXTLpdpzvi4HU7j/AI06PSrRpNpt2GP9o8/rQBy9FdiNFsMZMQOSRtDt8v61la5YW9rarJBHtYvtOCTgYPqfagDDooooAKKKKACiiigAooooAKKKKACiiigAoorQsNF1PUE3WOn3dwmcbo4WYfmBQBn0V2mlfDXxFfEmW3is0BwWuZAv6DJrq9M+E9jG4/tfV5Hx96O2ix+GT/hQB5BVizs7i8kCW0LyN/sjgfU9q9wtfCeg2cZMOnQFwSA0rGUj8+P0qC4iSBdkQVF6YACj8hQByWk6d/ZlkkPyl3+Z2U5yfSo9VYW9pJICOB+lbc5DuxC/Io7DiuX8Y3AjsY4lxulOf+AigDjT1pKKUcdKAFkbe5am0UUAFFFFABRRRQAUUUUAFFKOvNPI5JAH0oAYOvTNPZSOccUnAHHBq9p+lX9+G+xWs8o7lV+X8T0oAosOmB+PrRkdOK3G0OC1cLqepQQt3SIGVh7ccA04XHh+1QeVZ3d5KGHzTSBFI/3R/jQBggEvhRk9gBWnZ6Jqt+yC30+5kPZvLIH5mtWDxVPahhpttaWYIwvkxAuv4nJNZN5rOo3ChJ72eRCd2DIdp/CgDQHhhoEL6nqNlaYzmMP5j/gq/wCNQPHodowwby+f0IESY/U1jOd3LZLepPahsK25SCM9KANf+2IrTa2l2kdtMOfNJLMD7Z6VlTTSTzvNK7PIxyWPJNIVdiWIx3JIoU5UA4x/OgBYI98qIVJ3MFz061q6/GIreJF4CHaV/CmaBE094GKE+XlySeM9qf4hzsjLLhic5/OgA0L/AI9X/wB/+grRNZ2hf8er/wC//QVoGgApKDRjOaAENFKRjHPWl28479vegBop/l8DDDPpSEYOP6UAZwq5HvQAqjD9entSbtqkDr3NWRbr5e+4cRKT0Jyx/ChSiDdBGH4zljnH4UAQojucorMR12irMdk/G9kQN6nLfkKaZp5edwCkY9MflTbcTRfPC+x+pIoA0o9Nijspbt1vJYkONyRhE/Ek1QS8gjJMVmjEdPMJb9KVzM2ZGLsD1XP6kUsiwsAwzG/QjHBoAl/tbUH+VJhCo4xEoT+VSfb4pbeRJovtN45z58rk7R3OD3qj5u1cAjcMcCnfuioLKQaAGRoDgkggnk+1KIDtATAfPc8mmY2gjbg9sdxRAgIZmY4HAoAmUNsA6FvvH+tPtAXLHO7J4J7e9V9rZGGO48den1rRhiYJlnAYHgHoaAFP3yCpPqT0zWH4obNkgwf9aP5Gt9w3lD7pGeSeea5/xKvl6dGDyWmznGOxoA5iiiigAooooAKKKKACiiigAoroPDvha+1lftAXybFThp26H2X1NemaJ4QtNPtXaCBJpiC6SSqGbGOBnp+QoA8u0zwvq2oeWYrR44nOBLKNq122k/De0WISaldyTMeQkQ2L9Mnk130A8uCEkLjA3Kfp0qSZmbdtVmPZSMY/GgCj4f8ADuj6fhrXTLUg8iSZBI4PtuzXSmVmkV5ZszFQpY4Hyj+HA4/SsiK6VFiiRf3h+bJ54HerLSIWIADZ4PHAoAvJd+STG6hSehIwDVX7Sy+Y4UhTndgd81RuEVY1WR3CNnABxj6HqKqw29vGrDbK7Hkb2ZhigB17KCfkwzdcKeD9axbjLsxdt7EcqvQfjWnNLvwI02Kvb39aozqoKuecjGOtAGfOuEJ4wRge/wD9evMvFVwZ9YlQcJDiNR6Yr0fXrtLO0klcDEaEgDvnpXkUjF3Z2PzMcmgBtLSUUAFFFFABRRRQAU5fvCkHWpNgAJJwR29aAAL8xyBx1FIMAcjn1oY9ealtbee7mjt7WNpZmOFVByTQBFjjIx9M1r2OgXU1l9tula2sM4851+97KO5rXNpZ+ETHJeC31HW88Wv3o7fj+P1b27Vi6rq1/qCiW9uXdpCflB4A9h2oA0hqGg6Vsk0yxlvpwf8AXXuNmfUIP6ms7UfEGoagR5sxEYGBHH8qj8BWe7kwIFAwDzx3qIL36D1PSgBcliBzu/PNIB0GfalC7sk+vWnzRCNwob5v4s9jQAzaWI2ggGlGA4XOB370358ZJOOlL8pQDI3D2oAeyJsJD5xxjHUVGql8hASetIATx6U93JGMKPpQAfOwOT3xyacuNwVQDnsehNRjnlugqSGPew4UgnoaAN7RLeSOyLA8u56dcDrVfxF/q4x8xJbJJHWtsR+RaQRNuDIACB0rB8QEbFA6BsD2FABof/Hq/wDv/wBBWiaztE/49X/3/wCgrQ9T2oAPpSqMc8Y9KApDYPFOYrk4/HmgAJyAWGPT1pGzk5AGTSAEZP8AXrV37K0NuJ5FZskYTHA/3j/SgCuISI/Mk+VD0b1+nrWrbjTY9HmMs0y3ki/uUhUY6872PTjsKzWaSZ2kmO7HAB4A9gKnlUPpyyFFzG+0lT170ASnToxojXplMknnCPZjtjOarSqBBGIwAW79DnuKlS4kisXixuWU5HsRUSxvJbtGcYB3HigBQihhjoBn68VHGmEd2baAeRjr9KntYdsqoG+cnjIzmrd1PatbqoiJniyWdzwx+lAGaIZnDOCAncnjPtSxK7MEHzKeMHtT90t6GXc8kjdAvb8KtNZfZIk85wrkZKnr+NAFFopEUuSAucD3qPoBzu54FTHcSSAWU8ZJpPKYKSzYA7UAR5IPHHpn1pTyMHj2z3pecZZgMeh5NCE4+8Mnr34oAVYi3zSbgTxu7GrsIIijXcq55x3+lVoEEjbTuHfce1WHO3HGWJwN2KAHMzs2Cdhz8xxwaxfFYAs4uQxMgI9QMGtqRFwFwA57A8Vg+JgwtE3IAfMHI+h4oA5uiiigAooooAKKKKAFUFiAoJJ4AHevSPBnw/klnNzrsRCRkf6L3JPTf6fTrSfCnww9zcvqtxHGTEm61jkIyW/56FepA7e/0r2C3iW2gjt4lLAjJY9T6sT6k5oAzxaQx2zW+2MQ42bVXGO3FVtOV5bGMI2HjXacDuO1ajwBl9SemexHf61mWsnkXFxAxdctuG7uTzgUAFwfITewyFI7dKsuYzExMp2gfvMHpUGtXEUGlXklwwj2RHDMcAnHT3PSvNrPxdeyyx2skYZTjL45b60AehRuBct5eAJFA2qcYUdMGriyAxqsa8DhVA9ewrLsrh7mNMxopGCWxyc0ybTVl1W2khaRboEDhuCB7dMUAad9Bc2yLNcoqAME+Y8ZP9cConkwy5cNgdqhuWluA4LlgW3gH5gSPaqaO+Q2MHvuFAEjycMzbOuDVWcFtpw29vTg47VJO/mfMp+eo2LkxgMDvJLMeCCMYoA4z4h3eLNYVJAY9xjNeeV2fj6RpTFvYELwAOxrlI4f9HeVunRR6mgCvS0VJEFwzNggCgCMjBpKUnJJPWkoAKWkqTaOx7UAJgZGPypcEdQeaXJKEcEdc96Zyf8A61AFixtJ7+5itbSNpbiVtqIoyTXZ3623hXSpdOtJc6rMdt1dKuGTH/LOM+nqafYWjeGvDTXEauNZv4wyyKObeE88H+838q5G7uJLq4aSRZCcBcHsKAKykiUszlSRuznnNEjsYSDwc/pTW+ZWOMbf5VY0zZJO0EpG2RSgJPAPagCCNgyGM8Ejg/yoMbmMNwFzj8addQPBI0LoRIhwa6rw3o88NsZ7yNTBMvyAjJ4oA5e0jO1mePKsMKe+aikjJYAuGJ75zXb6+liNsOno6OwG9W459q5S72wyNFsVSn8QOc0AA094YvNuWxERuUrzvFVWjXy2kGQPp3zSeZJjZuO0nOM9aTecEcjH40AMbgj8+tLgFcrwec0g78cntjpSjgnIwTQAKD16A8AdM1d0dN9yoxn5siqXyluhzjpjFbPh9SsvmBo8L15waANuchAuSSzZG4jH51heICXijcvuGcAHqOtbNzKNmwZ2scjI5HtWLr0geGNdu3BzgDigA0ME20gAz85P6CtFc8nt3rP0H/j3f/f7fQVpsQG2jPTkGgBF4ycD8aZISMgnPqaXnoc56VY062a6u4ogucsNwzj9e1AFnTrTNxamQKjXDBYt5wMd2PsK1PFGqo6R6bZBU0u1baAOs7jrIx7+1db8XPAth4R0zSp5L9p9UuuHtxjCKF5247DIHvXnloiSRSRscSkYGRxj+maAKzSCVSrqdx5GK0raI3fnrAFEnlhlixy2Ov5CqAiOUYMRu6Z4B9qnsdQm0q/S5tvlZCQ4Iz8p4NAFdz5AZSN0ZOee3vXUfC3Qj4l1ttOdmiUxNKsmM4K9sdxXe3Pwttdc0/Trvw1ep5d3AHcSnhWPOc+ntXV+H9I0T4baQVu7oS37IVlmRfmI64HoKAONl+FuqaLFdXs8imPY2Co4A989OK4uTQbh4WlRQLfOCzkKFx3Oetewy+KrzVbcJp9u83mAKqtJ69OK4D4j6VefZkEJEix5NxkhSh7/AFoAwvC+oeHNPNzBe2k0tyfmju0ONpHQYrndbvje3ks0gCtIScCqaxrgktkLz14rrZPhp4nfwrp/iCLSp5bO9mENvDFGz3DZGVk2AZCNggH6HoQSAckMMAqtyOhxgH60+G2nuI7mS3t55obVVado4yyRAnaC5HCgkgDPU16DF4H0bwhBHc/EvUmjuyokj8PaZIHu3z085wdsSn659DnisvxN8QtT1PTRo+j2lv4d8NIf+Qbp4KiT3mk+9Ix75wD3B60AccFUEsgwB3xTNpHGVbucGhwpOACvsc1LBGXjO3G0nBA7mgB9s3yEEcHqema0NNgjLyz3A/c2w3HP8R7Cs5GReM72BwENXJJ0W0EB2ghslifvfWgCCRiS8pDZJ4Gc8fSsTxC6/YlUA7jKCSfoa1pcRhdu0Z+8VrG1982aKOV8zj8jQBgUUUUAFFFFABVvSbb7ZqdpbnpLKqH6E1UrU8NTLba9Y3DLuEUySbQcE4I6UAfSmn+F9N0rUFv7NJVmeHYu9shFPOP5VNLC0V0zqB5LHkH+H6H09u1akWo2NysYgvIJZGUHaGG7n2qKcDJ29uaAMm7RkKSqSVHDDGcj/GuS+ImppYaRAckXbyb4yOyjjmul8Q3kWk6VdXdyG8r0A7n0FeI6heXHiHxBFv8ANYMdqKeuM0APN9fatKn9oSSy24OQScAGr9lZiDUJDbwLPIuPlfgAVf17Rb3RdKhMLxtFLIEchskMOwq54Xtm+1PcSgrgYZSp4J/TFAFvRdM1NbqMohhgkGXA+bB9q6JRNbr58M37xDw3UgeualiuImLZc8D5QByTVWaVpDs8tVQHJHegAR2ONwALZ3FeAD/So7uVmUyeWzBuGIHT6/Wp4oJvLluYlbyo8ZY8cnsKrPJJDC7xngDacnj8aAKM24AEAhU/HNRzEzAMp+TO38akupUKfu2bbjJG3FZbyQgeSY5SWO4lWwM//WoA5jxrbulvucdG9K4+Z8xRIOij+teheLrYPprSI7Fc9Cd2BivNz1oASppFMcaqylSeeaiALEAAknoBV/WLKSxlijnfdK0YZhn7vtQBn0UUUASFQApHcetKpKkleoHNNx270dAPQ0ALngknn0rZ8HaaNU8Q2sEgBiUmSXccAooyRWK3/wCr3rr/AIZzImqX0bM6TT2rxI4/hzjJP5UAO8aeIZ76aTygERyMjrsHYD0GMCuXtt08m0uFPbJqbVLa5t7iZJ4XDKcMxXg++apqdpwM7icEf/XoAmZSk7F0GAcbT0b6GmbAZF8o/MzfKo6g1KHFwmxx86n7xP8AhXX6D4TuY/K1GWaNiuHiVTzn6UAblrpsH2WKS7hR7hEG8sAefXmsvXtWuJnEEbvEEO0bG+Rh2/Gotb12bT5DbyIssi5yzLyM9c1DPHZT6ZaXMO9LnJYK/CyUAVGurCJXa5MlxcqCzMDtGfauevrlZzmPIHfcOaL0tJcMGCrt5696gVgAXJy+ePSgBEYKcMoZevNBClsNnf0ppJYEk8k5PFAVjkqOnOfSgByqNw3nGOvvSlMEYbr3NESB2+Y98Y6mkkH7z7pBJ6UASRRKwYEgsOhB/StXT0CnlM8g5xwPwrLVAM5kwoPpk5q1Y3DZCqxwDk7jyaANqWQhct84OcHsKw9WfKooHAPXOa2pCTHkAheOR0rC1QtuCk5GevqaAL2hNizcDjMhy34CtEOF3DGSRxWZoZP2Vx/t/wBBWjgZzkkZ60ABJIJyfTOK0bBQmmzDJWWWRVBA7DnFZrMVQgD73FWbOZIjsuN4DOowOCuf4hQBLqH2x7gTX80s8mQC0jlj+Z7U+2u2hnjkZVdWODuUfqK9HuvhjdS6LLfWWoR3kkaBjGUID5GeDnrXBz+FNXhlxLp9yJHO1VCk8/TtQBBJZyPC88TRtbI2WB4ZCavaHo97rt/DDBEArHa7E4G0Hkn8KND8PeIZZWt00y6ZWl8uZpIioQj1Jr1W/urLwnolrYokP2oJukkhAJbnlQaAOw0eceFtOisYJElgCfIe0Y9DWF4zuL3XvDslxY6afPWcQuwYMuP7w9axPEHipr7TI5tFjZY3TbI4j3EN2U/WtzTtc1DSfh/FPrUcUc75BiC5P+yGx0JFAHF63rV54ftoUtxtdY9uIyMI3vXn+qeIby8lY3c0jI3LjOAx9am1/VzqF2/kpILdslInbIjPf61iiMJLGyvIJI3D8MAMjkGgD3v4M/CS2aGDxd49aGz0dcSW1ndsIxN3WSXdwE7hD16njg+reL/jP4CsbG6shrst3LLE0edIDSMoIIykq4QEdjur4+v7m81e6e41G9mvrlf+W11M0r49NzEn9aqtGVIJ2kLycUAMIdpJpllkk3uxaSb78hz95uT8x6nk/U08ozBWEm71HQUyR0kfjcF6gY70JuJY9sY3Ht+FADpUXeFWTgDOBzz61IjkIyjIGOccD60yNQeU24UfMMU6TkDCMMc4AoAZDIgnHqP4wMkVby3klfLAJbO4Ac571TQbnKGN1J54HSrEbZUnaVyeue3pQBDOxJBZuMbQR1rM8SR+TYwLxuZgzfka3VjBu0V9ojjXPPRvY1i+Kn326nYq/vOdvQcGgDmaKKKACiiigAqe3jxcxCbKJuGSRjim25xKrccHI471qwWb3d0TPJsDDLHGdooA6kX0NkIpYZGE4fKsGzg+vvTLnxNq85d4dVusBC7iHg5HbH9a5q5jZZjFAd8acJjuPWuh0SB7azNu0cHm3RGN+N4GDxntQBFeXN3dRKmr6jcSKyhxHKdwGRnp6ms2zuLJnCzedA0ZyJU+8PcVry2QxIj5eVh+7IHA9hSaHo7yarH9rQSopy6DhlX1/wDrUAdBp8U+ty2st7eSSRxH9ySMA+5HqfWuvEDRKNhABHGP5U2yazhiEGVikXngcMO2CePwqyoDJ8jMM9cD/IoAoSxncW53DuDjj6VAgmUEuUDf7B6Vf2BTjeN54JI4NRMiuoQM8eMjIPU0AVpGfyXjLl42ILRkkjPY0yV5DAY0jjVO4UdeOtSiN84EznHHK/rUe0NLneGXAzyeKAKUgdLYuVyV43OcAZ9qqyW4kYMWwV/Ct/UksbKxWa4ljubmU5ihX7qnoCfp1xWDHA204ZmB6/40AUvFCt/YdzjgAfgBXlFes+IEZdCnTg5BwfwryegC/oyB76EHIG8EkUuv3H2nVrh924BtoPsOK29Js1igt2b5WwZDx19K5aVt0jt6kmgBlFFFAD85xxk0dc5P/wCul/hBA570NwAR360ANH/16s211NZuJbWV45GBUsvGQe1XvCejPruuQWShvLJ3Sso+6g6mvZH0LQ7a6t47XR45LJOJFkGTIR2NAHn3hm8ubyxMU4MqnqG5BHvmrMvhfTG2yOHiXGWVfmz9BXqGgeC7XWZpprNFsbOFipCjB57AV0uueHtJ0LTFvbKMRtE3zSMnmEk8dP8ACgDxPR9L8NXGoomi2l7eMqgzeepAibHQevOaueJG1mzwIljjjQ8IrD5gR6V0dpDNGL/ybtZW1KYOSVKEHnLAeuKytYRhMYrm4UxRpwyEN+HufWgDk7m+guEI1SwYzDnzXbG4ehrF1vVnuII7Z4UWFQNnl8Db6VZ12cqpt0lVYs71I53e3/1q56a5lmiWN+iUAQvzz74x3pQBgl+46DrSknAYrgHgEU3d8248n0IoAe4RcgZ69xR5hV28s4zximZJPIyc9acvlgfMrZPfPSgAUoE6nJ447UhA4ww6/jQu0uf4R2zzT0Uu26FTxySaADLINoIKn36VLYyrHcrvIWPPNNfcSVwFGM52/epkGBcIX2kbsY7GgDp5WUImGLIBkjGOKwdVVQ2VA5Na+8CNcja2cZB4PvWRqxBdQpBHf1zQBc0HH2WTnDb/AOgrQ3hQxxn+VZ+hH/RHzjG84HvgVclA28k49aALml21zfX0Ntp1u91fTHbFGi7iT9K7JPhL4sbV9OTUNPe1huJP3kzMGWJB1LY6e1el/sweGTbafc+Jr1Y/34+z2pYZYID8xHpk4H4V6b4y8SyeHrOeXUkRbeRvLQqN7MPYUAX/AAToUujaAtnfSLNKSdzDGCO2Pas66s1v2vYY9R00yxMGR0GXQ9g2DXz78VPi34g12RbDQJ5NN0kR7WMB/eynuGbqPoKxfhXa6ks1xG017DbXP35YJtreYBxuJ7YzmgD0GTXdTN/dzeJZbC5SGdrBDZoyh2HRsZwa0NK8H6VdHVGv5ZHu7ht6l4v9WvZRjvVCx0+DUtZjMOrSzW2nOZdrRhYTMPugt3+td9oGt6JYaYZb+6s59TyxkwTtT60AeZ32gp4Zae8h1CTyo3DLBKNqOR9OtcL4s1WXUAZ1vQ3nvua3jY4DDvg10HxL8WWF5rAtdKImtJIsbkYkB8nJ5rz1rG6huhmFmB7gbhQBG8siP+8UAt1IbqKjkkLsVwo9/UVM0SsXWNwXz06jFRsvlLtbd16YoAagxn5z8o5x0FCE7sYIOOw5pWZSAApAPYH+dOSaSLcUJ3YyOeVoAXaMc9R0O2kaRwVJGARgDr+dL9onfG4nJ4xnrSxxO7MHVmVQcDPSgC5G3nQbHZME8tVaVF3YbDY5BB4Ye1Xo9O/0F52uFTpsgx8z+tUZVdSSEAVehJoAhky7KBlcD5VGeasoqjaW3jnjB6GoFLGQdnHPTpVtljCNkAMvTn17UAJaRCVpAHLADJHrXP8AiHP2aPJz8/8AQ10VuQIJIlUqcYGDzXO+ITm3X5cfvMfoaAMCiiigAooooA3fDGjHVmm3MUjjwSwGT9APWu2l8MrZ2i3WnXNnqZXCz28cn7+H3Ze/pxU3gKOPSNJW8IhnwEYb8hPMY9WxyQq/qa1dd0XS5Y31bTYxb3twclbWTbEPUc9RjrigBkvh2xt9AGoTW8yXRGWVm2nP071zVhd2sd6AlvGCG++43t+ANbWif2brMNzbXKvb3/KxiS8fyjgdQfT2rMXQdRheN7W2gmAJw9u4bHbOc/zoA1dZgCQR3jzvblixTIBYn2FZfhi21JGNw1pKY2clmJy3TqQOlaf/AAh99G0Ud5MXlf5hAg5BI6lj0rpNK0ODToBJPKbbaoXckpJP1J/lQBDPcLLIiucF1/3T7j0pmZoFxaqZIlGNgXG38av3EWnyWrR20F1O2D8y5O/6k1nbryKWT7VE8EWAQ5H4YJFAFwXPC5ikDY6U2WV3DKINwB78c+tZ0l9fxziK2iguAx5G7GB6+1Xtl3JgNEiDHRX5FAFKa56x5QSnjLPjFZcV3eCSVJpbcpnbkc/pWy9k42KYVDAH0JzWbNpKMxZ9/wA5zu24xg9KAKl1JF5aIN7zM/LKvCjvir8aBYk2keo46Vmanp91DIPs7u0D98/0rRs0cKolk3MBx0FAFPxAf+JVMpKg4Iz3zXkpRvM2EYbOMH1r07xQzCydCwy/GRxXms74ud46g/qKAOytZfM0K9nGF8qIRg4rhq6qG6MHgu4jIy0smT+NcrQAU4DNNpw4APvQAu00hPGM5HWnkAfePNMJ9aAPWvgTstl1W7kVRu2w78cjOTj6dPyr1S5ENtIt8YiWQH/VgHH0Fef+EbC38N/DOW91dXBvcvDGFO92K/KBj866r4caR4B1vS4hb+I9Qs/EjoVaO4uCmJCP7jcMue1AF+f4j+HtOCR3sro7KG2xgb/xHQmqmo+JrHXEM+n2Gq38aDcISRDGB1yccmuC8W+Av7Kv1TxR4gt7VUfZ5rWMuw98o4GDXpvhG20i306KOyurrUre6QR/6JbvErJ0yxPJ/E0AeT6hrM+oXSXJuIbN4n2pBa8+SM8lnP8AKrr6AbuK7vl1uC+vE/eLbWoLnPq5Ax+Ar1PUPgzoU1heanc3U0c6ktDbI6xqq/wo2Bya5jxDrfh/RPCzaPoeo2+ly+WEurOzj82R3PUNN04+tAHgmrRXEF7KtwpVzISOcAGoDuJkaeMFwOp4FdFePZPIMX8U6448xMtn61RktYbuQLayrljyMUAZAhlOQCCMZODwKj8qQgHBINaN7ZG2leKUDf2w3f0qu1ndCNmEcrRgdR0xQBWGVYjv0PNCxtIx2jAHv0pNh27iDz0p4mATCoM9MnrQA82y+TvEqnnGB6Y5NWLWW3V1wZAEU5yM5P0qJJI1CFlRgBg4X+dWbKOB5yzMVjOQR0BoApXJeRyxPJ/hz29aZb/NNGqpnJ571PqPkfaW+zgBfQ5NV4TiZc9CcECgDon8uOAbQABzgnODWJqLhnGNuTyQBWxMUTdg5wMAAckVi32N3ChRngAYxQBp6B/x6SdB8/X8BV2VQRgc5PeqWhAfYpepO/pj2FadshluY0RGbJ+6OSfpQB6l4J8c6j4RsLF1KywEBHicnasYPIx0B5rrvFvxFsPFOizrAyJBCvzgRkso9jXltxe3qXCWz20Q+zIolR1ALnqAw9cHmkh0yXUYpL+0mNvJb/KYOBGVPX5vX2NAEYv7eSaMfYbWaLAXftKvt7dOp+tX5tZcW8kMUX2a1DYRUPzH8Kxft9zaWz2CQxGdz8/HOOxzVzTIYPtTx3Uy+UIj80Q5Le3r+NADLTUriG8yryRQocuof731/wAKnuGmnF3cSzLHLNwzZzvH4dKqXM8hurC3twyWucNx8zAHqT0rXnc2UM8ypY28jyZVWYNJsA79gPagDmr2zWYRSW6BowmW28cjrmrFlfXmnqwtZipZNp5AJB9DSR3rTXbskB81z8oUAL9aU3LTO5u44RI3DMOAPwoAoiISPmQlSvO4nrULwzEZkZWA5A71ekjibCo25T2xnmrmkaI18SBd21qAuWaRvlAoA5zy2yXMgHP61Nbw/aXG5izdAFGc1euEijdoI54JNpI3KvDY71TmmaMhYnC49B1oA6Lw5d2NtK6S6PHdsOfMlJJAxjjt1rP1ASkuYVMJdsY4qhbXzxltgDEj7p6Va+1faI4ld442TIbahJY+p+lAE9raSPE01xO5RflKpHnP41lzZDOg3FScjJ5HtWvd3kS20UQjKyRfex91vcCsN7hixKqpBPAPagAZxtKuz5yMr7Vc8oLHExYEYJ3kdvSq3lSNhpdqlfT+dW3AFvsYnYnIP9KAKrTGN96neV46f1rG18lrRDtIw469+DWzLH5bu2WCEZB6cGsbxA5e0QkjPmDj8DQBgUUUUAFFFFAH0l8C9OtbvwE09xEkqvcshWQZHAUY/Pmu9v7a3eNYmgiK4wvygbfpXlX7PWtKNA1bTHOXhlSZFzyQ52nj2IH516ndOxcbsDqBigDktf0CCWPdsEKxAlTCgB3f3jXHaL4tW2jVdTtJXaJyn2iKIZHuwHavT7iUg5B49+awb6xhEsl1YQqJ1XDRY+SX29vrQBXj1i2urFJNL2XKk5AeTY4P41XF29xcbLyzmt0UbiDh9x7Hjt7V55qVtcxai+paWk0cJPlvEM/uWB6ZHatjTNSuYJQ3mXhV0ycgkEjjnvigDslv7aVdsEm7oNxBFTNu5jU5GPmyOtcvourLbq1vd3Me0HMe7IJHpzW+NQDA/Z+uD8zEdPwoAbMyReaTH8/XjAAH17VjX96sRJlgZUJ+8sijP0pbl7ud2ji8ybP3mIAQfX1+lUrnw415Ok11ducL/q9wwPfpQBPPLamJma51G2fAyZN21OPVQRWbKVwPI1cuBzhj/wDWrY+xPp7IIro7ADnndn8KQPJMhIv3kB6hoxzQBiQahbib57hiw7sPlq+zRSxBopkc4zkfWn3Cog2tIHxyBs61UE1p5m0+Wr9cA4oAwPFZdbFxIWyMlTXC20TXDyyF1Upz7knsBXoviwJJoVw24FlGVYd8Vwvh+2MupJuB2hS2aAJL92h0hbVwcmQMM9cYrEre8VyRmeJIuwJNYNABUkXUEgkZqOp4OcDJyDwAOpoAY3fPU85oRC8ioD94gD8aV2yx3gE+tNVtrhlyCDkH0oA90+JOv/8ACP3Wj2dqWEttZhkXgrHlQuR9BmvOv7b01fEFtdu92ojjBM6hS5k6hselX/i1M134ktLgnMM9lC0ZB4YED+tcVeQNBMYtwYLkD/D60AfROk/Ee08TaEPC/idZtRsroFWvJNqGLAyrcelcj4tsvE3gSOwfQdTvn0dysq3UUqtE5HIwBzjHY15Hb3Twb1bLKw5UmvS/D3xCtrLwjHplxAbyeK5WYRzfMnl4wVAPSgDM8ReP9d1WQS6ncG9t3wfLGVjDD2B549a5Ga6a8umkWGKGNv8AlkhKp/8Arr1RfD3h/wAbWsl74Min028Ub7jTmfcinuyd8Z7Vwt5oOq6fPMCUeEHDtuVjke3UUAZdxc2VqipaWyNKBhpHYtg+wqB7u8RVZZETjI8tQOPyp8FrJmSa4tQcLuCjj8cVReYtLuK8DoDQBOb2a4JE4Wd+oLDn86Rr+dVKAlF/ug9frVZS+4FAVOeoq7HbuDlywz34PPv7UAUwxZjvZ8H0H9KekcPJM2AeBlTxW5bWSR2zS3EyKpUlORnPoazJgm477eNlHUocH60AQRWyMwVrhFyOabsWMODMMY6DPNTbYWOBAV46l+g9aYJo45APIQqPQ5z+NAFcnOWUbcdcdqsWwj3KTncGBqT7RavGVMBRjzwciqzAqwZDmMHg9vxoA6O4Rt6vHGBvHGeufWuf1A5lyRgnt6V0ZYyCKQqT8vDDgYxzXO6oxe7dmIyT2GKANLQf+PSTB5L4/QVu6PPLbX6zQMVnjG9GXqp7EVhaCB9kfOR85wR9BWvZybZzgkl1K470Aaz67dyXdzcOkcxllMsrSKGZmzzz70PrKpMZo7dQGYsdpO30wR6VnQIBEwHVlJxnvUawlEXcRg8NzQB2On63aXFy87afZLM0QVGkZmy2MH6cVQuEnt3Y3FlE0BTPm24wcZxkHpWAEKEEE7c5Fb2m6/OsP2YytHhTGFGACD2/OgCKWCWeCIadMbo5JMDkB1HbA7/WqB0TWHl8ySzlWJuWL9APetCK5V7BraaJIzv3+Zj5kP19PapYLS5EXnLO62kjbThyQT2yM8igDEuHCXRigc/JwcZ/Q1HPASFaRwx7881pJayLORGokPJbaPT3qhdLIJD5oZSOTlcEUAV4lIYMCwbr9KsmWd0KJI+wjB96rLHvUBUwR/FV63tSShKK3TjJ5NADILOUwl/KdkU5+UVYe28m3D3Vl5asMruJO6up0LT9FM0za3qSW/lpuEEaH5vofWodV1OyMuzR5poS42hGPyoO/HvQByaPZBMGMKT1IJyPzq6kWmz7fIt5mkxzkk5NXZrqZZMO1kSo4JiViffp1qpPrmoLJiC7aPdwQiKvP1xQBTu7ZnAzGUboowe1VD8oYcrj0H+TWjLq+og/8fHmqeQrcgn6Uya8F2QJrfynIwZEHU0AUEkLghjlB3HepvOzDGrAiPO3JHb61XmjYSYJOB/FjaB7VYlRJIv3ZdnBGVHSgCbV9jD/AEcFoxgbh/Fx/Kuc15QLRPXeAc9ehrp5kl+z4jxt29O9cvr6hbdAD/GP5GgDCooooAKKKKAOg8D643h7xHaXwP7tWAkHZkzyDX1Gt9b3dh9rtJBJGyb0I7j2r48r0z4WeNv7PZNE1R82EpxC7H/VMe2f7p/Q0Ae1yqBF1bKjkn1qlM5wvlkHd3xwas3EoIw+Fx69KoGUkNIhDRdnx/If1oA524NtNq9xZSMi5VWKg4y3rUb2Iur9Vt1b7LENjOW4c/8A6/Sm3Oi28+qrf3IMj5x14z7Voz3iWkSAZ2DA+XsD/nrQAy4sYreLLvGXztX5Mj8M1Ve0vZZlkWUpa7cbGQAg/hVqxL3E8ssijarbYwOeAO9T6rfC0s3YMokMe1Q3f6UAU7GO9luH+zyRLAxO+4Ycv7AVovAiszS5O0jl/wCL+g/Cl0yQHT485aQKMoFwRnvtq8Im2hmBz6nnFAGRcPGoUqDhiNuF9aztTk2LFHAqrKz42kH8+K6EskjSLAVwvV9v6VSvkt7eNpD80hIU4GSxoAx2hymX3kNycjgmqf2S1WQlViUjlsLya1pDuBaONEyflEhyR+WapO7vldiehG7GfoKAOU8aIqaRdPHxlgCB936iubtZkt5LFYcDNqC/1yc5rr/FNsz6BeKjEbRuCH0HP515ezvKyKOSFCADuKALusyiYQsrq4JbkD6VmV0WsWEdt4W0mXH79pJA5HTHGK56gBKevQkZDD0ptOUkDjjmgBzlWCkcHvTAPfFKATzSsvy5BPvQB6HcNHrngLQ7yGMG50qU2lx3+U/MjH2xkVxEjtK7PIFxuzhT+tdD8Ndft9I1aez1PB0nU4/s1zuH3M/df8D/ADqj4s0aTR9ZuLKQ70RiInX+JDyG46jFAGMVCsCC3J+VjzkU5HiV8tguDgMOhpJjk7OhQbQD6UqLGEDT9COMdaAOx8Paw+jSmeynNreRp+7uY2+Zh/dPanX+sS6iyXF47NJN8xdVHLZ74rlNOje4uViVRgtlQeOavXMX2M+XcNtYHeV3Y+nFAGpc3NpJnd58TdA+f6elY93ZWETB/tBl35JAUjbVW9uDOwcsofGOOeKZtkW3V5SQM8AdvrQBIiMmfJT5DxuORRLcGJDFbMGY8NgZPuKbLeSXihWYIqrg4HaoJJyI/IgQIP4m7t/9agCOTzF4kJGeSO2aVXXO4l29R6imouVOWVR796kVkVSADjsT3+tAARHKcW8bnC5wx70jjnLRgc5I6Yqxa3YiVuQOOAF6moJZFlfcpKuwwc9qAEAg2kFiST1A5q3bizVJP3hbJwA44/GqO1AwGWIPcDg/SmhgBnqTxjHagDqrgr/Z0KhtqMn3l9fSuYugAVAYsPU9a6aCJbvTrEgMCgwMMOfasbVrJbWLdtO5n6ntx0oAsaF/x6tnp5n9BWrbsYrlZF5289ay9Cx9jkz03/0FaPJcEgA9MUAaU7/PPIoALsGQKOx9KrkmZQQDx0GefpUlvJHKdkoOR/q/6inqFyPLY7TwBjHNAECGSH52y/8ACVz0p5jSYAyEL0464odmACeXk5ycdKTe0TYRFYHkHHANAE5nxGYywJj6c+vrV2TzDaF0ZdhxlPM+7+FU7O2aSUMwAyM7h1xT3hlsniWbY6uA4VXB49/SgC35hWPczKigdyfm9qWSZb2JjKz5x93GRj0HpVa6v3mIQAJH3XOQKit2CK0nmqCxxgHnFAD7e3uJUyluyxk8t/hU7StHEI4lmll5XbjG2oIJ5FJQNsTPy85zRc6g1uGt7XILf6yQjk+3sKAK8lu8jsZ5Nsi8bAfmIqqwVWIiV9xHJY1KiuwBkHJ7nqaA+0biNu32oAliuCEZZLdT2Dd6e0u+PLqqBTwCKgadXUF13EcZFNeYugVFAOPv5oAcZpN2Cin/AHRjI7GrdrdWcMYSe2bB5J3/AORWfHJIFIT5ieTz6UbAww+GBBOc4IoAs6pPp07p9gjuFHQ+bICAfUVc0CHzb2Y7sFYGfOO4rJ8geVJKgbCgEuBkA+lTW11NEqPA7DKEP2zQBrWqRXFpdtPJ5YSInJ/ibso/nXF64jfZFcjjzAMn6GtiZnkQyZ64BVTWZ4hDGwQj7iyAfjg0Ac7RRRQAUUUUAFKpIIIOCO9JRQB6V4K8fMB/Z/iSdpISuyK5fkp7N3I9+1elx3CpaQhZBIMjZIrZBGOMHvXzVW3ofiXUNIQxQymS2PWFzlQfUf3T7igD3K5lxbyOhIwCeR3xVG0heaxja5+d2A3J25rl9L8b6dfIY7t2tZWGD5vI/wC+h/UV0dlexSW8TIy+XjCsrbgR+FAGraDyYgow4ySFBxin2lvK8jy3eC8jZCsM7QOgFURcmOWLC7kZvmP90diPWtu1G4KEC7Scg/1oAurbiVRx0GAQSD+dM+w3RkUR3bCMHoFyfzrStoGEI8s9enHXFbthYGTa/lNtccMeBQBzUekpEM5bOSxPTn1NZV5pIllMlxLJKB91CQqr+ArrPFer6FoOnSy3+tackq8m2WYGZvYL61zVlq+l6yGbSb2C6UEMxU4K5/vL1FAGNf6fgqbYqnc/KSSe1ZMvmGR0chXAycHg+4z2rrtSgcxkvgt/s9q47VgIZPM2fNnbuzkkUAZ2rsGtZiyHGwg+leeabZwSSySn7oGBg9/au08V3LwaJO0PVsDp0rh9IcvbGPdtweaAE1XUWbS4tLyWSCdpVJHIyMYrGqzqOTdt0wehHf3qtQAlSR4wcnHpmo6KAJGVd3FJ2GKC2cAD/wCvTgA2PmANADCMdiPrXpPhi+s/F+jRaFq7LHq9oMWF0WC+Yv8AzyY9z6V5yxyuMg4pAxRw0bEEcgg4INAF7VLCayvri0uEZJ4HKMCuMVCVbas08bbWHy9ga7O21Wz8YWqWuttDb63GgWG+b5ROOgV+273NcxrWmXel3H2bUEeKVDhQw4I+tAFeK5aJl8plBA6Y+7SXkklyz3CBiDw7E1VdWjbuP89atw3EYtnjfPPOPWgAt41JSZsYzubnpiori7aVsfwD7oHao1kcMdp6+tOEaoymUsBjcAOtAGnZR26WbLcMEeRDtY/w1mqiqTkqVPcZyfpTZmErlxwxP3aIiVdQw4FADAu8nLYPYHvT3jMaLliSRnAHarBuRESIlXcfX5sfQ1FPJLK2ZmO0cc0AMiV5ZFWEAYOasSQIpJJXYuOoxuPpUSXJjj2QqASOuOaaHJkHmjK5yVJ6n1oAcQrbjuCHHyrtPNRoxVvbGOAO9TMVkZhs2ueVKngCoH+ZhghgOMgUAdB4cuPKiZWblJMqrDqMVX8SzrJtRGLYbOfXimaSi/Z7id+WDBFIPr1pmtDEMeQAc44oAm0H/j0fJ439PwFaakEBSQWHQ+lZ3h9QbKX/AHz/ACFXzkZCjIPNACqWZwzNgDJzirXmh/3qKMgfMqjr71V8s7ck9entSISJc4Ckc8UAXy5cbyFwR0BpskghwFIJHAXsM96ricuuWbAz93tViIhyuE3Be470AOiuHjyc59y3b+lDOHkBIXcecAVBMCsr5PU7sDt7VJCURJXILEcjnrQBPGqlVOS+376gdKr3DBrklIykfZQMD8qJZZWGxX2ZP5molbaW84844PpQBdt443dWlYKF7nIxSXTG4uwbdy6NwSeCagWUsVBIKqvTH61IThCY3Geozx+FAD7pnOIyvlheAG4zRb2j3IywKxp9/njFPS5YqJJkWdlGMMOlQXGoyyBlj/dQkYIBxmgAuI0GeSqDsvWoMoSCilQB9KYhMsgUyEDjg96maGTacux2nrmgBo37fMHCnkFT96h3aQAEhT1BJyKY42nC5IB5B7GnbS2diZB6jpQBGHkAaMttj43DOAaW3XIC7TkHIwetLKVKlWQ7/wClXNHQG6ieVTtJyP8APagC6LGOPT/MYYkPLZ4Cj0Fc34kUppCj5dr3AYY6/dauxlUyW8iMMpyxBPPHcVx/icE6TAWY5EgGD9DQBytFFFABRRRQAUUUUAFFFFABUkM0sDboZHjb1RiDUdFAGxB4l1mAKI9QnwvQMd2PzrUg+IPiSDb5V+oA7eRHz9eK5OigDr5fiR4skGBq8ka+kcaLj8hWVqnirXtVeNtR1i/nMalEDTthQeoAzgVi0UAKSWJJJJPc1c0jU7vSL+O8sJjFPGcgjkH2I7j2qlRQB7T4a8fW2uTR297CLW9J4wfkcY7HqD7Vf1hkkRzGpGR0xivDbSY291DMvWNg35GvVrrUBKqyhsmQA47dKAKGqf6RYSwORyME4/WvPIWMNy8ZY4ztO3vXbzzEw7RgdRnPf1rgJBiRhnoetAEk7Fp3LZyDjn2qKgnPXkmigBKKKKAFHWnDjv06UyigCQ444GPSjGT6Z5pq/eFPbg8nLZ65oAQDOfmrpdL8VAWkdjr1mmpWMfEe44kj+jensa5rdnOQPwpFAyMnFAHa32iaTqkMbeGb0yTHlre4YKyj+771zN3pV5a+YbiF48Hrt+X86oqcHcpCkHIwcGtiy8R6hbR+T5vnwFgfKmG4Z/nQBjZPHbNSP86o2V4GMZreOvWVw2L/AEmF0GeYm2kf5NBPh2aPcxvbdz0AAYUAc8TnJ4+gpwlIj2DGK3Wi8NhAgu79uclvLA/SrMD+Drcl5otVuz2QMsY+vegDl1Xc6rjnpVw2cgRHaOQk9tp6fhXUr4w0iwsXtdI8M2uGbeZr2QyuT26YFVH+IGvBDHBNb28P/POGBQv6igDFfT7qHZP9mm8r+8YziopogmS0fzk5IOentW/aePtfD+Ve38l1ZyfLLCwXDL6dK0NV0dNQ099V0CbzrePAkiyN8R9D6UAcQ7jJVV2qOmKQnDZ556rS3BZZmVhtwegpgbjBGfT2oA6XSxCuhlFkBlL7wMc1m62zMqHgKT+Oe9JpVy4It9oIJ3A+ntTdZUhgzNnOOPSgC1oPNq4zj5/6CtTgqTnv1NZOhf8AHo/+/wD0FaJoAftwOCPahPlwQMZ7+tNXHU087dp6Y6jFADWKhsqpyO1SpI6EGOTBP5Gojzzn8fWlU5wdpI+tAFxZkmC+eRGyjHTh6V4QIwkSBlx94HPvVIH5Rg5wOg7U4MyngspHIwaALDIWO0kA+9I9uY0YE5xjBz1FItzNzuKuf9oU6W8MiKJYU3DgFaAISSZMx/TLUwjOxfnx6e1SkxFduJFXvmpY5YopN6K7EcdeKAGp5zRBYkGCefemxWsssqwjaMHGGbAzV+w1iWxu1mt7a3Esf3GlXcB+B4rPlnkkZ5JVUs5yxxwTQBuXfgzVYdIn1SP7PNb27BZDDMrFc+2c1jWkaiMFi2887fUVHDczxIfLuZFI4wrEA+2KWGUbwkhQKckMP4fpQBNcOsYDIrq54OQOar5Ibesny8ZJFXpoCY1eNo2B+UE5z9KpyHIw4Cn2PAoAZdMd3ynbkdKl04srhnBK+5wBTXUlApYMuOuc1FAxUbNw25/OgDeuJ0jt/wB2HYkYOG5//VXPeK2U6TCEQr++BOf901o22YiwjXdI69T0C1n+LiRpcKlt2JR/6CelAHIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXT2l639mxJv+ZUGOelcxWikrRxAYPAoA1ZLrhgHzxkGubJ3OzHuc1bmmIQ4PJ46VVU4U9eaAG0lFFABRRRQAUUUUAFFFFABRRRQA5eTTsYXcOmfWo6KAJCMYAI6UEAAnPPpUdFADyBjNGM9+9MpyHByDigBSAD1BowQffpRxxkCj+EAUAG3npkDrU1tcTWzFoJXjLDB2nqPeowSOc/MKaeST+dAGjbWaXdk0m8iRDg571QdGRsHGDxmt3wsYmF3DKxzs3KOxIrP1WERTtswU/UUAVbeQpKCOF71JfTmZI8qAMVXb5skjHNLKThQcYAxxQBsaF/x6yf7/8AQVo1naF/x6P/AL/9BWjQAlGKWigBKKWigATrgd+KeSVVR0x6d6ZRQAuOSMnBpxbqOoHT0qOg5oAeARkFuegzS7nWQ7ue1R5NBJJySaAHuwJIx+PT8aBlW55PYelC7sbsDAp2SwPrjpQBGwAIyCRg06NRtIIA9/SkJyTnv6Ujqc5B3f1oAkieXyyPmZAOmeKGlVmySQDSI6rnJJHoO9GSi8BiAfyoAC2Uyp/HHepYR5sYQMN2fxFRIBjKuNpPQ0+2GSzeYqkHsOaALNquBtaRiAduCPeqPi5FXTIyJAx88dP901cj3eYCrN7HHWqPi0g6dFlgSJQMAexoA5KiiigAooooAKKKKACiiigAooooAKKK2dD8L6/r8MsuhaHqupxRNtkeztJJgh64JUHBoAxqK6JvBHitdRTT28Ma4L94zMtsdPl81kBwWC7ckZ4z0rH1KwvNLvZbPU7S4s7uI4kguIzG6H0KkAigCrRRRQA5AC6g9M1oXO0MRnp29azaKAHyNnA7Cm0lFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRWtoXhvXPEAnOg6NqepiDb5v2K1eby85xu2g4zg4z6Gnar4Y1/SLm1t9W0PVLG4u2228VzaSRNMcgYQMAWOSBx6igDHpR1qxqNhd6Zey2epWtxZ3kJxJBcRmORDjOCpAI/Gq1AD6Px70yigB3H+FOGAnbJqOigDR0e9FlJLJ1JXbg8g+tQ3swlk3DkE5waqUUAO4ob0zkCm0UAbmhui2jhmAO/wDoK0PNj/viuTooA6zzI/74o8yP++K5OigDrPMj/vijzI/7wrF0XQ9W12d4ND0u/wBSmQbmjs7d5mUepCg4qrfWd1YXL21/bTW1wn3opoyjr9QeaAOk8yP+8KPMj/vCszQ/DOr67p2rX2lWnn2ulQi4vH8xF8qPnnDEFuh4GTVPTNL1DVZJk0uxur14YmnlW3haQxxrjc7BQcKMjJPAzQBv+Yn94Ub0/vCuTooA6zen94Uu9P7wrlYo3mlSOJGeRyFVFGSxPQAdzU+pafeaVfS2Wp2lxZ3kRAkguI2jkQkZGVYAjgg/jQB0yuiq2WU9qDLGBkMvPb0rj62vEXhjWPDkOly6zZ/Zk1O1S9tD5qP5kLfdb5ScZ9Dg+1AGs0kQI+YZHNCyRZJZh7Vx9FAHYxtHjl15Oee1IJwrEBvkPUZrj6u6hpeoabHayahY3Vol3EJ7dp4WjE0Z6OhI+ZT6jigDovMTsw28jFG9VJKuMdDk1yFFAHaGYKR5RUc/dz1ql4lmibS4o4/vCUFuec4NcxRQAUUUUAFFFFABRRRQAUUUUAFFFFABXpv7Nf8AyW/wt/11l/8ARMleZUUAeleG/Buu+O/iXruiaFJNDay3krX8wLeVHCJScuB97kfKvc4+ov8A7SV7NfeOrXOk6pYWNnYxWFrNqNq8Et4sROZsOATktjPoB06V5NRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB3PwO/5K/wCEf+wjF/Oulb+2v+GmNW/4R3+0ftX/AAkM/m/YN+/yftJ8zds52Y654x1ryGigD1H9pXT7yz+MXiCe7tLiCC6mElvJLEyrMoRQWQkYYZBGRXl1FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHtXwZ1CSTwLrPh7UfBmp+I9B1C8WSR9HkP2qKRAv3kX5igypBOFycck8dnqPg3QE0v4r6RorjxJqVhaWUlg1wq3V3arzvjjcAn5OAdvTgHmvmKigD7HvdFj0u++INl4Z0a1Sd/Clk0dnaWaMssxMv/LIKQ5Jx1Bz3zUHh6HT9K+IMlhpVjpdn4hvvA7NqGn21pCFF/wDKfLCbcBj8xaMDBAUkHAr4/ooA+gb94PD/AMEtI1DUPCfhw+IdS1W7sLubUdLWN7bJcEhVCbCuOBjC44ArsPFXgTRLTwR4ztNT01bg6XZ2Vzb69HptpaJOXJLm38iJSVC4B3O+T2GOfk6igD6N+LVjdeG/HtvJo3hjRLTwXbCxltdSGlwKpG6LdJ5xXMjliVKkt8uW2j71dX4h0a01f45eLz4j0+3aRdNabw8H02F1vZPKjyyhti3bqeiu59OAOPkeigD6ng0DQL6TVbyw8GyW/iu38OFrXTtT0qG3+2XKkq9wliGcA9CFK4OeAetcP+00s6Q/DtbyIQ3Q8N24ljEYjCP3G0ABcHIwAAK8QooA+utC8LaK1v4HOpeG9ITwtP4TF1rN++nRLsk8obZDcbdyyE55DAnk844xfBHhrQJ9P8AfY9D0u/8ACl5Y3UniLUbm2jd4JQhOJJyN0BVsBQrLn3r558QeJ9Y8Q2ulW2sXf2iHSrZbOzXykTyolAAXKgE9Bycn3rFoA+lfDXhnQtY+HDx6Vp83h2Szgup5Na1bw/Fc2t/Hu+RxczJ8mVwAEIIJOAcVgfH251HUPAPw5vYrS3k0l9Ft1mvILCILHcBSDEJVTKd/3YIXjpxx4TRQAUUUUAFFFFABRRRQBoaJreq6DdPdaHqd9pty6GNpbOd4XZCQSpZSDjIBx7CvQLS5+NF5aw3VnN8RJ7adFkilie9dJEYZDKw4IIIIIry+vsnWLnVv7A+BOm6Tc3Spf6eiTW0Wpz2CXAW0iIDyw5YAckYB/WgDwHVNS+MOkWEt9qt58QLGyix5lxcy3kUaZIAyzEAZJA+pFc//AMLH8cf9Dl4k/wDBpP8A/FV9DeINWvdS/ZV8aW+q311f3+maoLCaaeQy8pdwkBJSSZFAYAMeT6Divk6gDq/+Fj+OP+hy8Sf+DSf/AOKo/wCFj+OP+hy8Sf8Ag0n/APiq+gotL8L6Xp3w/n8Q6f4TtfC914ZWfVTPBapd3ExhG1o8Dz2csRynHXPNcNoXwm8N3lx4L0y9u9XGpeLLWa8triF4xDZqql41eMoTISB82HXB9aAPNv8AhY/jj/ocvEn/AINJ/wD4qj/hY/jj/ocvEn/g0n/+Kr0LTfhHp134JF/pTT+JNdi+0C9s7HVYLU2ZjbAHlvE7ScAt1XIxjORTPinpHhdPCPw4WzsotGutQ0tZXv5JB5YGeTOsUBeVj2YdPQ9aAOA/4WP44/6HLxJ/4NJ//iqP+Fj+OP8AocvEn/g0n/8Aiq9E+EugeGU0T4hf2kLHxKLTRGuo7m0DIIeWBWM3FuGSXgEOAQMjg84iHw78GjwH4S1Se58QRax4oee3sYkeGSCKYTbIzKxVW2DK7sAk8kbelAHAf8LH8cf9Dl4k/wDBpP8A/FUf8LH8cf8AQ5eJP/BpP/8AFV6V4z+EfhzSINYsdP1gnxBp9zbwW9pcaraNJqm8qGEcCfvIWBbgPuyMH1xN4g+EmgaP4Y1PWDJcpfaHf2sOoaaupJd5SWRVKGT7NGqP82eBIPX0oA8v/wCFj+OP+hy8Sf8Ag0n/APiqP+Fj+OP+hy8Sf+DSf/4qvbfGPw98I+Ifjp4t0SGxu9Ig0vR21Bl0+SGOJ3WKAqEi8rCD523csWJzleQcrw78HfCut33g6GO51uBfE+lT3cW6eJjaTRAE7j5Y8xDu6DYRjqc8AHk//Cx/HH/Q5eJP/BpP/wDFUf8ACx/HH/Q5eJP/AAaT/wDxVek+F/hH4bbw34Yv/FmtmxOvRzy/azqVraw2SoPkzHN885JxnYRtzz61b8O/CDwtd6f4D+33urS3PiSe8tnmtLmIQxtCX2ugMZLKdo4z3znsQDyv/hY/jj/ocvEn/g0n/wDiqP8AhY/jj/ocvEn/AINJ/wD4qvR/F2g+HNF+Atuz6S0urQ6/c6f/AGhG8ccjugkAZj5RYx/L/q9w553Ve/Zk0Xw1qnhjxy/izTbO6t1NlbLcTwo72wmaWMujEZQglTkY+6PSgDyr/hY/jj/ocvEn/g0n/wDiqP8AhY/jj/ocvEn/AINJ/wD4qvevGHgXw74Z+E2l6bFY6fd63p3iC1sdR1D7MheWRwJXTfjJQCVVwf7tXfir4a0aw0z4nXC6P4futPsUtrextNL0yOG60yZ4kYyyOsaMUJYNwzgjjjBAAPnj/hY/jj/ocvEn/g0n/wDiqP8AhY/jj/ocvEn/AINJ/wD4qu9+Jv2aP4G/Dy9g0zR7e91X7T9subfTbeKWXypAE+dUBGB1wRnvmvF6AOr/AOFj+OP+hy8Sf+DSf/4qj/hY/jj/AKHLxJ/4NJ//AIquUooA6v8A4WP44/6HLxJ/4NJ//iqP+Fj+OP8AocvEn/g0n/8Aiq5SigDq/wDhY/jj/ocvEn/g0n/+Ko/4WP44/wChy8Sf+DSf/wCKrlKKAOr/AOFj+OP+hy8Sf+DSf/4qj/hY/jj/AKHLxJ/4NJ//AIquUooA6v8A4WP44/6HLxJ/4NJ//iqP+Fj+OP8AocvEn/g0n/8Aiq5SigDq/wDhY/jj/ocvEn/g0n/+Ko/4WP44/wChy8Sf+DSf/wCKrlKKAOr/AOFj+OP+hy8Sf+DSf/4qj/hY/jj/AKHLxJ/4NJ//AIquUooA6v8A4WP44/6HLxJ/4NJ//iqP+Fj+OP8AocvEn/g0n/8Aiq5SigDq/wDhY/jj/ocvEn/g0n/+Ko/4WP44/wChy8Sf+DSf/wCKrlKKAOr/AOFj+OP+hy8Sf+DSf/4qj/hY/jj/AKHLxJ/4NJ//AIquUooA6v8A4WP44/6HLxJ/4NJ//iqP+Fj+OP8AocvEn/g0n/8Aiq5SigDq/wDhY/jj/ocvEn/g0n/+Ko/4WP44/wChy8Sf+DSf/wCKrlKKAOr/AOFj+OP+hy8Sf+DSf/4qj/hY/jj/AKHLxJ/4NJ//AIquUooA6v8A4WP44/6HLxJ/4NJ//iqP+Fj+OP8AocvEn/g0n/8Aiq5SigDq/wDhY/jj/ocvEn/g0n/+Ko/4WP44/wChy8Sf+DSf/wCKrlKKAOr/AOFj+OP+hy8Sf+DSf/4qj/hY/jj/AKHLxJ/4NJ//AIquUooA6v8A4WP44/6HLxJ/4NJ//iqP+Fj+OP8AocvEn/g0n/8Aiq5SigDq/wDhY/jj/ocvEn/g0n/+Ko/4WP44/wChy8Sf+DSf/wCKrlKKAOr/AOFj+OP+hy8Sf+DSf/4qj/hY/jj/AKHLxJ/4NJ//AIquUooA6v8A4WP44/6HLxJ/4NJ//iqP+Fj+OP8AocvEn/g0n/8Aiq5SigDq/wDhY/jj/ocvEn/g0n/+KqhrPi7xJrlmLTWvEOsajahg4hu72WZNwzg7WYjPJ596w6KACiiigAr6B0/9oDRR4T0DRNe+HGna2ukWcVpFLe3SSDKRqhZVaBtu7aDgH8TXz9RQB7t4/wDj1ZeJvhvf+D9L8F2+iWlz5YRre8UpDslSTiNYlHO3HUdc14TRRQBteIPE+seIbXSrbWLv7RDpVstnZr5SJ5USgALlQCeg5OT71qaR8RvFekaVb6fp+qmO3tkkjtmaCJ5bdZPviKVlLxg9wrCuRooA6jTPHWv6Vp0llpc9nZLJA1s89tp1tHctG3VTOsYlOe53ZqtqPi/WtS8N2OhahdRXOm2IItVltomkhBOSqy7fMC9ON2OB6VgUUAbnhXxVrHhW4u5tDu1gN3A1tcJJDHNHNE3VXSRWVh9RT9Y8X65q+laXpl9eq1jpbySWcUUEcQgaRtzbdig9eg6DtisCigDsNQ+JHirUEc3eoxPcSCMPeLZwJdOEYMm64VBKcFVPLdhUut/FDxdrel6jp2o6nE9rqLxyXYjsbeJp3QgqzOiBiwKrznPAHSuKooA7iX4q+MZdTfUX1WI6hJZvp8t19htxLLA23Ku/l5f7i4LEkc4Iycw6Z8TPF2mTaHLY6t5UmiQSW1gfs0LeTG+A68od2cDlsmuNooA6rSfH/iPS9Kt9Nt72CWxtpTPbxXdlBdC3cnJaIyoxjOeflxzzU9v8SvFtuNEEWrkf2LLLPYE28TGF5CS5yV+bO4/ez1rjqKAOmk8c+IZdDv8AR7i9in029uXvJoZ7WGQCZ87pELITGxyeUK9TioNC1/XNN0LWdI0q58vTdWEaX0Xlo3mhCSvLDK4LH7pFYFdFoFr5lhI5IAZscg80ASWPiXxFY+HF0G1uvL0lb5dREHlRnFwoAD7iN3RRxnHHSrg+Jni0a9rOsHVt1/rEAtr9ntoWjuIwoUK0ZTZ91QMhc9fU5q3UHlW8sjZ+6Tg+lcvQB1Ot+PPEGt+HbPQtSnspNLs+LaFNOtojDzk7GSMMuSOcHnvmuWoooAKKKKACiiigAooooAKKKKACiiigAoopyruBII4oAbRT1QkgdPwpfLPPoOM0AR0U/YdwXI+tBQgA0AMop4QkAjHPFIBjn0oAWON5HCouWPQVJPazQKGmjKg9M1paNFHLK7lgGUAKCPz5p3iDLRxPklScD2xmgDEooooAKKKKACiiigAooooAKKKUYzzwKAEope1KBwePegBtLS4475px2AjhiMc845oAbsOcY5xmkxS5GOOtWdO0+81K4WCwtprmYnAWJCxoAqkYpVRmBIGQBk10N34b/sm68jxBexWM2wt5UY8+QHGQCFOBn603VtS042sFlpOnvBagZmlkbM1y3YnsoHoKAOfp2xioYDgnH41M7tcEGSRQc7QCMY9/pV3So4pLwRy5EiBirK235h0PT2oAqT6ddwTiGaErIVD4JH3T3pLuxubRInuIiiyglCSDuxWxqmpS3N837wSjh+mD05HPXHpWXfyzOiCZSozlVOeB7Z6CgCjRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFa2keHtW1gE6dYTzIOrhcKP8AgR4oAygCSAOT6V6Tp+nfY9Jt0YEvsy4x0PemaF4IbT7iO41QpJKhysScqD7nvXQX8ZZdu0gn5jtPUUAcb4lCw6e7k7tw2c+tcVXZeP5URLS3QfNje3t7VxtABRRRQAUUUUAFFFFABRRSgZOBQAlFSGM7c5H0oETE4OBxnmgBqLuOM4pwjG0HePcd6FwEPPJ6Y7UE857+tADdo45py5C8d6Bk5wMkelbWkeFtd1cE6bpd5OoGd4QhR/wI4FAGKTuPJxT4/mPHUHIPp+FdiPh9dW0Zn1zVtI0yNfvrJcCSQf8AAEzzSpYeBrGTE+q6nq7n7otoBAmfcsc/pQBxTYPcls1sab4evr1S8iC0tgfnuLnKIo+p6n2Fa914qs7GEQ+HdDs7CQE7riU+fMfozcCudv8AULzUZib+4nmbqBI5IH4UASau0SOtvaKRbRcb2HMh7t/9aqHVRjGOwp4AZs5+Re/QGnQRmaVFXA8w4yo5FAGzokJ+zmT5fn5O4YFVvEMYjCBQdobqTXRW9v8AZrcQlTlQGZj71geIE2WsO7buLZwvbr1oAwaKKKACiiigAopaVV3HGQPrQA2lP1o79KlLb1CkKu0fT/JoAYV+bC80m3BG7IH0qSOGSRSURiB1OOB9T2q49lDbNi6vE5XcvkfvOTjr0FAFBiCcgAe1S28E1zlIIZZCo3YRS3A6nAqWKSOOJ9luHkIwGds7eeu33zU1nqd5byDyJ7hEPLRxuVDDuBjpQBLa6JNJKkV3JBY7hv33D44xnoM1G8WmRwo32maafksix7VHtknOfw71JYaRf6xq8Ntpljc3txdSEQwopZ3PX/JPbk16Nq/gPw14F0S7TxrqD3ni2eErb6RpsilbFiPle4k5GRkfIP1ByADhhqVjHIW03SLeEP8Au83JMxQ/3hnjPtikk8S6vbQXVrZanMlpPhZBCPKU47cfhVLyllKKZSIA2xS3UE8c06Zrjfsed5Is/dixnI7dOvegCtJbIHG2R5pX9FwOe+aDbS7lSKMyCIbmIO5Sfb2qQoJIBJGwUKxTBP7zJPX+mKhjdkR0WWSMEgEoeCfegAjQB1lQhVUEgSLkBuuOe1XIIY101bgu4ldsOqgAYPTPt9KgNs73iq0Z8wqCBIeGPv8A4Vs6jocVvMsc91m4CK3k+TjknhQM8g+tAGRhrWXziXFuSwjyNpY8Z6Z496r3LK1oCOXL5JPUZzwParosXa6gQ7yJpcQqvGDnHTtiodXtJrQyx3QQTRy+UcdeAcn8eKAMuiiigAooooAKKKKACiiigAooooAKK0tH0PUtZlCabZyz8hSyr8qn3PQV6P4d+D9xMQ2uXqQg9I7f5j+LHgfhmgDyatLStC1XVjjTNOu7rkDMURYZ9M9K+jPDvw+8OaW7EaVHcTf3rj94VPrg8fpXdwBrdIoI9qxDBSNcAZA7AcUAfOui/BLxdqEkf2qG106JhuLXEwJUf7q5Ofau8039n7TLZo21jXbq6/vR2kAj/DLE/wAq9ejvVXazlQuNpB4wacb1RuZZFJHAGaAONtfhn4R0eRPsmiQzED5pL1jOx+gJ2j8qt38UcSosYWOJflEagAJj0xwK0727ZmP74NJjG1Rk/Tiud1F53WTeUWLGEUH58/XpQBgapIHJRFzI+cAdMdz7Vg/ZkEx3E/KMsSOwrqLmKOKEERlQoGCv3uetcd4znOl6JczR8SMNoJOc5oA8o8VXa3msSvGSUX5RmsilZizFmOSTkmpIYxIVBbBLY+g9aAIzwAOKbTnxuO3pnim0AFFFP8s7gDgZ5FADKUdaesZOeQAO5pWiKNgn/wCuKAARDGS6jjNIFAfh+nQgd6UucZODnuat6Vp15q+oR2umWslxcydI0XP4+woAptxkZp1vFLO/lwRySSHoqAkn8BXcReGND0LA8Uagbq9YErYae4O3H/PR+g/Cq9543e2gaz8L2MOk2pXbujG6Zh33SHn8sUAV9P8ABephEm1eSDR7OQH97euEJx6L1P5Vclt/BOkcPc32uTADcsX7iLPfDYzXHXE9xdzb7iWSVz3dif51Gq5PUA0AddD40+wkjQdE0yywThzD50hHbJfNUdV8Y+I9UEv2vV7wpKMNEjlEIH+yMDFYakQycuCcHOBmlVwAmF+YZORwcUARPneeWJPc9af+7BO0tzwOcVIuxXB2yFiOxzyadJG0LhUHmELxlexoAYsDOX8vkLyTkZ+tJHtLAsGdx154xS7SFQuwGeDtPX61KCAOSMg4BJ5/GgBuAqDdGcrncCc/iBWv4VtYJbwzXIKxpwFHJJ/wrKQJI6lsYUbRj+f612nhyzFnZ+ZsEkpGd5HAz1FAE126OuYsNzlO2R6Gub8VhjbxM+1WLcoD0ODXWCSEXDYcAfeDNxg9hXJ+LmJSHBypJbIXAzzQBzNFFLQAuOM0hFTEk7QXBOCOe1M+ZSDw2Bn1xQA0j5QRz/Sn7QQWJHAzgUzOevJrcOiHTrCO81xZYBOu+1gUgSTD+8R1VfcjntQBlWlnPdFvKXCJ9+RuFT6ntWpo+k/a5gkZQTBGYedyrEc4AHOMdzxQ8sd7AxuT5QjA2wWy4UHoAfc9c1o6JcfZ7PWL0qyXkdsYYjG3LBiFYk98DjjFAGJd3lzdK7TvlNqp8gAQAdBgdenWo7W1WUb1IHQFeGIB7/zqSN47dSu1zFIoBMgI2tjkgDr6U21WJgJ5JkUo4URBTkjHXNACxWxlZFt4pLh5GEaRAEs5PAwB3PQe9fV3gX9m6yk+HU8XiVjbeJ75Vkjmj+b+z8HIUDOGJ/i+uB0yfOvg5rHgfwFbp4o8W3Y1HWmYtYadYxeb9nB/5aO/CCQjopbKjkjJ+XpPFH7SviDVI3Xwzp9notsdwS4uSLiZsdCAcIv4hqAON8Y+OoPAD6j4V+HOnT6TPEzW2oazdgG/uGU4IUj/AFS8cY56EbT18oWdxC0syid5GLu0h6885PUkk1Z1zVb/AMRa9PqmuXTahe3XM0jMEZiFwOg4AAGOMcVTYLMvDfMhCRoeQSepz6UAI8hAjxGiMzEkM3AYd/pg07Yq58gSmZTkeWMBSenBqvIH85zK8TSIQoAI5PqMcGnM7QSpJvDsBlQpPT3oAknYYdZZGCk79uBkt9R3zUENvumjEoYIw3YT5jj8KlPlGJpCBljtCbslvf2NMT5IkUTBAxBkAOSB2NAG54fjew1BbvzYH8nlFJL4bryPWp7m4svMnGmSLHO7bt0kv7vHcYx3ye9O0u2ES28ySpCjuVeVZMsP9rDdyD09KS4t7QxKk1skNukm1SFw7rnkk57f1oA1/D8H/COQnVGt0mtI3ZEmmYFBKRwxA5+mKw/GEkBs4IhOLm6VlZ5UPyjIOVxk8g96fc6xJeLuKBrZISDFkADHQ4PXsa5++uRcQlmSFZZHDN5akYwCP1oAoUUUUAFFFFABRRRQAUUV6L8Mvhtc+KWW/wBQ8y20ZG5YD55vUL7epoA5Hw94e1HxBdeTpsBcD78jcIn1NetaH8LNN022S51iSS8nwuYwuEUk9Md/xr1C10Sx0fS1ttOto7a3R1ACcdxyfUn1NaFzayzWsscTIrjDAeu0gkY+lAGbY6Zb2USwRwrCuOFUAKPYAVbaImGRFUcc/lUzkKi+ZngjBqWUxjBJAzyCeCMUAUYGaIEKCzyMAB13GtTBVFBJZ/pms1JflR415HCkjOPepjMkBVSXZ26sRjJ+tAF7fk7ZQCh4wRnNUbqxgkK4hiij4zgfe5qcSEDIyPUHtUDSuyFGYjJ/CgBJvNVAqLHGuDkLxj0rJnxkZAc5ycDvVi4ZQ4WR2IzggVVnnAXaBleS20UAZc+9w3nttwD04FeSfFe6kjmSy3BkBDFh346fhXrD3UU+Qpyuc7h0JHYV458Vo5H1oSbMJjGc5oA4QAkgCrExSFgkYyQCC3qagU4Yc49xSHJPNACUUtKEJXcOecUAO2DaDuGT2pxXO0gEDoaRTtxkA4P50ZIJyOf5UALJsBIUkr79aYSfU4FG7OeOtdv4M8N2y6a/iXxJHJ/ZMJPkQZ2m8kH8Of7oPU0AV/C3g8X1o2s+IJxpnh6H70znElwf7kK9Wb36Creq+K1jhmsPCVr/AGPoyjHm4/0mYdy8nU59BxWN4p8Q3/iTUPtOpuuI1xBbwgLHCnZVHbFZBdzHIMAAgL17UAWY5lKSyAgygAbz1/CqccO4bgcMPQZAP1pyRMCQwIIHz49KW1w0hXgIxChT69qAI2YuwBxuU4znk1MYFQ7gC3ZMHqfetvTvB+q3MrbIT5SjLvngVi6iTb3AhQ4WM8EGgCFGwGMiZLHPA5oYEsSSFYj7mMcVJBhlbfjgZDd6Y58xSrkFhwr+vegByPtQjc6qeVx/F9af5jELGXcIOgJ5H+TUfl/LknegHAANMUlygboOgPSgCVgNxkUhTg8AfofekX/VbiQ27hhjkU/oVZW3c/NwTg0bBCuGJ83+FAOB3/GgCaya2ilRijZ46jgiu0srlliKwuY4V+cITjfx6VwCu4YFgSWOMHjJ9vauisZSp3XbbmUAqF45/wAKANqX95/r1LcdAeMVzvinP2WLMjPl+M+mDitgS5jMsZ/dleWJwd3esfxUqrbwiPBXIxg57HrQBzeOM8VIVAjBDAk9vSkiJRg6n5gflx1zS58w/dUd+BQAhO/BZugx0pnenKu4gL973NdH4asLSC2bWtZQyWUTlLe2/iupsZC/7g43H8O9ACppH9j6WuoalG322VFktbVkyApPEj+gPOAeuKorLGLndcSecZF+aVznnGSPYVu6pfTaitvC2Lm52+bPKefNkbkIf9lFAUDgda52OMYWcsqRhiQgbkn6Y6UAXPJjhtihfmYpLhhjdg9OPXPGatabqkFhcXJeMvYXCmKZCepIzlfQj/CqelwLOLhAyeZKhZVfjPoAOmeuPpTLmGQ2JimRUa3O11bCnd6570AMQ5kMNwkh+YJGXONnPH9K6K28Haut6tqtkLqRQGVlHyD13f4moPBnhy51SSG9vpFtdMiP+tkXPmeoUdSfevVdJ8Y6N4f1i/vJGfUJJoREICpXDcDJK9unJGaAPG/E1rcaVeLpl2ytFDhXWIjG4dcfT3rL8xZnUCN2QfNjkhB0xj8ua7208F3XjnWdSbTL6OG5gLSyJevs3knpGOSfxrl/EGg3nhm9msLy6tTcAYkMEu5cnHylh+dAGfdMbgyKVEMafMg2Adf89arzhEwjSszIuPmGV9sUxgsXlkMjEg5VgeAf85pcJHlgQ4B4IB5Ppz2oAR48xghgVySuG4x1x9aWOQGMKoDENznABHX8Kcsfmgqq5IOQUXAXPUGkjg34EYYzM4VE9P8AGgC3aIqmMx+U0koyqu3GRzk9hz2prypGT9pRGkx1UYyCcnnpz0zV+0gOmlkcRvdTKAsbxbiM5ySOwqMtHOPnUM+CFXYPLBAwTu/yKANjwrNbrG1vc2CyFiJICjbmGSMnP+IrR1W3vt00sRAwubeI9QC2HIyMknFcjoxAuwbeacSgBVESde5xXe29wrWEcmtNtIdfLiVfnKDPVhkAnrj60AcubeW3u52gQzpBGG2hS2CeoJxx261na1FG2mi4SJ4CswhaMgYLBSSSe55HStNLx5NQeY3DWRkDPKo+469Av6VS8UtbNpeki0u4p1iRo2CqVbdnJLA9TyBn2oA5qiiigAooooAKKK6/4W+DJ/HXi620mOTyLcAy3M//ADziHUj3OQB7mgDe+D3gFvEly2qX8ZOnW8gjijI4uJuoH+6OrflX1BBYJp9pFbwRrtRdoPT9KZoNnDpekwWltYLa6dbyGC22jBZOnmH0JOeT161dMb4Ik+Z8E7R2+lAGFrcLGznyoYph9pPBAwRUoXc8MqgAH5lz2yKvFPPgYtgxsMHI/Q1xfi3Xl8ILIHm+0RTMBbQH7wyvIHtmgDa1m6tLGwnu9QKpbxKdxbjPoB6nNeNS+LdU1TUF0q2kEVowDMSN7AE9N3pTr3Vr7xXeI2tBo7OIF4raMYUnpk9yfQV1ngGwt5Irp7G22jzADNKBjAHQev8AjQB1mmz2/kJ5U0cuxcHLAMfXIp105eUPjI5Ix/CKzb7wvpc2pLf3Nvvusjc+SPpnB5FbDKI/kThVHU+9AETqpVAcnntyDUMxVQwKABjjANVrlGRsR5IHAO7O30P0pxIxkqcheGPrQBDIDLnJCoMYFZWpXSNMlpG/lF1wz+gxWjezG2tHmcogxn0Arz6W8nuNVMw1RPJB+aNFwSPTPpQB08ckEQRBwqg5bHA//XXnHxStjIftBTYQPlAPrXoKTM0LNCMwjjLrgH1AH9a5PxjaC5skDkKZGIH0oA8YpyoXICjJJwAKku0C3UiIDtVjjPWo4mKOrKcEHrQBb1Cxa0jic5KuOSf73eqiHHsexqW6neYqHJIUYGTmo4yAM4zQAHOc4568UZzjHXuMUufu+o4Jz2p1vE0tykMYJldgiY7knAoA6TwRoNrqlxNfa5P9m0OwAe5kUfNIf4YkH95v05qXxv4jbXJImiTybccQWw6QRDhFAHGccn3NdVrer6b4OsItAtbSK7e3GbnzPmEk5Ayx/wB3oPxrzK4uPOuZZyqIzuTtXoufT6UAINoI3KSQQpPUVZtQbndBIfnYbU44HoPbmqiuTIFLA++aI0kkYbVBIIXOep7CgCTyLi3uWgKMtwpwy+tdj4R8NQyM2p+IbuGytYTlFk5aVj2ArYttPs9J0m2utXlZtVkGZAygmMdgc1z+qu+q3PmRBpI1baFJ4I/pQB2XijxppaaSbOw82dpBjCkKqr/U15yun21/bT3MV1FbFDuMc/DEe3rUWqy20EvkW0YTy/3bZJ/MVl7mG9nbcScZJ6j1FADwRGuQ3I/i9aUqybWQgk/Nu39KjVVOcMpYjqfWpoYgpzuwSOV9PrmgBsSBpONhB4Izgn3pZvLBIjYbAMkdcn+lR5RGZgOvAUNUtvH5jL2LdcDIxQA61UxPmRCh4xgZyKjnRWcsWJZTyGzyPQVpNH5CMtvcwmQYBXHWqFwJVunaQqD3AOaAIUOGZn2kn7u49KlSfht7HdnAAJAx9aiD4OwbhFn+LnFLujbaeAFONoJ5oA6G1nJSOMAFhywPp+NVPEzZghUrt2t90dF4PFQ2sjLcKy5YBdwB7/Wq2qziZEAbcQfmYnOTQBnDOMjsetGentSrkDqR6fWk64wSfagC3p1k+pajbWlsArzOEyx4X1Y+w617Tp+rfD6H4Yai1/bQXWqNHLp2m27ruaHC5E57IzMdxbrgKB0rzbwy66Vouo6iHCXl0p0+2GOV3j53B9hxx61ho0cdi7RyMHYCMrjGfXPY0AX4kVdMSSdARJGUSYH7hB5zgdxjGfSoNOtYJiUknEYddomfhEOOhz296LZXFs8ERnjcNieM42kdsA+lOl3YAMkStHlCzNw4zwQOxoASC4ea5QAhFjPyOpwNw/ir2uz0mCx0zTdf1TSIponhX7Qksiqs82MhsN145xXA/DzS4dQ1SG5uFE1tEwd8gYaQfwgn1wK7rxv8QLO/1PzL23U20CrFFCJBy/8AFuXGCf6CgDn9c1aG8maRbIowkYCKPaQADjIK8YGcY4rI8XR2elQwi2XF3L+8d1bIQkZCEjq38q6/w7PottoyR2Vn9qmuCZnMrbY41ByGb6g9PavOPGOrx+INdvZEkjRnY52f6sqowNoPJPHWgDHs9RvDetewySi+5DSByp575zxzVLUJZZ7yeS5O6ZuWI559TRIyKysrSkZwxKhOnpjNMijkaQNHt45z1/P86AHxtLKEEgG0/IrFep/x96vWriziLLIjxLJyhI3HjB21WWESBjI6CTO4juTjhdv9aluplmRQYkREJKEnlx06+lAFJ2JPnKRucnABJI7c5roPC2ky3d3G2nvZTSL87yXDtGsQ9Se31rnt4ecCMYXopbqv416BaalpMXh6HS7O2mBVSbmXzW/et1JwvRRQA/UZr+zs44ILPTbozB0eSxm3yFieN2ecenauOnSNN0ctwzM3VFIIXHGD05rS1G9NlBZXFkFgaVTIqpIzOqjgFs1jPeRGeJp4RMi/Ngk5OeoJ/WgCa2C2txELOZWdiu1sbwDnOcY4IroZ9Ye9hEDoWiVgrvAOA3Zl9Pf61U0/w7NqVo0+gzGZFBee2Vv3sfoAP4vwrTsbiPSrfbdwB0mBkA3bXfjjJPYelAEHiazWG8sku/LigYr5hyQ0vGQxXnAHTI6ms3x94kTxLfQT29hFYWlvEsEMMagDgfMxPck9a0vFNr5t1FbQM6SwxASyopYyB8MB9AK5XU4YhbxTxI0YY7QpOd2Ore2T2oAzaKKKACiiigAr6n/ZZ8JJaeHZvEM6hpr5mSMY5CKcD8zk/gK+c/Bujy674htrKGPzM5kYZx8qjJ/lX2h8Dri2b4b6XbIAlzao0M0TcMrhjn8+tAHUXcMTIVfcPY9B+FZrJnKquNo4BrTnu7cyNHLPFG2M7ZHAJrH1DU9Os1zLqFqidiZBz9KAMrW7n+ybG6vjH5iwKZWjLYDcdPrXz7b3Nx4y8Q319dQu8qcQqpykWTwDn2/xrofiZ45fVb+90uO6J06MMU8tADIccbj3ANZ3w/8AF2m6D4blguIJPt+Tlo03b9x4J9PSgCj4luf+JlaWVnCY5rdSh2ttDfT9a9U8KRJZ6JZ27REMIgCOgHrXO6JoLXt6dcvYlW6lHywAhgF9Tnua6151toi0/wDF05xz24FAFq4mkSAPcAiNSSGx976VSN004yBhG53txQmpXDIkYTdEQQocgcfTrSOzG3QGNY1HAAwMigCIKC+JCU9SvenyEHAyc+7du1QTSMCZOWGMfuxy1cxeaxfXFy9pbWkyxEt5kpXIx6EdaAHeLtQtrWON5J41w23bKTsb/gI6/jVHR5YNQV7ghrpxkDEOxc+2avWXh3RrmDzbxTc3AJYh2K7SfRSaJtI0/T42Chkt0+YKzHA9frQBMsLgF3Z0TOSp9PasDXjBE7RRuSNgK7ueT6Voadd212u+xuARGPmTJ/SqOt2L3MZjaEl8ZRgcHP8AWgDxq9ty1/eNnARGOSOpqhbxmQbFRmZj1HYCt3UbWe3GqPPjeBsC9wC3JP4CpNJs8WCKisJ5cjg89M0Ac3c7fMwilUHTJyajU4H9aJPvt1696VSR0oAczZTGeB29K7D4bWiRXl7rkqq0ekwmeNWGQ0n8A/PmuNHJy3T2r1rwvp6p8M7uHcoe8w7MF5GTx9eB+tAHlV3PLdXU08zM0sjF2Ldck0gyoLMAeMYz0q1c232W7eJwwdMjevzDOe9XNP8ADmtamkrWdq0qqhlb5gMqO/JoAyAOQAu8dcV2PgWxkiu4dVu1WK2gfEYkX7zew/rVbQ/BurahdROYykJcZZTk/hivU9G8L3Ec8UtwyrFE2x9/AODyBQBxviLxVZnVOER8jbM5AbJz2FbF3Pptj4YF9Enz3AbymYAhB/jTPEHgrw7a39zqMVzdGHJkNucBRk4IDdSM1wWqajNdytbuhhsIv3cUQ5Cg9Me9AGNK/mTsuc5PLYzxTViiPzOfk/VqmW2kQEyqADyGZu1JKuFA8qRjn04P4UADtFDCViADjkv1PPpVdd7IxbcUx/epWw7rtCgA4AI4/GpUaMSbW2CM9celAEMcfzjdtKj0PWt/QrSYh1WMs7d/T6moYIbFbV3ecq/PlBVwGPue1VTNfFS0d0cKMlVfBBPb3oAva/ZvCrKJIgExiOFOD75rFwgAZGdyeXGOn+NL5tw0oilldCeuTirEdhOytMjKFxk/OOaAKe4sxLnMmMEetKYm8wKyFQv3uPu0mPnK/wCrI75qe1uJEmDZVtx24Hc+p9qAJ40KbnYMyooIbPGf89qp3z7yCSpbvjirTpKkTO4yu4sQOh9BWbIxdiT3oAQdAM4FB4GMfjSVbsVkNxCQFWIyLkyD5Mg9z6UAamvwRw2GlpCXEMaESZHWQ4LEHPI5x7YrMjhHkeaxl8kOQCoH5n0rV1/Uft8oZhAGaRv9SR5a5IyF9Aak8IfYJtQjg1ElIXfDFI95YY6L2HTvQBnzK7wxzPDcqgyI3VSAzfXHXFWdJguNQ1O3SbhEP/LyT5a47HPU47V6zd6Pd6Nr1jY+FoIJ4dXkijH24gm3JP8AcB4GDyccVn3dj/Zep6hpKR2/m2M7/abiUmQYUnAUDp9fzoAhk1SOOY2FoYjZRkebBkHC/wCz/dOO9cQulC7112tBNdW29nYsm8QoTjLnp/8AXr1Dwj4K1HUtFvFs1t45LwLIhC+YzhckAH/az17YrL1C21Pwvp9wuoxSWME8DxgIqEh1bJDDPPOaAMPxd4jhSwttD0m2byrZNjNMmPNIHLeuD2FcPJaT3Iia2jeWSbJKIucfQY4FTfaXbA+1/aCXDBHYjaQOuT2xT0udRs5PNLGOORTgFgcgjsfWgCFbJobQvO5VgMBU5KqTg7vSq4htnnGJGEKYDH+IjuQKtRajfi3VI3ZlKk4Bz055Xpim3l7dXUYL3UTADJ2oEwT24FAFZonF6zRBwgbA2cMAfb6Vft7CbUd0UCqWXiQo2ew+Y+3sKgyVjSWCxlMRUqZGZvmOOW46damiuzb6fJEmDvZSrBsbQvIwfrQB1GlaDa6Rd2ct6FvN7bkiYDy32+2eehobx5GYJrN9ItBbmQvEpAUxHPIBUdOlcVLJN5qNNJ5gmALANuOM9K2dRuo5IrVZrSMPHD5art4b0wBg5oAuX2uXV9ezu0J2umC0cW8gY4GMY/Kuea2eGVnlt7gwHK75UK49efWmmTypFMI+zS7vmUFx9Ac+hrpU8QvJp39mXo8osxcl0GzJHOc9Og5oA5qxeZdSgktJ5VuFkGxkJ3Aj7pGK9I8Q219aWc/9s3A1LVLmAXHKbdoznAPoMegzmuCttTS3uklhgVSrA5j45/2frWne61cX32ibUVIYhpIwRsyc8EccjgDFAHT+Hm8rwnfX/wBmWW3d1cyMqlnlA+Zef4R2rzfU7r7VMX2bBk8dcDr1rstVu00rwfb6dIXa8vV8zeMfIM5bIBzkk4z6Vw1xtySpPXHPf3oAhooooAKKKUcmgD3X9k60sm8U6veX+1jHaeVGpGcliCf0Fdz4+8X6boOqTpoizR3suRKvCxqccEj1+lcp+zzPF4c0HWNQitkvdak2tHbP8vloD1z6n0rodL8PHW/FF/r76QrM0jSw210TtV+uT/eOefQUAcxrtl4o1tYbi7gzBtDeZO4MajHXBIri7I3UGmfO6tOkjbj5e4DngrngCvbdfjivJ2m1rXrKORm2yxW489zxjaFHC/hXCaxY2RkSy0q1nmlBwiOd0jD6Lwv50Aef64kzFJpImww6gZzkcmrfhfT3v7+KzgYRJMRlbk4V8c49Tmu91DwpKtgGubJ7Ga4kSCMOxxGveQ4zhR057moLj4fXeiajDJNejUvKAl8pSAAevB7/AIUAenWNg9tCgeMnao+4QRx2/CleC2dmDJL5mQf3n0/l7VQ8P+IIdRjMQLRSx8FJSPzB7itSZpAchoyo4yQf0oAqCCCEkRQBSD/cAyfWo2SVBkJhzzhSCR7f/Xq9uDAo4Xr/AA+tQyRqxUYbcvYHFAGWH87fEd4baRh8oQfqKkgt0tQwUAOfvY/iPvVXVort5VYMgToSOTtrBmupLMCz0+7e8Z8ErEpMqDuSeg/GgC9MdMvdTaTa0zouzcVIQHuM+tT/AGeKFNseQMdByM1zrTXemSQx3gu50uXISSQgLH/vDpzXQ7HSArsi2khSFOAvuaAKcdqiBwqhdwOcjbuNVzEqNI8khUKMLjkkj0q9MzGZNrKjcj6jFZupzoSE2lpD1z0FAHnPiuOJIrx1bczsqjdxnPWqduNmlajczs6zQwFYUUY2ZwNx+tP8bX+23uIBjJdeR68k1j6LO0nh/WxIWPyAgls/WgDmachwe349qZS9qALERj2ElSXGTjPBr2r4c6PfeIJrG2s4DFaTRqED5CsMfMcemAefatP4P+E9KvfClrK2mwXkkxMt09wnXn5UX/ZGMn1r2mS40vRrJ9fvp4IZ7CMhET5IgmMbcfpmgDnZPgt4U0rTp7zUnuZpBHhmQgc+ijnrWV4j8HeBdS0aC2VfLvVKoJWvBE0aAjcOMg/Lkcj8aybf4p6h448Ri00jQbrVYIgWENodmB6s7EBfTNVdXn8WaddtCdH0vwpps52S4VLmds9yw6mgD0c65oGlaeLHwxDB+6iBxbxGXbGox988f1rkrfWoL1THMJLdWYsuR19ya4m61nw/4csZLW5u54g+MRxMJJHB6k4OBn0Jqx4JibXNB1+9tdRm/tAg/wBmWJYBxEpyzeXnqeaAIvidqjWOn+T/AGf/AKORgzZ3EDqO3Q14fczC4Id3cYHHGRj/ABr2zV9NudU8P2a6ndeRckF5YJPvlezf0rx/WdMksbxlUApngnnd70AUpRIxUvcrIAMD5skDHSowTGhCN1HzMD0HpSptPyhHEg4+U5pJFUNjk+vbNADopA0mHI2MMDdVgLIj+a8Ue37xZVzj6VTxGQoB78kjtViOXy0G4PlRxn+tAFeaUy7mJOSen9afDE0i5aREGcZY9TWhHam7QyeWkCpjlyMfgO9Wbe3t74i2je1ilzyzJkEfX1oAxVYkyK+GJ4DdcUA7iFRhwMnHQ0tyqwSeWnDJ1bPWmqQrHZySNvX86AHBCz/eJ7jPBP4/hTrZ1SZeDuIwR2FQDAIwW25HOO9S+WxGwAt3yOooAs+aI4BFuLIW+cA4zmqMqYG4A7CeDU4jHlqdyKQMZyQSfSkvWDohGeOOvX3oAqdq68+DtTfSrG7lljSO+b9wJHCbYgceY4P3QTnHrgnpXKWq77mJNpbc4G0d+elez+Dp4tYv7zUb6SXUNTguM2GntEWLoFx8yY2gdAMkYxQBzFh8OJJ/Es+lC5MtuYw0F95TLC5/3j268+1a0nhW50L7VaeGIpNTlaIibUoY/PUZ48qPHyqf9s/hiuk8S+Idf0jw8LrXtIQXF4jkrdIMqikKrKqnao3Hj1rmPByav4pMVjfeKLmDT7yQtJpmloxmkXpxEoCgHplvl7mgCwDbaPYh/EmqxQapG6gRJcC7utg52/L8kZ9zk10vhj4gpo/mS2uixJBHHkfa5x587k5y3Bx7gdazvF3g3SPCrrPJPaaNE8ZBtBN9puxFnHmM3Khy3G1en4VweqWUkt5Fb+H7e8Mtyvnb7x8Tqowdx7Be+fSgD3HRviL4dmh083lw2leSC73KEhd5z8q4OSBn7uOnNZ/xAh8Hz+EZ08NX8erao486SSQkiJGJJlw3I5HQEnmvJ/7C1Gzv7ezibe8X+kvdHEsTgdML2XJwSetayxaXZ2CtLZXIkkh+dtm9Ys8/umJGVGOFPPNAHms0UkCL5sUsZJywcYVvQColVZJFVSACMndwAa9x8aeGNF1HwnoVxpGpQztLCHkTZmRDgZ3oDlQORxn8a8v1DQorOANHcRPLG+HZWOCCDt+UgHPr6UAYjbolDxSMoI2M20jb7VEzho0jBJIGAEGAT7+pqdbV4nkjkVA+NpMjADPt61tWXhLUbrTVvIZ7JSsgiCG4VZCx6cHt70AZdnfGFZLbdLDEx2uofjHcH8cVvHQ9JsLaeHVbxDcyKrxmI7lizyMke3aoofCF5Jqf2WNUunjB3CM7tzjqqkD5uh5rb0nQobW83eKFa1VgwRNynY4+4zr3GeCKAMHRtOntdRjaC5s03MQHLK6hcjnceM81r+IbdpNXeWaO4nbbt81owctnjG3gD3rH8Zaib3U7mawJjsC3kiLYiKrY5CqvAHvS6f4lS28My6He2IkJuPPFyuPMRgoAAJHTjpQBl3Uzx3Mi7VjJcAZT5hjtk+tVZInYyEttYncEZsFh24qW6895AkyDK9w42kdQM9KFLHypiHhBUgSZyTz94+1AFSLKSocAOPm+fge1dLc3bPaJd3zB7hVHl5ORgdCBjnnH0rnXlSSXdcO8i+qgAjn/AArpvAekyax4g06BS1187PJbs2BtUZ79TjJoA5x5Znlka4ncTsCDuXOM9s9u9V5YxEm11bzCchs/KRiteWKOG5uZ57iOVFckBMjzW6rkVkyBnhMpV8F8FsfLnr1/pQBBRRRQAVf0KybUdWtbSNlV5ZFVS4yOo6iqFbHg+6+xeKtIuOvl3UbY9fmFAHv+jeBrSLQCkXjm30a6vJHU+Yix/aAvXaSwYDPGRXdW+sQr4NOheHTc+JLyOMpLeoCIWfvmQ9QPbNchq2geGPFOvadf28sh1Kd2jntVkDCONeSUQ85OevQcmui0vxVrwu/7P8PeGTHo6OYj5pWOOCNSRkAcnIGc96AOR1DwffeGtEk1nX9RZUjkQPY2Sbh8x6s3X+ldJpmqM8EU+h2iWbzAeVDJHkle8jnt3+tdj4mtX1Dw/JZwEedKwDMgHygnJ/DFVn0q2NobIqW3ALLjhmXHegDAsNav7vz4dPZbwq2ya6Kfui38S5PX8Bio28K20zSErNbvICu+KYggcdB2rq7W0htU8mKOKCJVJCoMKAB7VVSZ3jLNmHvtkXBxQB51afDm8025kksNWcjnaZ8ll74z3/KtSGHWLFAt6RKUAPmocfoeK3tQ1izsgftFwzyHosal2JPfC1QttdkvyRBo2pCPoWuFWNT74JJ/SgBk+oCGJGafykb5Q7KNpYe9YtxJdqXe41ZxG7naphyG9Fz1xXRyZ8lWaBTg5O8cLWNramZMoyswO5QvUAc9f60Ac0+j313cStLfTHzfmSRQy8ehq74Z0dLBpJXt/LuT1LTkkn3H59ai1fxXfWVoqw20CgMBid8H8AO/1qyurGeKBhPYR3knJSMmR/YYFAGld6hbmMqYpZcdAISVNRonlxln+VJCPlKbQox0xTNOnvFthJfl9xJG3y9vfrU8gkPAVgH6ktkUAYNwyxyyHdM6tj5D1H07VavplksFVWW3YjJE45Ix+tF00gbIePjjB/iH+yKlZIry0NvcQEM4IXfgZPtQB4JqWoRvPOjHzGEhVW9evNOlvJNO0iWzWFNlwgDMy/N65HpUcVk0PiO4tmC5jkY8nHQ07xa4e6THJ2gnA4FAGBS0lL296APu3wDbad4f+G2jLYp5jmzjZii72YsoJ49yf1rz34m2/irxJdDQ9K8G3tta3gELXZYeWQTy7c/Lj0NY/wAC9c1R/CD31hEt/d6UHhWzZsebhdy89uMgV6T4mn1HxvqOmeGy40+0hhW819Y5jxlAy24YAEgkjceMigDlPBWqeE/g1pN9Yya9b6xq0zjdZ2Ch33j+EsO/1Ix6Vm6h/avxl0S81O5ltfDmj6dMdzBiZDhcsH6c9MGuT8d+EPBelui+GtW+2+IvM+eG0IEVv7n0x0AJz61geEvHTeDtB1SwWE3Gt3U2VmmAYRKO5B6nOaAF0XwrDBNJ9v0trvUbkf8AEts9zeYFBOZJF7A9QD6VmeIdRbw3q5htJYYtWt2Vjc2h3FG7rnpx0I6Vztxr2py3lzeXGoypd3AxI6MdxX0z1AqhbweerNG6KVyxZ2wcepoA66P4m6ub9bq7SzuZ2TY0kkXOPw6fhVzVfHOlatplpbTaXHDOu7zZAowee2ORXBCC5XMpDbuvHUD1+lSQ6Xdz4KRsEz1Y4zQBrXNraXI/0J1WQcgrIGGf51npZSgsvkyTHOFYLlfzqe10lopHMl5BCVHJEnQ/hVaO1cStELw7jwdmTuoAsmFYWWOLTfMIALPknHrWol7Yw2+4bQ5+Uq6Bgp/rWdaC5tm8lU37hhdz8HP41csfDD6jdtDdXZt2XknYW/AYoAo6lfrcwKnnp5S9AkeM/iayfs0yHJ+Q9c5xW1daKIpzb2873KLkHZGVBPqaztRszbMIl3sQPmJHQ9aAILjKDZKEeTA+YHPH+NRqwQbECsTghuuDTCy5X5QAOozUi43IVDA4+/05oAkFvMUEw4bqBxn61PYIkryeVuKqNxLHBJqqfMToSwXvnp7Vq6M0chkjwiNtBB6n8/WgDO1FVWUKn3QvQ/zPvUNw6GJI1QKV6kHOauXNuzBzK2SuSGz1FZrggLnoRkUAXvD95Hp+u6deTpvht7iOV1xnKhgTx9K9VRjPNrmiaba3lx4hu7pfs99bIVMVu2CSQh6YYDHvXjYGeOB3rtNNeebTrC50qa/j1Hb9hkFvNtZyxIi54wCTjn0oA6+18GXMr3lz8QfEeof2FYSxWSxQym5murjGRbxLkjcAeeuM/Uhk3j9oLm58OeAbK28IWEh8lpH+a7mbJyZZjkr9M/L6111/YeH9X8VQ2+oXix6F4ciisbPSIV8rF24+YuwOeGG53H90ehzyWq3+lPFcaN4OsrHTdJtJxDdarcDzJ75s9STyIuM7R2I9cUAS+AfC8eqo4bT49ee2Vrz7Hb3Cxwh87RJNK3zFTgnaM9DxzWVrWuWkso0/T9QhTUbh2fVtXCbAqDgQQDqIwOMD7xx2qhd+J5LDw/qXhbw5LHLBe3BnnvFTyzLCB8sKKeiA5PXPP1rnpbPyw8drZw3VwuPNaFjcKAe/AwOeDQBuatrcM5bTfDNq9np5YFJZ2/fMQPmLP1JP93oK5fU7yd5d0s0zybtx80nDY6HHT6Yq6LRopYZtTtJIbWOXJiQ7W2dWAHp79qp/Lqd+wVEt1LbYyGJSNeeOevFADN88MQaG6VJDHsKrIcgHHHtU6alceREl5dTNBu3EHD5/Hr2q0tvpXnMby7jkt4son2eFkeUjufb611th4y8N6bpZit/BGmXYPzPPfoXdW7KP9kYJP1oA423vLa58i2YAylz5k83KMD0AGMritFxa/wBqR6bbS7VeXcZD1UH39Me1Saj4rur8C3isdPi85QFW1gGUT+4B1/HrTZfDvlXfk3N/aQGZd5MnyAD72B3z0GKACWfUNHu44tMCrdMA0bJK4YZHJHPeqkl3Lf3NxFeytALg7pZWBZS/Ugn196u27WsVyryGWW6ibZE/mEhAOQCBz9O1el+PvEV1ceGNN0iI2NvHHGs0ghiV5Y0I4Unu3BzwKAPHRai6YvYwyyRr1UjOSo4OT2z2pizzW1zHNLaQmRwQysMiXPHQcDFbct9a6YhMNybuS4hLIQoSOHJ52juw71lyTpdqUYYlmYEyZLBATgfj/jQBmXvl9PIIduQVbgdsAelJFHLJGYopEOV3FR198/SpzcMlyFcRAq2A7A/KB/U0RtFNcqQfKG3MgXKh/Tn+tAFEGHDBi4XsFGefXmt7wJqkml6pJLDku0Ui7QxBIKkYHvzWZqFkYrjEb2x3nAWNw23Hr6Vp+BtGOq+KNMtvNQObmMmMH5iN3IHvx+tAHYeNPBq6L8PtN1aeNJru7UF2VseVgcDHfGeteZzXDyWqoznG4ZXtwMA+nevcf2hp0Wzt4rW3KW08pWPLZKhAN3GOmSOfrXhk07SRqjHO3AXB4AAoAr0UUUAFPjdo5EkQ4dSGB9CKZRQB9Pfs3OviPxtqeuzhTNHYrE6jACliBwPopGa+gGtbezZmijRVfqoHWviv4C+NF8G+OIZrt9un3S/Z7jPQKTkN+B5+ma+09SkFxaK0UgMTgEMuMEHuD9KAMvUJoxHIsA27u/T88Vx0dzYzzPGL2eK6iJDiAYdiPVj2rsLlRFujACr0rjNWjitivkSRwHBOW5z9aAJr658uzka3S8muFUmJPL3F/btnmvOf+FlAzS2esaZdQXEWVKRqXBYdcj8K29T87V4sRarqEZACj7PiMMSP4e/41paFoVpodoIrOFUyAGbnc59Wbqep596AMLSten1C6hCQS2aNj5fs+GI98jofWtG616C1mfL/ADq+xykUkmG64OBWxkjl5fmPXnIxTVX5GIwD3J/z6UAcvqEz6q48y9u548eYttDH5EZXtnu34mrtjGzRqCjpGB0IGfoTk1elQbJJYhkgfe28Y74FZDaswufsoYGWWMvHt6H29qAJ76wiuZYg9ohWMhtzkFfzPU4q1Db2lvu+ywwI+3aSuBu+lZJ0zW9QhRLuZLKHkkW3Dtjp8x5rWgsvIgCtJMxXGC5LHP8ASgCsfMld1u44pIiML5RJ/A56VQj2CXZbWTDA6l/lIrVu1kNsxjAUg5DZKgH0J9KzIBdRQtLczQ5Bydg4x9eP5UAVbuB3JdYoSRwPm+7WPrc5sdEvbtwEeLBR1Y7vvAfmK27ojKlZVCZJGVxuJ7Vg+JogPDuo8+ZJtzy3HB5+tAHmGqNFD4rld1LFkDEd2J5/Pms7xHCsaJICTLI2XAIKrxwoqvr8pOrGZHfcyK2W69Kov5ph+beVznntQBXpw+6eBSU5cd84oA9n/Ze1sWHiu+sZZMRzQi4RN2NzxnkD3KlvyrP+KHxD1WP4meILnw9qUkdpPLEAUPDBI1XB9sg1534Y1ibw94gsNVtSfNtZRJgH7w7j8RkV1fxO0O1tfEL6laPu0nV0F7aODnAcZKn6NkYoA5OO9upHcrlJXYvJIpPJ9auaTCZbqQh987DcuOpbtjNZwxEp5Pmgn5R0UetWdLvjayPKmTIh+Q7uB+BoAt6hMLjJubCaV88yucOB6YFW9B8Ivrk6w29wLZ2OMTDAA9/8aqSXVrcws91Pc75CCABnv0rpdM1/QtEEU0Wi3N1fxLu8y7lGxW7HA6/Q0ARXfw18S6ZcywsFAIwZUkBjI9zWHq1jcadvilv8yKNuzP3R+FN1XxPrGs3crteTpG7ZMaOQuayvMdotzTNIA38fPP1oAkh085/fCTb/ALMZJx61swRWUMKw2ljdyzHgzTkKoPsB2rJgvbr7QWFxKEUYck55q1LPJcpFEspUlg4LdR7fSgB0tqyozrHIkiHIxIAp9TVyG/voocrcnzTwNx54/r71Ta1ed0d2cEtgknj8atRWFtC5/tC6G1fuiEZYj60AZFxrOoEPF57hGP3QcfhxVdlkY+b5kbEcsmauXQskb/RbZyo+YrIck+2ao7UnOVQR/wCyp6+nWgB5d5IywhiTPTA5NQrIVIKEKG9eR+VSOjW8assgYjqAaiZjyMJl+/8Ad9qAD1YOgbnIx1/CtexhELwsqYaSNnPOO3H4VikKwAB2sOuTwa7XSbZ5lsjdY8swcljjjPpQBiXsE00KRttZwoORwce9YbrgZyOuOK9DfSI5i8kPmFixK5GOMevtiuAvY/LuZRxgOQMdKAIBXbfCzV4tP8SixvZNtjqiGymkOCsZb7j4PHytg5PTmuJFOU4I5/8ArUAdD4qu7+78TXrT7Y7uZzDM0ZwHZTtY/jjP41QcvIPKjc3CkbhhioPPPH4V2vie0HijwvF4rs0ga+tI1s9WgUBdhHEdxjOSrrwT6iuKuHhlaNrUtH5gy6gYC44wMc0AS2jBbqO5heJpVcFIm9uxA6/Wtm6+0faiI599kq7RbQsQm05+UlcZwR1PXFYDpJZsv2eLlv765cH8OmavWbQRpBc2emszo+1vNfcJDgcbPT1oAlS8ieG2jmnBP3fLtFIdh0+9ycnitfWtLj0nQ7GzvbNreQnz3nkfa8b902YwSOOvTNMbUNY8P6hKI4rDTbpUDOLaFTs7gjk/NzxXM3V1e6s7+ZLNcyljIzyNuLEnliSeOaANiS6tJ4oIkmaGBNxhJ4ZjjJZiOhz6cVWWztoYY7hrmF5zJva3kBLKp6lueevTg1QS1fyxIYpMhgNvA6/3athp5tQLyKsshyRJIDyufvcdSKANy0WCK3XyNQt0aZwVWGHbIrNngt1wBzVS0hFtC0kEoeUNy+AwOOSBnkHp19aqQQQQxz3QmeWKBR8oxhyT3B7Y7VY0qAX7taacpjW5+VZHOOfQk8YoArpOUvVuja3ZLvud87txBPT0z05qG9lv9am3RxyzeW2wCIF32k8A4646VejurMWktleWshu4pNshkfamAenHOSf5VqzeL9Uu7GKysBHpdoikLFZjaJSRt3E/4mgDnU87SW8u6tEuEjcgxuCGRuwY4/Sq97d29/cmWK2EG0gkxKFCLxk4HU5zUtwtwI1jvJZDGWxJKsmRkdOe/wDjVnQ7eFC0sllJeWcTBvNCbVznuT+HFAGfLJYeWVtIpAUcP5kxyWHcdKqM+Q8xZ1djhR6itR557qSeW33W6oeVCjbgdgKozJcGUIm9g5yq7NpHuB2oAakjSxM0w8ybegUuB0/z1rv/AIfS2Fl8S4b2/vRYWaTmMMTtbhcnPbkcfjXnix3UhUlHl2MAoPIyTwPfNdfrjSTWeorfxK7i6zCkaiNVJHO1euT0oA3vid4k03xJe6hqEiXLT8JZq8vEcZyCuPfqT715dcQmGNNyMrNzk9O/FdRby2UunzotjdDUJc+VtO9cY+6PXHWsrU0P9jxyGHbvmyrEEEDB7ehPP4UAYlFFFABRRRQAoJBBHUV9B/BX4tiz0yPw7r10Vth8ttcyDItj2DHvH6H+H6Yr57pyO0bBkOGHegD75e7aRCSFX0IORj1964+/sm1LUWMxzCpBEfQZ9/X6V4T8Nfi3e+G5Y7TVxJeaQx2mMfeg/wBpPbr8vT0xXuul+IdG1wfatHv4bmNwPlBAZSR0ZeoP1oALu1CavbTl9kYyNq/dzjAollZ5G2lVCjGc/eqW6ZVAccOO2eorPD7mbJBRm24Ixgnpg0AWSQ0JTB3YwAOOKWFiLcsz+WAvzemMVCFOSeM9Du6kUMrSRKAcsCOnTGc0AW4I/nOQFjbnBzjPeso2cdtqbtyu8h14G0+w9PxroITuHzgEk4AqW5tFeF2AyQvcY5oApxwm8Vto2InClhyfXFNubNRag7mT5eSGOfwrR0tWuNNt5UTDsOh4I+tWDYORiQs3YZOaAORWztnZGPmzIuD/AKQ5ZV/4D61VuI45SHIEigkrg4Uf7vrXVT6buDCRnyo7YAHtXG69byNqtqlvbGW3QHzZ5ZPli91zzn1oAz5YyrzvcKkcchAWMkEjjr+NYeuzSS6TfpHjy3hKKgIyOf8A61b1z9mgiLW0kOOuSxxz3J71zHjm7l0/RJZVRGfbgsnofWgDx+1t21HUyvGAcHPT2FWNXZYree1nVftCyqyso4IxyPw4q94fmjW0uHSPEjtn1xj0rJ111l1ViV2DABAOccetAGYaepwh5IJODx2ph4JGaegOOvFACuc8EKGXv616T8OtX0vWNGfwZ4nkWO3mfzNOvm/5dZj/AAH0Rj+RNebyDOOMe1N6cDIOaAOk8T+H7/w/qEmn6tH5UyOVyT8rDswPcVixRKZwGfEeRz2Ir03w54z0bxTocfhz4iBl8hQtjq8YxJFjgLJ6r7/n61yfjTwjqfhm+BmButOkG63vYRujlU9CCOM47UAU5ri1tMLbkM4wC4Ayo9hVXU5JLhINrnbJ8zbj1PTNZJ4br+IpwlYKFJPByPY0AWCDCu1c8HJ9M/WjEjOVGQXHLHv+NMD+bI7TZLMM5x+tBy3Eakxg4GOaAH5XekbMSQMMQKkNxsulZPnU4wufu+31qCBwqylxlyMDsR70xJCMKMHvzQBuy3coiaOENuPzZPOT3rJAc/O77NwwpJyT7VYju32BHyvH3scg09mFxIFm2RKTgNtyOaAK6GJmAld0Hf0OPYVaMVvuYxQPIAOBK2FA9ajlghgYgsznPDKPxxTp7jL4m+ZP4vL7+5zQBWkcO29kUx8jAGAPQe9Q5VFOxuC33T6Vr2MIvYJfLHmRxjIDfJs9/esuVkeQiKLawOMls59aAGgRyfdfZwd3HFdroSj7FazST+Xsi2gEYJGema4ZELyqMFy3oK7iyElra29oISNo3Me5B5wfxoAv3GpPDcI0sEohB2iMMMDjk1xGtQFQ84JKPKeSe5zXT6hMX04hgvmFtgZTyM9fxpvja0it/DGnvFjEkobg5/hbrQBwgpQeT059qQY709gcEuMHOOmDQBq6Fq9zpszPF+8jZDHNC+Sk8WRlGHpTGiJnMloEETEuobI2A9OO/TissnPPTFbegX9h5iWWtrN/ZzOWMtuB5sRxgEZ6gddtAFcC6kkRFjEbBQuAQuRnI981eu3gaNQYhCoUJJgksrdgvPPHWk1rRbzT4Y9RkIvtOnOIbyJ/l+h/ut/smsdUcxAoQ6Lnv933x2oA0JlQRRwqoyjFju6yH0JHp/WorIywhnAIQA5fsD0HHeqcc48opJuYbgcE9R/jSB1VQQgZR3JOQewz9KALsEkk0+ZctFtKgo23kjA/H2pBG8KPI8hdsbE2k5A7H+lQR3BjVPKIyOgx0b+97+lPSR5LpTOpLg4YO2wE/XtQBIY/JKxiN3WTK7G4YHg5PvW3olxDZaVdNLHA43BY1dmyW7kYOAaxYbqFZjK9u0hPXccbifU/h1FTXF3EblERzHCDuDAAgHufU0AW7izBZrqG5EUJUK/mcuHxyMd6qx2VsLNppboRx5Cqu0lzznnsKsw2ytaLLIplUSYe5PGCfUk+mPpVecW6YhhlFzJ955GX+HABAP8AWgCW0lNss0MFlHO0pWVHmUlmAPAUdDzycVY1DW7zWB5upTs11GuIoIEwuO4KgYHuetVobnDKY4WW2jz5bs58wf7pzxxVS4bMmLFJI5XG0orby465J9aALU7tqU0SefFEsaYJjU7Uz1HqT703WrsXN+66b5wt40ChiDubAwW9s+lK8cNnZwXMMsBvCf8Aj2QEtH1zu9eMVTSfzUkV0dpEAwIuRt759KAHpdyW9jPbzSyLvwQiY+VlwV/DrXqWjaZc+LvFltp1ldxys8Ucs9w0IK28WwB2DHuOFHvXkWnwpdahBDM5jhkkAdhyQM9frX1J+zPolhp1r4mvrlczvOtsCykhYVGcDjuTyPYUAcZ+0N4Kh8KWHh260y0SG2hQ2rSQk7R1ILHqWb5iSPSvNfEk5u/DAuZA+57qNI/kAURrG4UAj+tey/tQ6tb3GgeHNNWTZLJNLeYY5Koq7VyPQliBx0FeS+K/9H8CaZaR3MMii4WSRYhkByjDkjj14oA4KiiigAooooAKKKKACrem6heaZdJc6fcy206dHiYqaqUUAeq6F8ZNUhdF1y1hvkGAZowI5fr/AHT+QrtbD4k+G72SHyb17Nyfniu4iqnPfcMgEetfOtFAH1lbXy3zCXT57e5RR83kOr5+oB6Vcsxex23l3MiP15SLaR6da+RYZZIHDwyPG46MjEGt3SvGniTSyfsOtXqA/wALSbx+TZFAH1zZ7fLjkUgg/wCsA6E+o9K6CziSZACA2eo718j2Hxg8Y2m0Nfw3Cqc7ZraM5+pABrbg+PviuEHbZ6Ju9fsrD+T0AfWNjpgEShV24POFxipX03YSAg+Yfez+dfLSftJeMUX5bDQgfUW8nP8A5EqndftE+OZs+S+l23/XK0zz6/MTQB9MXkO1RGcDjG6uU1SFQhTGcdFxzXgdv8dPGnn79RurTUUxjZPbIoH02Bea9N8FeO7DxfaFjELbUIVzNETuGexU9x/KgCK9hFtORGI41kAR0C8Fux9vSuS8YxvNo11FlVyvHHFdj4gcBJMkbF5YdMj2ri7+Qv5zNL+6CgYAPze9AHk2l3TW/nQ45bI6cg/Wqt4yvLlWLZ5JPrTrtgl/OUyF3sMe2arHGeOBQAUqnFJSUAPBBYZz15pxBJIGW9DUdSNJ/d4x0oAVid3LbuOtdN4V8a6joNtJYyBL/SJT+9sbgkxkd9v90+4rltynBYc98U4uCMc7AcgUAdvc6f4f8U3BOgyx6TeN9y0uzhGPor/44rm9X0DVNGlI1KyliAOA+Mox9mHBrNRlLjcPlHJ7Vt6V4t1nTYDDBeM9qTk28wEkf02tkY+lAGIhIBOeP5+1A3yPnkmusOu6DqTous6FHBnrPp7eWw/4CeKlTSPCV8CbPX5bFj91LyEnB/3l4x70AcyJ0+zkSxneSfn7KfpVdwCVHII5wetdWvhG8u42S0u7W9QEANDOm368kGm3ng/XIoxv06Xdu+RtpJPpgjIIoA5bzNu0ryFPQ9qul1lZn3fvZTnOOA3tWx/wg/im4lCjQ7+ZgMkLAwwD+AFTw/DPxpJLEkfhjU/3h+XdEf69B7mgDmQGjCtnO4/ePY0wvtWRMbj0Pb8a9Lm+DvjLynA0VgyqOPMQf+zUi/BPxo8HmfY7ZuB+7ju42kb6DNAHmuSYzmUEkDjJGalnmBhTagVx8ueoPuPetLxFo934fuXstUs5ra7Hzt5qYYf4isMtwVYlsmgAcKzgI+AT36CvRrtYm0vTrq2LKPL/AHjk8jt0H515wuzB3Hb26ZyK7XSbg3Ph2JJHQbcruJHbp+lAEkL21zcqyZZw2EypIJP/ANatr4wRQw6HpqRGMkSLkquCPlPesvQyrXVtFCoZt/ygL1yec+vSr/xgldrG0R+NsuNoH+ye9AHlgOKdvYrimUUAPOD2PA5I5pygleAMYyTTQ2Bj14PvQzbieAATnAFAGlput3licRyBrcja9u4DRv8AVTwfrWmh0q7jzbudO1GTGIvv2zj0OeVP1yOa5jPHSlB5yc57YoA0bvTrmzkKywlYs7XkjO9CBjPIqskYkRkhXcxOc5xgU+3vLq0aN4biRCpyuG4GevFTNqKSxzLcWltJK4AWULsK49hx+dAGeCFJI6joastJAJnMq+aCo6E/e+v9amePTmeIQzXEJx87OAwDe2O1RtZb2AjuIHYnGAx59+lADH+ytO5VpUj25UFed2On0zUSyDzAXBAzyB6d6swaeZZRF9ptkkL7cO+B1xnPSrP9iXAMg8+0BiTzCDMMnnoPU+1AFd7yT7KlupYWoZsA98jqauWknlW4maUSjf5KKUB3DGeeM4yas2/h642pBd21xHPIqyx7m42E43AY59fwrVsPB12Z5ZLxri2sVjcm5ijLK+Pu8DkA8CgDEmj+0aZcM80aCHb5cIRgxz1I4wAO4NU7G9ljgW1jCBGbJcrz+Br0ax0myk0mSPxJqMWn2/8Aq0eNAzynrjBOenQ1TvPBem30IvPC+tx31tn97buhhk2jGflJ5P0oA4N1aGTLDbOmTmMcc8gk/pTzK0ZSS0kEZdD5ojXgA8H/APVSai9xA32eZ1ZACAyjrz61TB4ALBlBGATigARMugBKNxg+p/pX0p8G/Flroi36eJb9INPaJZAhBdg2CG3Ed+a+bGURxdUfeucf3Of511zai/8AYcECGGEsisuxgXkXn5GPUDNAGx4wzr19a3s88U6303moJT+8gttxEUZPb5VJx6msXxkV/se32yw4MoISNCpIwwDN2z1561YtL21m1a2uDFKsLKViijwVTjGxfbJJxTfH181zYrHJb+U4nXJA2rgKwAAoA4WiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK2PCmrzaHr1rewtgKwWQZ4ZD1BrHooA+hdT1A3LFxtaNlDIQRkZ7flXJ390PtLqhOGAY5HSsy01jdo1tEucBBk5qjeXoQNJ5h3FSSM5zQBx14d95NjJzIf51CQR1Bqa3QOzb89OPrUR569qAG0UUUAFFFFABRRRQA5CAckZ9qdvXrt5NR0UAPLZznv1pRJyOMD0FR0UASM4Jyoxzxjirdvqd/FgQXt2mOVCSsMVQp8bKpO4E+1AGwfFHiB0ETa5qez0+1P/AI04+KfEbZP9u6uQFwf9Mk6f99Vij5mJOafhWGFHPTr0oAuz6zqsnMuo3zg9C87H+tVbe8ube4WeCeWKdG3LKjlWU+oIPWo1wuGODz09aFzkEc+1AHSX/ii613TFttbdr28jceXdSsWk2f3ST1x1rBuIVilZCGUg8n0qPZg4I4K5rYuds9jGzfJIEwWyCGPTP5UAY0gwTyeRzmuo8P3CporRMgJ3ZHHXPv6VzOw54IIx61rWUojsfl3K/VJNucetAGxpl2Ir2EJjbvwAeSOam8f3QutKtmyAwmwQPoetZuiKwuo2lAO+T7qnn6mrXjsgWlsispUP0A9jQBxdFFFABRRRQAUoODx9KSigBc8YqUygxqvlqMHqOpqGigBSeciikooAerYyMDkY5o5C5z196RSATkZ4p0eCcAZJGBn1oAlea4CIxml4+UAseB6D86YJpGYbpX6YyWNIwb5i2QRw2TSANsJA4Jx9TQA3+VOBdAHBxk8MOvFIANpJz+Hag44ABz3zQBaeRJ1IClWC7s9yfc+mKruMEFTuUHAOP0pFALDdwM847U4kLjKfKckH1oARSG3ltq5GRx39q0tNuHtHVzs2t8rJ/eXGOhH61nMY2YcEIpHGeSK19Isrq4T7RZR+f5JbknO0AcKQfXOaAOs8D6jpp1yS4vrcKWgdIYlOF8wAAE46Dk1zviqe4mtwLmYHEuUj5JCkN37+/wBRWVpNxPBqA8mNHkf5Cr4C8+tXNe3LYx+ZD5MkkpYqrblwM4IP4mgDBooooAKKKKACiiigAooooAKKKKACiiu1+FnhHTPHHiS00G61i803UbyQpAY7BbiIgIWJdjMhX7p4CtQBxVFdhfaH4UstcvrOfxJqq29nuR3Ojp5ssqvtKxoLgqVxzuZ1+hNHxO8Ey+BddtbFr1L62vLOK/tZxH5bPFJnG5CTtbKnjJoA4+iiigAooooAvQ3vlxKmGIApZL5WRgoKkjGR/wDrqhRQA5W2+tJSUUAFFFFABRRRQAUUUUAFFFFABRRRQAUV1fw48N6Z4s8R2mi3+qXmnXd7OkFq0NitwhZs5LkyoVA46Bs5PTHOnqPgnR4fiIPCdr4lkWaK9exuLq/05ooxIsgQCMRPKz5Ocbgg6ZIzwAcJGwU85I9AaV3DHgEDsK6D4i+GP+EN8a6r4f8Atf237DII/tHl+XvyobO3Jx19TXN0ASOUzhS+0dM+tIGA+uOtMooAk8zgZGSOmasteA2UcADZBJOentiqVFAEpkBYtt/A81KlzhArE/L90gcj1FVaKANSx1COC4BkMrQcEgAbsj05qzr+rw6jbRRwpKCjZy4AwMfU1hUUAFFFFABRRRQAUV3/AIH+HMviPwjq3iW4ubyLTNPmW3aPT7E3lzI5APEe9AFAIJYsKy5/BV9c2Os6n4fLalo2kLG17dOot2gL8BWjdtxIIIO3cOOtAHKUV654Y+D91Lp/i9PFEU9hqul6VHqNnGl1AI3D7sGRuVC/L/eXHfFVfCnwZ1zVde1XStamg0aez0ltVjZ5YZVuEyNm1hIF2HnMgJVcDOMigDy2iu5sPhR4z1HRp9X0/SEutMh87fdQXsDx/us7yGD4IGDgjIPbNZ134E1+20S71dYbK70602faZbHUba78jecKXWKRioJ4yQKAOXpRXczfC3xPZahZWurW1rYm5MJYSX9sZIo5XVVkePzNyrlgMsAM8ZzVzxf8Jta0bx7eeGdIkg1h7eMzefHNDHsjVFZnmXzD5AG7/loRnqOtAHnWachXcA2duecda68/DLxcNXOnHSCJxZ/2gZDcReQLb/nr5+/y9n+1uxWl8XfA1h4Kh8J/YZ7iaXVdIhvrnzJo5UWVh8wjZAAU9DlvqaAPP1k29ByCCPr9KTdyW5DZyCK7WH4VeMp7G0uodISRLuyGo28a3kBlmt8A70i3724IyAuRkZHNVdI+HHivWNLttQ0/STLBdJJJbIZ4kluVT75iiZg8gHfapoA5IGpvOULjYCe+R1/wrfh8Da9JoUGsS29paadcBzby31/b2pnCfe8tZXVnx/sg1s/Eb4bXHgrRvD2ovqdnepqtlFdMiTQh4mcZ2qokZpEGP9Yo20AcEMZ5/Kum0/xMlpoC6X5JaLezM2ACwYjI6+gFcvRQBbkugJpPs67IGLERsA2MikubuWaCOJp5WjT7sZ4VfpzVWigAooooAKKKKACiiigAooooAKKKKACuw+EXiey8G/EXRtf1OK4ls7J3aRLdVaQ7o2UYDEDqw7iuPooA7zwfrHg9fiDea34ytdTu9L+0SXMFnbQxv5rFyyiXc6/KO4BOenTrW+K3iaHxf4ql1qPUr6+knGCtzYpaLAo4WONVmkyoHqQc+pJNcZRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB0nw41y28M+O9C1q/SaS1sbtJ5UhALlVPIUEgZ+pFakviLRr/wCL174mvX1C20uTVpNSjWK2SWYjzvMVCpkVRkcEhjj3rh6KAO2+MPiDR/FnjvUdf0J9Q8q/cSSQ3lskTREKFwCsj7hxnPy/TvXE0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAd58N/FkXheKWSDxF4k0O9kky76bBFcwyxgDarRPIg3Z3fMSeOMck13us/GbQ/ED/ABAt7/Tb6wtPEdtbRQTW0UcsqvDn55VLIDuyOh4xjnrXg1FAH0Jq/wAYfCurX3ihZYNct7PWNCttJSRbaKSSJ49+5ivmqCPmGPm59qq2vxl0KLxPaq1jqg8O2vhhvDcUgWNroghf3xQvt/gA27/fPavBaKAPSde8Z6JN8K9C8JWEeoXMmmarNeNLcwpCk0TFtowsjFWIbkcgc4Jr0HX/AI3eHrnQ/FFnpcWtQw6lZ2sOn6W1tClnpzxZLhdsvIZiSWCAngY4GPnWigD1b4n+NfC/irxm3i/T01tdWk+zO1lPDEkCyRbAxEgdmKlUIA2g5Oc9q6aT4v8AhyP4h+KNctrXU5dO8T2P2W7ins4GezcIqqyKzsky8ElXCg5HWvA6KAPdYPi7pcmmapomr3ms3+m32kHTVu49LtLR7TDEosdvE4Xy8HBBk5xxgcVx/wAX/GWkeLIvCcGhx36w6NpEWmu15GiNIycbgFZuCPevOqKAPpy6+I3hnwnH8PNdjvH1TV9N8LLaRWVkYnjSdo1Uid9+6Mjn5dhP0xg8r4f+LmhQSeCdW1a01T+2vCtpNaxW9tHGbe73IVRmcuGjxnkBGz7V4bRQB7foHxb0uDwrd6d4nWfxDHJDOYNLudIgWG2mkbd8lyZWcICSR8memMYrlPiN4v0bxZ4V8IRW41C31fRdNi0yWF4UMEioP9YsgfcD0+Up368c+d0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Breast MRI can be used to document the response to neoadjuvant chemotherapy. This series illustrates the response to chemotherapy in a patient with a palpable right breast mass and nipple inversion. Mammography and ultrasound confirmed a large irregular mass and biopsy showed invasive lobular carcinoma. The patient was treated with neoadjuvant chemotherapy. MRI prior to therapy showed a large irregular mass extending from the nipple and involving the upper and central breast (A). Post-treatment MRI showed a partial response and scattered foci suggestive of residual disease (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_62_30694=[""].join("\n");
var outline_f29_62_30694=null;
var title_f29_62_30695="Options in the management of renal and ureteral stones in adults";
var content_f29_62_30695=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Options in the management of renal and ureteral stones in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/62/30695/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/62/30695/contributors\">",
"     Glenn M Preminger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/62/30695/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/62/30695/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/62/30695/contributors\">",
"     Michael P O'Leary, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/62/30695/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/62/30695/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/62/30695/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considerable progress has been made in the medical and surgical management of nephrolithiasis over the past 20 years. Approximately 10 to 20 percent of all kidney stones require surgical removal, which is determined based upon the presence of symptoms and the size and location of the stones. Larger stones and proximal ureteral stones are less likely to pass spontaneously. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Facilitation of stone passage'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=see_link&amp;anchor=H21#H21\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\", section on 'Stone passage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stone removal is also indicated for pain or obstruction or for an infected struvite stone. On the other hand, no specific surgical therapy is required for asymptomatic stones, particularly those that are less than 5 mm in diameter.",
"   </p>",
"   <p>",
"    Three minimally invasive surgical techniques that significantly reduce the morbidity of stone removal are currently available:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Percutaneous nephrolithotomy (PNL)",
"     </li>",
"     <li>",
"      Rigid and flexible ureteroscopy (URS)",
"     </li>",
"     <li>",
"      Shock wave lithotripsy (SWL)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These techniques appear to offer comparable success when compared with open renal and ureteral surgery, and provide significant advantages in terms of patient morbidity and cost. In addition, improvements in urologic equipment, fluoroscopic technology, and interventional radiologic techniques provide many additional treatment options.",
"   </p>",
"   <p>",
"    The choice of intervention for stones that are unlikely to pass spontaneously varies with the location and size of the stone. Studies suggest that either SWL or URS is a viable option for managing ureteral calculi. SWL is the treatment of choice for most small renal calculi, while PNL is the preferred method of stone removal for larger (&gt;2 cm) renal stones, including staghorn calculi. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40231?source=see_link\">",
"     \"Management of struvite or staghorn calculi\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally, a nephrostomy tube may be placed as a temporizing measure, usually for patients who present with an obstructing stone and sepsis. Proper drainage of the infected urine is essential. Once the infection has cleared, the stone may be removed by one of the methods previously listed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PERCUTANEOUS NEPHROLITHOTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term Endourology was adopted in the late 1970s to describe the \"closed, controlled manipulation of the entire urinary system.\" This term was initially used to describe the technique of percutaneous nephrolithotomy (PNL).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;PNL and open surgery are equally effective for the management of renal stones. In one study of 129 patients with renal calculi, for example, we found that PNL and open renal surgery were associated with a similar success and complication rate [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30695/abstract/1\">",
"     1",
"    </a>",
"    ]. An important difference was that PNL shortened the hospitalization time by 60 percent and allowed the patient to return to work in approximately one week as compared to greater than three weeks after open renal surgery. This less invasive technique is also 40 percent less expensive than open renal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30695/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although comparable in efficacy to open surgery, the advent of SWL has limited the need for routine PNL (see below). Percutaneous stone removal procedures are currently reserved for patients with the following clinical characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30695/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Large (&gt;2 cm in diameter) or complex calculi (filling the majority of the intrarenal collecting system, such as staghorn calculi) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40231?source=see_link\">",
"       \"Management of struvite or staghorn calculi\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cystine stones (relatively resistant to shock wave lithotripsy)",
"     </li>",
"     <li>",
"      Anatomic abnormalities, including horseshoe kidneys or ureteropelvic junction obstruction",
"     </li>",
"     <li>",
"      Stones within caliceal diverticula",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Technical advances and increased operator experience have resulted in considerable refinement of the percutaneous approach to renal calculi. Significant reductions in morbidity and cost have occurred because of the development of nephrostomy tract balloon dilators, improved grasping instruments, and the use of improved methods of stone fragmentation and removal [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30695/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The key to successful PNL is the adequate placement of the nephrostomy tract, thereby allowing appropriate access for complete stone removal. It is extremely important that the urologist and radiologist confer prior to placement of the nephrostomy tube to ensure that the nephrostomy tract will allow easy access to calculi.",
"   </p>",
"   <p>",
"    The nephrostomy tract may be placed either as an outpatient procedure in the angiography suite just prior to hospital admission or may be performed as a \"single stage procedure\" under the same general anesthetic as percutaneous stone removal. We employ the latter approach, which is performed in our special procedures-angiography suite within the operating room. The procedure involves the following sequential steps:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With the patient in a supine position, a retrograde ureteral catheter is placed using a 15F flexible cystoscope.",
"     </li>",
"     <li>",
"      After turning the patient to a prone position, the renal collecting system is accessed via an 18 gauge needle under fluoroscopic guidance.",
"     </li>",
"     <li>",
"      After dilation of the tract to 32F with a nephrostomy balloon dilator, a 30F working sheath is placed into the renal collecting system.",
"     </li>",
"     <li>",
"      All calculi are extracted with grasping forceps using a rigid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      flexible nephroscope,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fragmented using an ultrasonic, pneumatic, or combined",
"      <span class=\"nowrap\">",
"       ultrasonic/pneumatic",
"      </span>",
"      lithotripsy probe using a rigid nephroscope.",
"     </li>",
"     <li>",
"      Following successful stone removal, it is standard to leave a 10F Cope catheter in the renal pelvis as a nephrostomy tube with a 5F catheter placed down the ureter.",
"      <br/>",
"      <br/>",
"      However, various studies suggest that foregoing the nephrostomy tube at the end of the procedure (ie, \"tubeless\" percutaneous nephrolithotomy) is just as safe and effective as the standard approach of leaving a nephrostomy tube in place [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30695/abstract/8-12\">",
"       8-12",
"      </a>",
"      ]. A meta-analysis of 50 reports document comparable complication rates between tubeless and standard percutaneous nephrolithotomy. Tubeless percutaneous nephrolithotomy demonstrated advantages such as less pain, less debilitation, less cost, and a shorter hospital stay. The mean stone-free rates for tubeless percutaneous nephrolithotomy were as high as 89 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30695/abstract/13\">",
"       13",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In addition, some studies suggest that an internal ureteral stent does not need to be used with a tubeless PNL. This so-called \"tubeless, stentless\" PNL procedure offers a further reduction in patient morbidity, as the internal stent-related symptoms are avoided [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30695/abstract/14,15\">",
"       14,15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13320426\">",
"    <span class=\"h3\">",
"     Procedural complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complications of PNL were described in a large multicenter study that included 1448 single large kidney stones [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30695/abstract/16\">",
"     16",
"    </a>",
"    ]. Procedural complications were more common with larger stones. Compared with those whose stones were 2 to 3 cm, patients whose stones were 4 to 6 cm required longer operative times (91 versus 71 minutes) and longer hospital stays (4.0 versus 3.7 days), and were more likely to have a postoperative fever (18 versus 8 percent) and to require a blood transfusion (13 versus 4 percent). Stone free rates were also significantly lower (84 versus 90 percent). Calyceal stones were associated with more procedural complications than pelvic stones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     URETEROSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of the ureteroscope has had a significant impact upon the management of ureteral calculi. Although many proximal ureteral or renal stones are currently managed by extracorporeal shock wave lithotripsy (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Shock wave lithotripsy'",
"    </a>",
"    below), ureteroscopy continues to be the treatment of choice for the majority of middle and distal ureteral stones [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30695/abstract/17\">",
"     17",
"    </a>",
"    ], but also can be used to manage proximal ureteral and intrarenal calculi. In addition, ureteroscopic access is frequently useful for the management of ureteral calculi that have failed shock wave lithotripsy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30695/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Rigid ureteroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ureteral access and dilation are often the first components of ureteroscopy. We routinely employ ureteral balloon dilators, which are passed over guidewires that have been fluoroscopically positioned within the renal collecting system. After dilation of the distal ureter, the ureteroscope can then be passed under direct vision throughout the ureter and renal pelvis.",
"   </p>",
"   <p>",
"    If the obstructing stone is small enough to be extracted intact, stone baskets or grasping forceps can be employed for stone removal. If, however, the stone is too large for intact extraction and requires fragmentation prior to removal, laser, pneumatic, ultrasonic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    electrohydraulic lithotripsy, as well as laser fragmentation can be utilized to perform \"intracorporeal lithotripsy.\"",
"   </p>",
"   <p>",
"    Devices that combine pneumatic and ultrasonic features are also being developed. The initial experience with this device is favorable, with the instrument being efficacious and safe in removing large renal or bladder calculi [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30695/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advances in semirigid ureteroscopes have obviated the need for ureteral dilation in many patients. These small-caliber, mini-ureteroscopes are ideal for the management of middle and distal ureteral stones. We routinely employ a 6.5 French semirigid ureteroscope combined with either intracorporeal laser or electrohydraulic lithotripsy to manage stones in the lower two-thirds of the ureter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Flexible ureteroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further innovations in fiberoptic technologies have propelled the development of flexible ureteroscopes. The widespread use of these new instruments has enabled routine diagnostic and therapeutic procedures to be performed within the ureter and kidney. As an example, patients who present with hematuria and a filling defect of the upper pole collecting system can undergo direct visualization of the upper urinary tract. A therapeutic maneuver, such as extraction of symptomatic ureteral calculi, can also be performed with these devices.",
"   </p>",
"   <p>",
"    With the addition of deflection capabilities, these newer endoscopes are now able to access the entire upper urinary tract, including the intrarenal collecting system. Renal lesions or stones located in the lower pole or extremely lateral calyces can now be reached with a combination of active and passive endoscope deflection. Rotation of the operator's hand will enable a 360&ordm; access to the entire intrarenal collecting system. While flexible ureteroscopes are used primarily to access the proximal ureter and intrarenal collecting system, the semi-rigid ureteroscopes can be utilized to reach lesions in the mid and distal ureter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Indications for stent placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stents are sometimes placed after ureteroscopy, in part to help prevent ureteric obstruction and pain resulting from ureteral edema. Routine placement of stents after uncomplicated ureteroscopy should be discouraged. Two meta-analyses that combined randomized trials of stent placement after uncomplicated ureteroscopy reached similar conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30695/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The largest meta-analysis included 16 randomized trials involving 1573 patients who underwent ureteroscopic lithotripsy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30695/abstract/21\">",
"     21",
"    </a>",
"    ]. Compared with those who did not receive a stent, patients receiving stents had significantly longer operative times, more pain and lower urinary tract symptoms (dysuria, frequency or urgency, and hematuria), while there was no difference in stone free rate, fever, urinary tract infection, requirement for analgesia, urinary strictures, or unplanned rehospitalization.",
"   </p>",
"   <p>",
"    In contrast, stenting should be performed in patients with urinary tract abnormalities or solitary kidneys, and when bilateral simultaneous ureteroscopy is performed. Stenting is also necessary if there is residual edema or inflammation following stone removal. Ultimately, a more comfortable ureteral stent will reduce patient morbidity while protecting patients from post-operative ureteroscopic problems [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30695/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SHOCK WAVE LITHOTRIPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of extracorporeal shock wave lithotripsy (SWL) is perhaps the most significant advance related to the removal of renal and ureteral stones. Many renal and ureteral stones are currently managed by this technique. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27079?source=see_link\">",
"     \"Management of ureteral calculi\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, SWL is not the ideal modality for the management of large or complex calculi. Alternative modes of stone removal should be considered for large or hard calculi, stones located in a caliceal diverticulum, or in patients with complex renal anatomy. Procedures such as percutaneous stone removal or a ureteroscopic approach can greatly facilitate stone removal and correct underlying anatomic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30695/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. In a cohort of 137 patients with renal calculi measuring 11 to 20 mm in diameter, single treatment success rates were significantly better in those who underwent percutaneous stone removal (95 percent) and ureteroscopy (88 percent) compared with SWL (60 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30695/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SWL employs high energy shock waves produced by an electrical discharge. The shock waves are transmitted through water and directly focused onto a",
"    <span class=\"nowrap\">",
"     renal/ureteral",
"    </span>",
"    stone with the aid of biplanar fluoroscopy. The change in tissue density between the soft renal tissue and the hard stone causes a release of energy at the stone surface. This energy fragments the stone.",
"   </p>",
"   <p>",
"    While current lithotriptor technology is quite effective in fragmenting the majority of renal and ureteral calculi, there continues to be some debate concerning the potential deleterious effects of the high-energy shock waves, such as hypertension, renal injury, and, in men, sperm DNA damage and a temporary decline in fertility [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30695/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/10/27812?source=see_link\">",
"     \"Renal complications of extracorporeal shock wave lithotripsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We believe that \"fine-tuning\" of shock wave parameters (ie, shock wave intensity, rate, focal position, etc.) may allow improved stone fragmentation with reduced renal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30695/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/10/27812?source=see_link\">",
"     \"Renal complications of extracorporeal shock wave lithotripsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     OPEN STONE SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There continues to be a limited role for open stone surgery. Less than one percent of patients are candidates for such surgery.",
"   </p>",
"   <p>",
"    Open stone surgery is primarily reserved for the management of complex renal and ureteral calculi that cannot be removed with a reasonable number of minimally invasive procedures. Current indications include patients who have failed endoscopic stone removal, patients with complex (staghorn) renal calculi, and patients with complex",
"    <span class=\"nowrap\">",
"     renal/ureteral",
"    </span>",
"    anatomy or morbidly obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30695/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MEDICAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Prevention of new stone formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The enthusiasm for PNL, ureteroscopy, and SWL must not overshadow the importance of medical therapy to prevent new stone formation. A treatable metabolic etiology of stone formation can be detected in more than 95 percent of patients evaluated for stone disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link\">",
"     \"Risk factors for calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of medical treatments may correct the underlying metabolic defects responsible for stone formation, thereby reducing the occurrence of new stone formation. Examples for which controlled trials have demonstrated benefit include a high fluid intake for all forms of stone disease, a thiazide diuretic for hypercalciuria,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    or potassium citrate for hyperuricosuria, and potassium citrate for hypocitraturia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link\">",
"     \"Prevention of recurrent calcium stones in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=see_link\">",
"     \"Uric acid nephrolithiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With medical treatment, we have found remission of stone disease in more than 75 percent and a reduced rate of stone passage in more than 94 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30695/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. In a study of 80 patients with renal stones treated with lithotripsy, medical therapy was highly effective in reducing the recurrence rate of stones in patients with residual fragments (from 1.17 to 0.00 stones per year) and in those who were stone-free after the procedure (from 0.67 to 0.00 stones per year) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30695/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although it prevents new stone formation, medical therapy does not dissolve preexisting calcium stones. The passage of such stones can occur and does not represent a treatment failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Facilitation of stone passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of spontaneous passage of a ureteral stone is related to both stone size and location. Most stones &le;4 mm in diameter pass spontaneously. For stones larger than 4 mm in diameter, there is a progressive decrease in the spontaneous passage rate, which is unlikely with stones &ge;10 mm in diameter. Proximal ureteral stones are also less likely to pass spontaneously. The data supporting these conclusions are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=see_link&amp;anchor=H21#H21\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\", section on 'Stone passage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several different medical interventions increase the stone passage rate of ureteral stones, including antispasmodic agents, calcium channel blockers and alpha blockers, which have been used in combination with or without steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30695/abstract/39-48\">",
"     39-48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=see_link&amp;anchor=H22#H22\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\", section on 'Facilitating stone passage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/5/37970?source=see_link\">",
"       \"Patient information: Hydronephrosis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/53/28499?source=see_link\">",
"       \"Patient information: Kidney stones in adults (Beyond the Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5286840\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 10 to 20 percent of all kidney stones require surgical removal, which is determined based upon the presence of symptoms and the size and location of the stones. Stone removal is also indicated for unremitting pain or complete or non-resolving partial obstruction or for an infected struvite stone. Three minimally invasive surgical techniques that significantly reduce the morbidity of stone removal, are currently available, and offer comparable success when compared with open renal and ureteral surgery (see",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Percutaneous nephrolithotomy",
"     </li>",
"     <li>",
"      Rigid and flexible ureteroscopy",
"     </li>",
"     <li>",
"      Shock wave lithotripsy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Percutaneous nephrolithotomy, which requires general anesthesia and hospitalization, is currently reserved for patients with the following clinical characteristics (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Percutaneous nephrolithotomy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Large (&gt;2 cm in diameter) or complex calculi (filling the majority of the intrarenal collecting system, such as staghorn calculi)",
"     </li>",
"     <li>",
"      Cystine stones (relatively resistant to shock wave lithotripsy)",
"     </li>",
"     <li>",
"      Anatomic abnormalities, including horseshoe kidneys or ureteropelvic junction obstruction",
"     </li>",
"     <li>",
"      Stones within caliceal diverticula",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ureteroscopy continues to be the treatment of choice for the majority of middle and distal ureteral stones, but also can be used to manage proximal ureteral and intrarenal calculi. In addition, ureteroscopic access is frequently useful for the management of ureteral calculi that have failed shock wave lithotripsy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Ureteroscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Shock wave lithotripsy can be used to treat many renal calculi, but is not the ideal modality for the management of complex calculi, large or hard calculi, stones located in a caliceal diverticulum, or in patients with complex renal anatomy. Shock wave lithotripsy employs high energy shock waves produced by an electrical discharge or piezoelectric crystals, fragmenting the stone. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Shock wave lithotripsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medical therapy, for both prevention of new stone formation and facilitation of stone passage, should be considered in patients who undergo stone removal procedures. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Prevention of new stone formation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Facilitation of stone passage'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/1\">",
"      Preminger GM, Clayman RV, Hardeman SW, et al. Percutaneous nephrostolithotomy vs open surgery for renal calculi. A comparative study. JAMA 1985; 254:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/2\">",
"      Jewett MA, Bombardier C, Menchions CW. Comparative costs of the various strategies of urinary stone disease management. Urology 1995; 46:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/3\">",
"      Grasso M, Beaghler M, Loisides P. The case for primary endoscopic management of upper urinary tract calculi: II. Cost and outcome assessment of 112 primary ureteral calculi. Urology 1995; 45:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/4\">",
"      Meretyk S, Gofrit ON, Gafni O, et al. Complete staghorn calculi: random prospective comparison between extracorporeal shock wave lithotripsy monotherapy and combined with percutaneous nephrostolithotomy. J Urol 1997; 157:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/5\">",
"      Al-Otaibi K, Hosking DH. Percutaneous stone removal in horseshoe kidneys. J Urol 1999; 162:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/6\">",
"      Pietrow PK, Auge BK, Zhong P, Preminger GM. Clinical efficacy of a combination pneumatic and ultrasonic lithotrite. J Urol 2003; 169:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/7\">",
"      Auge BK, Sekula JJ, Springhart WP, et al. In vitro comparison of fragmentation efficiency of flexible pneumatic lithotripsy using 2 flexible ureteroscopes. J Urol 2004; 172:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/8\">",
"      Akman T, Binbay M, Yuruk E, et al. Tubeless procedure is most important factor in reducing length of hospitalization after percutaneous nephrolithotomy: results of univariable and multivariable models. Urology 2011; 77:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/9\">",
"      Limb J, Bellman GC. Tubeless percutaneous renal surgery: review of first 112 patients. Urology 2002; 59:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/10\">",
"      Desai MR, Kukreja RA, Desai MM, et al. A prospective randomized comparison of type of nephrostomy drainage following percutaneous nephrostolithotomy: large bore versus small bore versus tubeless. J Urol 2004; 172:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/11\">",
"      Shah HN, Kausik VB, Hegde SS, et al. Tubeless percutaneous nephrolithotomy: a prospective feasibility study and review of previous reports. BJU Int 2005; 96:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/12\">",
"      Rana AM, Mithani S. Tubeless percutaneous nephrolithotomy: call of the day. J Endourol 2007; 21:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/13\">",
"      Zilberman DE, Lipkin ME, de la Rosette JJ, et al. Tubeless percutaneous nephrolithotomy--the new standard of care? J Urol 2010; 184:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/14\">",
"      Mouracade P, Spie R, Lang H, et al. Tubeless percutaneous nephrolithotomy: what about replacing the Double-J stent with a ureteral catheter? J Endourol 2008; 22:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/15\">",
"      Crook TJ, Lockyer CR, Keoghane SR, Walmsley BH. Totally tubeless percutaneous nephrolithotomy. J Endourol 2008; 22:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/16\">",
"      Xue W, Pacik D, Boellaard W, et al. Management of single large nonstaghorn renal stones in the CROES PCNL global study. J Urol 2012; 187:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/17\">",
"      Segura JW, Preminger GM, Assimos DG, et al. Ureteral Stones Clinical Guidelines Panel summary report on the management of ureteral calculi. The American Urological Association. J Urol 1997; 158:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/18\">",
"      Kourambas J, Munver R, Preminger GM. Ureteroscopic management of recurrent renal cystine calculi. J Endourol 2000; 14:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/19\">",
"      Kourambas J, Delvecchio FC, Munver R, Preminger GM. Nitinol stone retrieval-assisted ureteroscopic management of lower pole renal calculi. Urology 2000; 56:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/20\">",
"      Auge BK, Dahm P, Wu NZ, Preminger GM. Ureteroscopic management of lower-pole renal calculi: technique of calculus displacement. J Endourol 2001; 15:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/21\">",
"      Pengfei S, Yutao L, Jie Y, et al. The results of ureteral stenting after ureteroscopic lithotripsy for ureteral calculi: a systematic review and meta-analysis. J Urol 2011; 186:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/22\">",
"      Nabi G, Cook J, N'Dow J, McClinton S. Outcomes of stenting after uncomplicated ureteroscopy: systematic review and meta-analysis. BMJ 2007; 334:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/23\">",
"      Lingeman JE, Preminger GM, Berger Y, et al. Use of a temporary ureteral drainage stent after uncomplicated ureteroscopy: results from a phase II clinical trial. J Urol 2003; 169:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/24\">",
"      Deliveliotis C, Chrisofos M, Gougousis E, et al. Is there a role for alpha1-blockers in treating double-j stent-related symptoms? Urology 2006; 67:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/25\">",
"      Damiano R, Autorino R, De Sio M, et al. Does the size of ureteral stent impact urinary symptoms and quality of life? A prospective randomized study. Eur Urol 2005; 48:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/26\">",
"      Streem SB. Contemporary clinical practice of shock wave lithotripsy: a reevaluation of contraindications. J Urol 1997; 157:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/27\">",
"      Streem SB, Yost A, Dolmatch B. Combination \"sandwich\" therapy for extensive renal calculi in 100 consecutive patients: immediate, long-term and stratified results from a 10-year experience. J Urol 1997; 158:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/28\">",
"      Matlaga BR, Assimos DG. Changing indications of open stone surgery. Urology 2002; 59:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/29\">",
"      Wiesenthal JD, Ghiculete D, D'A Honey RJ, Pace KT. A comparison of treatment modalities for renal calculi between 100 and 300 mm2: are shockwave lithotripsy, ureteroscopy, and percutaneous nephrolithotomy equivalent? J Endourol 2011; 25:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/30\">",
"      Gupta M, Bolton DM, Irby P 3rd, et al. The effect of newer generation lithotripsy upon renal function assessed by nuclear scintigraphy. J Urol 1995; 154:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/31\">",
"      Krambeck AE, Gettman MT, Rohlinger AL, et al. Diabetes mellitus and hypertension associated with shock wave lithotripsy of renal and proximal ureteral stones at 19 years of followup. J Urol 2006; 175:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/32\">",
"      Gulum M, Yeni E, Kocyigit A, et al. Sperm DNA damage and seminal oxidative status after shock-wave lithotripsy for distal ureteral stones. Fertil Steril 2011; 96:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/33\">",
"      Zhou Y, Cocks FH, Preminger GM, Zhong P. Innovations in shock wave lithotripsy technology: updates in experimental studies. J Urol 2004; 172:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/34\">",
"      Weizer AZ, Zhong P, Preminger GM. Twenty-five years of shockwave lithotripsy: back to the future? J Endourol 2005; 19:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/35\">",
"      Maloney ME, Marguet CG, Zhou Y, et al. Progressive increase of lithotripter output produces better in-vivo stone comminution. J Endourol 2006; 20:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/36\">",
"      Preminger GM, Peterson R, Peters PC, Pak CY. The current role of medical treatment of nephrolithiasis: the impact of improved techniques of stone removal. J Urol 1985; 134:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/37\">",
"      Preminger GM. Renal calculi: pathogenesis, diagnosis, and medical therapy. Semin Nephrol 1992; 12:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/38\">",
"      Fine JK, Pak CY, Preminger GM. Effect of medical management and residual fragments on recurrent stone formation following shock wave lithotripsy. J Urol 1995; 153:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/39\">",
"      Preminger GM. Editorial comment. The value of intensive medical management of distal ureteral calculi in an effort to facilitate spontaneous stone passage. Urology 2000; 56:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/40\">",
"      Teichman JM. Clinical practice. Acute renal colic from ureteral calculus. N Engl J Med 2004; 350:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/41\">",
"      Porpiglia F, Destefanis P, Fiori C, Fontana D. Effectiveness of nifedipine and deflazacort in the management of distal ureter stones. Urology 2000; 56:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/42\">",
"      Dellabella M, Milanese G, Muzzonigro G. Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones. J Urol 2003; 170:2202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/43\">",
"      Porpiglia F, Ghignone G, Fiori C, et al. Nifedipine versus tamsulosin for the management of lower ureteral stones. J Urol 2004; 172:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/44\">",
"      Saita A, Bonaccorsi A, Marchese F, et al. Our experience with nifedipine and prednisolone as expulsive therapy for ureteral stones. Urol Int 2004; 72 Suppl 1:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/45\">",
"      Dellabella M, Milanese G, Muzzonigro G. Medical-expulsive therapy for distal ureterolithiasis: randomized prospective study on role of corticosteroids used in combination with tamsulosin-simplified treatment regimen and health-related quality of life. Urology 2005; 66:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/46\">",
"      Dellabella M, Milanese G, Muzzonigro G. Randomized trial of the efficacy of tamsulosin, nifedipine and phloroglucinol in medical expulsive therapy for distal ureteral calculi. J Urol 2005; 174:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/47\">",
"      Hollingsworth JM, Rogers MA, Kaufman SR, et al. Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet 2006; 368:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30695/abstract/48\">",
"      Yilmaz E, Batislam E, Basar MM, et al. The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones. J Urol 2005; 173:2010.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7371 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-403C6C9E42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_62_30695=[""].join("\n");
var outline_f29_62_30695=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5286840\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PERCUTANEOUS NEPHROLITHOTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13320426\">",
"      - Procedural complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      URETEROSCOPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Rigid ureteroscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Flexible ureteroscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Indications for stent placement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SHOCK WAVE LITHOTRIPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      OPEN STONE SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Prevention of new stone formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Facilitation of stone passage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5286840\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=related_link\">",
"      Diagnosis and acute management of suspected nephrolithiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40231?source=related_link\">",
"      Management of struvite or staghorn calculi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27079?source=related_link\">",
"      Management of ureteral calculi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/5/37970?source=related_link\">",
"      Patient information: Hydronephrosis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/53/28499?source=related_link\">",
"      Patient information: Kidney stones in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=related_link\">",
"      Prevention of recurrent calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/10/27812?source=related_link\">",
"      Renal complications of extracorporeal shock wave lithotripsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=related_link\">",
"      Uric acid nephrolithiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_62_30696="Male condoms";
var content_f29_62_30696=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Male condoms",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/62/30696/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/62/30696/contributors\">",
"     Katherine M Stone, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/62/30696/contributors\">",
"     Markus J Steiner, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/62/30696/contributors\">",
"     Lee Warner, PhD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/62/30696/contributors\">",
"     Willard Cates, Jr, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/62/30696/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/62/30696/contributors\">",
"     Mimi Zieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/62/30696/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/62/30696/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/62/30696/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When used consistently and correctly, male condom use can reduce the risk of pregnancy and many sexually transmitted infections (STIs), including HIV. The condom acts as a barrier by preventing direct contact with semen, genital lesions, and sub-clinical viral shedding on the glans and shaft of the penis. It also prevents contact with penile, vaginal or anal discharges.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF CONDOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Condoms are available in a variety of shapes, sizes, colors, and thicknesses, with or without lubricants or spermicides, and with or without reservoir-tip or nipple-ends [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/1\">",
"     1",
"    </a>",
"    ]. They can be straight-sided or tapered toward the closed end, textured (ribbed) or smooth, solid-colored or nearly transparent, and odorless, scented, or flavored. Most are about 7 inches (180 mm) long, 2 inches (52 mm) wide, and up to 0.003 inches (0.08 mm) thick.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Material",
"    </span>",
"    &nbsp;&mdash;&nbsp;Condoms are made of latex rubber, natural membranes, or synthetic material.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Rubber (latex)",
"      </strong>",
"      &mdash; Approximately 97 percent of male condoms available in the United States are manufactured from natural rubber latex [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/2\">",
"       2",
"      </a>",
"      ]. They are generally less expensive than condoms made from other materials. The dual protection provided by latex condoms against unintended pregnancy, as well as many STIs (particularly HIV), is well documented. However, latex condoms cannot be used by persons with latex sensitivity or allergy, and are not compatible with oil-based lubricants or medications.",
"     </li>",
"     <li>",
"      <strong>",
"       Natural membrane",
"      </strong>",
"      &mdash; A small proportion of condoms are made from the intestinal cecum of lambs (\"natural skin,\" \"natural membrane,\" or \"lambskin\" condoms). While any type of lubricant can be used with these condoms, in contrast to latex condoms, natural membrane condoms contain small pores that may permit the passage of viruses, including hepatitis B virus, herpes simplex virus, and HIV [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. No contraceptive or STI prevention effectiveness data are available. Because of their porosity, they may not provide the same level of protection against STIs as latex condoms and should not be recommended for prevention of sexually transmitted infection [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Synthetic",
"      </strong>",
"      &mdash; Polyurethane and other synthetic materials are also used to manufacture condoms. Compared to latex condoms, synthetic condoms are generally non-allergenic, compatible with both oil-based and water-based lubricants, and have a longer shelf-life [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/6\">",
"       6",
"      </a>",
"      ]. The effectiveness of synthetic condoms to prevent STIs has not been well-studied and FDA labeling restricts their recommended use to latex-sensitive or allergic persons; however, synthetic condoms are believed to provide STI protection similar to latex condoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For pregnancy prevention, synthetic condoms have rates of contraceptive failure comparable to latex condoms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Spermicidal condoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Condoms prelubricated with a small amount of the spermicide nonoxynol-9 (N-9) are no more effective than other lubricated condoms, have a higher cost and shorter shelf-life [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/10\">",
"     10",
"    </a>",
"    ], and may cause adverse effects in users. In one study, spermicidal condom use was associated with increased risk of urinary tract infections in young women [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/11\">",
"     11",
"    </a>",
"    ]. Given these disadvantages and the absence of any advantages of spermicidal condoms, their use is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Quality control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Every condom is tested electronically for holes and weak spots before it is packaged and released for sale. Samples of condoms also undergo a series of additional laboratory tests for leakage, strength, dimensional requirements, and package integrity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/12\">",
"     12",
"    </a>",
"    ]. If the sample condoms fail any of these tests, the entire lot is rejected and destroyed. A 2005 Consumer Reports Survey showed that all condoms tested met industry standards, and that test performance did not vary with price, thickness, or country of manufacture [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Condom effectiveness depends on the motivation, skill level, and experience of the user [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Couples vary widely in their ability to use male condoms consistently and correctly. It is estimated that 2 percent of women will become pregnant during the first year of perfect (ie, consistent and correct) use of the condom, and about 18 of every 100 will become pregnant during the first year of typical use. The typical use and perfect-use effectiveness of a variety of contraceptive methods, including condoms, is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef70218 \" href=\"UTD.htm?12/56/13197\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The marked difference in contraceptive failure rates between perfect and typical use are attributable to failure to use condoms during every act of sexual intercourse and failure to use condoms throughout intercourse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Protection from STIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary noncontraceptive benefit of condom use is the protection offered against STIs. This is an important benefit and an indication to use latex (or synthetic) condoms even if effective contraception is provided by another method, such as hormonal contraception or sterilization. There is general consensus that male condoms should play a central role in any",
"    <span class=\"nowrap\">",
"     STI/HIV",
"    </span>",
"    prevention program [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A condom placed on the penis before any genital contact and used throughout intercourse reduces the risk of partner-to-partner transmission of infectious pathogens associated with semen; penile, vaginal, cervical, and anal epithelium; and penile, vaginal, or anal discharges. Laboratory studies indicate that latex condoms provide an effective physical barrier against passage of even the smallest sexually transmitted pathogen (hepatitis B) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. The level of protection observed during actual use varies because STIs differ in their routes of transmission, as well as in their infectivity and prevalence [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Condoms greatly reduce the risk of STIs transmitted primarily to or from the penile urethra, including gonorrhea, chlamydia, trichomoniasis, hepatitis B infection, and HIV. Condoms should also reduce the risk of STIs transmitted primarily through skin or mucosal surfaces (eg, herpes simplex virus, syphilis, chancroid, and human papillomavirus) when these areas are covered by the condom. However, the protection may be less when condoms do not completely cover the entire infected area [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/2-4,23-25\">",
"     2-4,23-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Well-designed clinical studies of discordant couples (where one partner is infected and the other is not) have shown that consistent use of latex condoms is highly effective against sexually acquired HIV infection. Meta-analyses suggest that consistent condom use reduces the risk of acquiring HIV by approximately 80 to 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Across 13 cohort studies reviewed in one meta-analysis, there were only 11 seroconversions among 587 couples reporting consistent use [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Other STIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical studies of effectiveness of condoms against most other STIs also suggest protection, though the level of protection observed has been inconsistent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/2,22,24,28-31\">",
"     2,22,24,28-31",
"    </a>",
"    ]. Much of this inconsistency can be attributed to limitations in study design [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/2,22,24,31-40\">",
"     2,22,24,31-40",
"    </a>",
"    ], as the overall quality of clinical studies for these STIs is considerably weaker than for the HIV studies. Despite these limitations, studies and systematic reviews have found condom use to be associated with reduced risk of gonorrhea, chlamydia, trichomoniasis, syphilis, genital herpes, and HPV infection in both men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/22,28-31,41-58\">",
"     22,28-31,41-58",
"    </a>",
"    ]. By preventing STIs and their long-term sequelae, condoms also protect female fertility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Condom promotion for STI prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although widespread support exists for targeted interventions to encourage condom use, concerns have been raised about the potential negative consequences of condom promotion. Some interventions promoting condom use may result in risk compensation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/59,60\">",
"     59,60",
"    </a>",
"    ], thus facilitating the onset or frequency of high-risk sexual activity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. No randomized controlled trials have evaluated whether such a compensation effect exists or whether it outweighs the protective effects of condom use for persons at risk. However, a systematic review of 174 sexual risk reduction intervention studies concluded condom-related interventions do not undermine sexual risk reduction efforts by increasing the frequency of sexual behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevention of STIs through use of condoms, as well as other methods, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=see_link\">",
"     \"Prevention of sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ADVANTAGES AND DISADVANTAGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no contraindications to use of condoms, except for allergy to latex material for some users.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Male condoms offer several contraceptive and noncontraceptive benefits to users:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They are a reversible method of contraception requiring no delay in return of fertility following discontinuation of the method.",
"     </li>",
"     <li>",
"      They are readily accessible without a medical examination, prescription, or special fitting, and can be obtained from many sources, including drug stores, grocery stores, clinics, vending machines, gas stations, bars, and mail-order services.",
"     </li>",
"     <li>",
"      Condoms are among the most inexpensive and cost-effective contraceptives. Some programs offer them at no cost.",
"     </li>",
"     <li>",
"      Condoms can be easily and discretely carried by men or women.",
"     </li>",
"     <li>",
"      Condoms have minimal side effects since they are relatively inert and the body is exposed to them only with coitus, not at other times.",
"     </li>",
"     <li>",
"      For some men, condom use may help prevent premature ejaculation.",
"     </li>",
"     <li>",
"      Condoms provide protection against STIs (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Protection from STIs'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Male condoms also have disadvantages that may result in inconsistent use, incorrect use, or nonuse.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many men and their partners complain sensitivity is reduced when condoms are used during intercourse.",
"     </li>",
"     <li>",
"      Foreplay is interrupted to put the condom on, although placing the condom can be incorporated into foreplay activity.",
"     </li>",
"     <li>",
"      Some men cannot consistently maintain an erection when wearing a condom.",
"     </li>",
"     <li>",
"      Some men and women feel embarrassed or uncomfortable when obtaining condoms or suggesting use of condoms.",
"     </li>",
"     <li>",
"      Using a condom requires partner cooperation. In some instances, men will not accept wearing a condom, thus making male condom use impossible.",
"     </li>",
"     <li>",
"      Some individuals are sensitive to latex (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Latex sensitivity'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Some men have difficulty finding a condom with a proper fit, which may decrease satisfaction and increase problems such as breakage and slippage [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/64-66\">",
"       64-66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     COUNSELING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;All clients should understand why condoms are recommended (protection from STIs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pregnancy), when to use them, how to use them most effectively, how to discuss condom use with their partner(s), and how to integrate condom use into intercourse. Counseling should be adapted to each client's needs since clients may have formed their own attitudes about condom use and may have had varying experiences with condoms. Similarly, the counseling session should be tailored to each client's risk factors, abilities, needs, and readiness to change [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with all contraceptive counseling, clients should understand the risks and benefits of the range of contraceptive methods available (",
"    <a class=\"graphic graphic_figure graphicRef57795 \" href=\"UTD.htm?31/46/32488\">",
"     figure 1",
"    </a>",
"    ). Pregnant women at high risk for STIs should be counseled to use condoms to protect their fetus, their partner(s), and themselves. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Latex sensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;When exposed to latex-containing products, persons sensitive or allergic to natural rubber latex may experience irritation, allergic contact dermatitis, or systemic anaphylactic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. It is estimated that 1 to 6 percent of the US population is allergic to latex [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/69\">",
"     69",
"    </a>",
"    ], but the prevalence can be much higher in certain groups, such as health care workers and patients who have repeated exposure to latex-containing medical devices (surgical and examination gloves, catheters, intubation tubes, anesthesia masks, dental dams) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of dermatitis\", section on 'Latex allergy'",
"    </a>",
"    .) Additional comprehensive information on latex allergy can also be obtained from the American Latex Allergy Association (see",
"    <a class=\"external\" href=\"file://www.latexallergyresources.org/\">",
"     www.latexallergyresources.org",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    All clients should be questioned for potential latex allergy: as an example, does the client experience itching, rash, or wheezing after wearing latex gloves or inflating a balloon? [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. If latex sensitivity is suspected, the client can be referred for allergy skin testing or offered nonlatex condoms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Allergic reactions that occur only after exposure to latex condoms and not after exposure to other latex-containing products may be due to brand-specific condom attributes, such as spermicides, lubricants, perfumes, local anesthetics, or other chemical agents added during the manufacturing process [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/72\">",
"     72",
"    </a>",
"    ]. In these cases, clients are advised to try a different brand.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     STRATEGIES FOR PROMOTING EFFECTIVE CONDOM USE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Effective use of condoms depends heavily on the skill level and experience of the user",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate counseling can minimize problems with condom use [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/25\">",
"     25",
"    </a>",
"    ]. Interventions promoting condom use should address user-related behaviors that result in inconsistent use, incorrect use, or nonuse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Emphasize that condoms should be used with every coital act",
"    </span>",
"    &nbsp;&mdash;&nbsp;Make sure clients understand that condoms are most effective when used correctly during every act of anal, vaginal, and oral intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/73\">",
"     73",
"    </a>",
"    ]. Strategies that emphasize condom use for contraception in addition to disease prevention may help decrease nonuse [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/74\">",
"     74",
"    </a>",
"    ]. Recommend that clients use a new condom for each act of intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Instruct the client on use and supervise practice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Encourage inexperienced clients to practice using condoms. Many problems that occur during condom use can be attributed to inexperience and can be overcome with practice [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/76\">",
"     76",
"    </a>",
"    ]. Users who have had negative experiences with condoms may be at risk of discontinuing condom use altogether [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Inform the client to use the condom during the entire sexual act",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some men put condoms on after starting intercourse or remove condoms prior to ejaculation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/36,78-81\">",
"     36,78-81",
"    </a>",
"    ]. These behaviors could expose partners to risk of pregnancy or STI. Clients should be counseled to use condoms throughout intercourse, from beginning of genital contact to after ejaculation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Provide condoms at low or no cost to encourage use",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some settings, providing clients with a large number of condoms at low or no cost facilitates use. Providing clients with only a few condoms is only a short-term solution for clients who find the health care system inaccessible or who find it embarrassing to return repeatedly for condoms. Selling condoms, even at a low cost, dramatically reduces the number of condoms a client will obtain from a clinic compared with the number of free condoms",
"    <span class=\"nowrap\">",
"     s/he",
"    </span>",
"    will take.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Discuss what to do if a condom slips or breaks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although users often fear that the condom will break or fall off during use, these events are rare. The majority of studies show that condoms break approximately 2 percent of the time during vaginal intercourse; a similar proportion slip off completely [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/82-86\">",
"     82-86",
"    </a>",
"    ]; however, these rates widely vary across some studies (0 to 22 percent for breakage; 0 to 9 percent for slippage) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/82,87,88\">",
"     82,87,88",
"    </a>",
"    ]. During anal intercourse, rates of breakage and slippage may be slightly higher [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. If a user complains of repeated breakage or slippage, review proper condom use with him or her.",
"   </p>",
"   <p>",
"    Because breakage or slippage are possible, advise users to have several condoms available in case a condom is torn or put on incorrectly, falls off, or repeated intercourse is desired. Emergency contraception, now available over the counter without a prescription, can be used as a back-up method against pregnancy in case a condom breaks or falls off. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/5/31833?source=see_link\">",
"     \"Emergency contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, immediately gently washing the penis, vulva, anus, and adjacent areas with soap and water may help to reduce the risk of acquiring an STI, although the effectiveness of this practice has not been well-studied. Inserting an applicator full of spermicide into the vagina as soon as possible may also help to prevent pregnancy. Women should not douche.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Discuss use of lubricants and medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Water-based lubricants (eg, K-Y, Astroglide, saliva, glycerine, silicone) can be used with latex condoms, but oil-based lubricants reduce latex condom integrity and may facilitate breakage [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/91\">",
"     91",
"    </a>",
"    ]. Common oil-based products that should not come into contact with latex condoms include baby oil, cold creams, edible oils (olive, peanut, corn, sunflower), whipped cream, hand and body lotions, massage oil, petroleum jelly, rubbing alcohol, suntan oil and lotions, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"     mineral oil",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Clients should be aware of whether products they use (lubricants, medications) that come into contact with their condoms contain oil. This cannot be determined reliably by the look, feel, or characteristics (eg, water soluble) of the product. Spermicides are water-based. Other vaginal medications, however, often contain oil-based ingredients that can damage latex condoms (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/23/40306?source=see_link\">",
"     butoconazole",
"    </a>",
"    contains",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"     mineral oil",
"    </a>",
"    ); therefore, clients using these medications should remain abstinent or use synthetic condoms until intravaginal medical therapy is fully completed. Oil-based products may be safely used with polyurethane condoms; however, they may not be compatible with all synthetic condoms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lubricants are best applied to the vagina or the outside of the condom. Adding lubricant to the inside of the",
"    <span class=\"nowrap\">",
"     condom/outside",
"    </span>",
"    of the penis increases the chance of slippage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     INSTRUCTIONS FOR USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;During a World Health Organization Experts Meeting (Geneva, June 22 to 24, 2005) to develop a Global Handbook for Family Planning Providers, consensus was reached on five key condom instructions. These five messages, with minor modifications and additional explanation, follow [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/13,25,93\">",
"     13,25,93",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <strong>",
"     (1) Use a new condom for each act of intercourse if any risk of pregnancy or STI exists.",
"    </strong>",
"   </p>",
"   <p>",
"    Clients should discuss condom use with their partner before intercourse and should have an adequate supply of condoms readily available. Extra condoms will be needed if the first is damaged, torn before use, or put on incorrectly.",
"   </p>",
"   <p>",
"    The condom package should be opened carefully to avoid damaging it with fingernails, teeth, or other sharp objects. Condoms in damaged packages or that show obvious signs of deterioration (brittleness, stickiness, or discoloration) should not be used.",
"   </p>",
"   <p>",
"    <strong>",
"     (2) Before any genital contact, place the condom on the tip of the erect penis with the rolled side out.",
"    </strong>",
"   </p>",
"   <p>",
"    Unrolling the condom a short distance helps to make sure the condom is being unrolled in the right direction. If the condom does not unroll easily, it is probably inside-out and should be discarded because flipping it over and using it could expose the partner to infectious organisms contained in the pre-ejaculate.",
"   </p>",
"   <p>",
"    <strong>",
"     (3) Unroll the condom all the way to the base of the erect penis.",
"    </strong>",
"   </p>",
"   <p>",
"    The condom should cover the penile glans and shaft.",
"   </p>",
"   <p>",
"    Adequate, appropriate lubrication (natural or synthetic) is important before intercourse (see",
"    <a class=\"local\" href=\"#H25\">",
"     'Discuss use of lubricants and medications'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    <strong>",
"     (4) Immediately after ejaculation, hold the rim of the condom and withdraw the penis while it is still erect.",
"    </strong>",
"   </p>",
"   <p>",
"    The condom is held firmly against the base of the penis to prevent slippage and leakage of semen.",
"   </p>",
"   <p>",
"    <strong>",
"     (5) Throw away the used condom safely. Condoms should not be flushed down a toilet.",
"    </strong>",
"   </p>",
"   <p>",
"    After removing the condom, it should be checked for visible damage, and then wrapped in tissue and discarded. Condoms should not be reused.",
"   </p>",
"   <p>",
"    A new condom should be used from \"beginning to end\" with each act of intercourse. If the condom breaks or falls off during intercourse but before ejaculation, it should be replaced with a new condom. New condoms should also be used for prolonged intercourse, and for different types of intercourse within a single session (eg, change the condom after anal sex if vaginal sex also is planned).",
"   </p>",
"   <p>",
"    If the condom breaks, falls off, leaks, is damaged, or is not used, then pregnancy and infection are possible (see",
"    <a class=\"local\" href=\"#H24\">",
"     'Discuss what to do if a condom slips or breaks'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     STORAGE AND EXPIRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Condoms should be stored in a cool and dry place, out of direct sunlight, as excessive heat will weaken latex. However, latex condoms can probably be carried, for convenience, in a wallet for up to one month [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30696/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clients should check the expiration or manufacture date on the box or individual package. Latex condoms should not be used beyond their expiration date or more than five years after the manufacturing date.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/2/22563?source=see_link\">",
"       \"Patient information: Barrier methods of birth control (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Condoms are made of latex rubber, natural membranes, or synthetic material. Latex accounts for 97 percent of male condoms and has the advantages of low cost and protection from sexually transmitted diseases (including human immunodeficiency virus), as well as pregnancy, but can be damaged by oil-based lubricants. Natural membrane condoms contain small pores that may permit the passage of viruses; therefore, they are not recommended for STI prevention. Synthetic condoms are approved only for people who are allergic or sensitive to latex and may provide similar protection against pregnancy and STIs as latex condoms. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Types of condoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Condoms prelubricated with spermicide are no more effective for STI prevention than other lubricated condoms, and have a higher cost and shorter shelf-life. We suggest avoiding this type of condom (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Spermicidal condoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Condom effectiveness depends on the motivation, skill level, and experience of the user. It is estimated that 2 percent of women will become pregnant during the first year of perfect (ie, consistent and correct) use of the condom, and about 18 percent of women will become pregnant during the first year of typical use. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Contraception'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Latex condom use provides protection from acquisition and transmission of sexually transmitted infections. In couples at risk, we recommend use of latex condoms (and synthetic condoms for latex sensitive or allergic persons) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Protection from STIs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Appropriate counseling and instruction can minimize problems with condom use. The most critical factors for protection from unintended pregnancy and sexually transmitted infections are that a new condom is placed on the penis before any genital contact, remains intact until the penis is withdrawn, and is used with every act of intercourse. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Strategies for promoting effective condom use'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Instructions for use'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acknowledgment: Support for this topic review was provided with funds from the United States Agency for International Development (USAID) cooperative agreement #GPO-A-OO-05-00022-00, the CRTU Program. The views expressed in this review, however, do not necessarily reflect those of USAID.",
"   </p>",
"   <p>",
"    The findings and conclusions in this topic review are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention (CDC).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Consumer Union: Condoms: Extra protection. Consumer Reports 2005; February.",
"    </li>",
"    <li>",
"     National Institute of Allergy and Infectious Diseases. Workshop Summary: Scientific Evidence on Condom Effectiveness for Sexually Transmitted Diseases (STI) Prevention. July 20, 2001. file://www.niaid.nih.gov/dmid/STIs/condomreport.pdf. (Accessed May 4, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/3\">",
"      Carey RF, Lytle CD, Cyr WH. Implications of laboratory tests of condom integrity. Sex Transm Dis 1999; 26:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/4\">",
"      Lytle CD, Routson LB, Seaborn GB, et al. An in vitro evaluation of condoms as barriers to a small virus. Sex Transm Dis 1997; 24:161.",
"     </a>",
"    </li>",
"    <li>",
"     Consumer's Union. Condoms get better: tests of 30 models show far fewer failures than in past years. Consumer Reports. June, 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/6\">",
"      Gallo MF, Grimes DA, Lopez LM, Schulz KF. Non-latex versus latex male condoms for contraception. Cochrane Database Syst Rev 2006; :CD003550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/7\">",
"      Steiner MJ, Dominik R, Rountree RW, et al. Contraceptive effectiveness of a polyurethane condom and a latex condom: a randomized controlled trial. Obstet Gynecol 2003; 101:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/8\">",
"      Frezieres RG, Walsh TL, Nelson AL, et al. Evaluation of the efficacy of a polyurethane condom: results from a randomized, controlled clinical trial. Fam Plann Perspect 1999; 31:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/9\">",
"      Walsh TL, Frezieres RG, Peacock K, et al. Evaluation of the efficacy of a nonlatex condom: results from a randomized, controlled clinical trial. Perspect Sex Reprod Health 2003; 35:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Nonoxynol-9 spermicide contraception use--United States, 1999. MMWR Morb Mortal Wkly Rep 2002; 51:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/11\">",
"      Fihn SD, Boyko EJ, Normand EH, et al. Association between use of spermicide-coated condoms and Escherichia coli urinary tract infection in young women. Am J Epidemiol 1996; 144:512.",
"     </a>",
"    </li>",
"    <li>",
"     ASTM (American Society for Testing Materials). Annual book of ASTM standards: Easton MD: ASTM: section 9, rubber. Volume 09.02 Rubber products; standard specifications for rubber contraceptives (male condoms-D3492). West Conshohocken, PA: American Society for Testing Materials, 1996.",
"    </li>",
"    <li>",
"     Warner, L, Steiner, MJ. Male Condoms. In: Contraceptive Technology, 19th ed, Hatcher, RA, Guest, F, Stewart, F, Stewart, G, Kowal, D, Trussell, J, Cates, W, Policar, M (Eds), Ardent Media, New York 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/14\">",
"      Halperin DT, Steiner MJ, Cassell MM, et al. The time has come for common ground on preventing sexual transmission of HIV. Lancet 2004; 364:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/15\">",
"      Conant MA, Spicer DW, Smith CD. Herpes simplex virus transmission: condom studies. Sex Transm Dis 1984; 11:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/16\">",
"      Katznelson S, Drew WL, Mintz L. Efficacy of the condom as a barrier to the transmission of cytomegalovirus. J Infect Dis 1984; 150:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/17\">",
"      Rietmeijer CA, Krebs JW, Feorino PM, Judson FN. Condoms as physical and chemical barriers against human immunodeficiency virus. JAMA 1988; 259:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/18\">",
"      Van de Perre P, Jacobs D, Sprecher-Goldberger S. The latex condom, an efficient barrier against sexual transmission of AIDS-related viruses. AIDS 1987; 1:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/19\">",
"      Judson FN, Ehret JM, Bodin GF, et al. In vitro evaluations of condoms with and without nonoxynol 9 as physical and chemical barriers against Chlamydia trachomatis, herpes simplex virus type 2, and human immunodeficiency virus. Sex Transm Dis 1989; 16:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/20\">",
"      Cates W Jr. The condom forgiveness factor: the positive spin. Sex Transm Dis 2002; 29:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/21\">",
"      Mann JR, Stine CC, Vessey J. The role of disease-specific infectivity and number of disease exposures on long-term effectiveness of the latex condom. Sex Transm Dis 2002; 29:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/22\">",
"      Warner L, Stone KM, Macaluso M, et al. Condom use and risk of gonorrhea and Chlamydia: a systematic review of design and measurement factors assessed in epidemiologic studies. Sex Transm Dis 2006; 33:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/23\">",
"      Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     Stone, KM, Thomas, E, Timyan, J. Barrier methods for the prevention of sexually transmitted diseases. In: Sexually Transmitted Diseases, 3rd ed, Holmes, KK, Sparling, PF, Mardh, PA (Eds), McGraw-Hill, New York 1998.",
"    </li>",
"    <li>",
"     Steiner, MJ, Warner, L, Stone, KM, Cates, W Jr. Condoms and other barrier methods for prevention of STI/HIV infection, and pregnancy. In: Sexually Transmitted Diseases, 4th ed, Holmes, KK, Sparling, PF, Mardh, PA, (Eds), McGraw-Hill, New York (In press).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/26\">",
"      Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2001; :CD003255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/27\">",
"      Pinkerton SD, Abramson PR. Effectiveness of condoms in preventing HIV transmission. Soc Sci Med 1997; 44:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/28\">",
"      d'Oro LC, Parazzini F, Naldi L, La Vecchia C. Barrier methods of contraception, spermicides, and sexually transmitted diseases: a review. Genitourin Med 1994; 70:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/29\">",
"      Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 2002; 29:725.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Report to Congress: prevention of genital human papillomavirus infection, January 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/31\">",
"      Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ 2004; 82:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/32\">",
"      Aral SO, Peterman TA. Measuring outcomes of behavioural interventions for STD/HIV prevention. Int J STD AIDS 1996; 7 Suppl 2:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/33\">",
"      Crosby R, DiClemente RJ, Holtgrave DR, Wingood GM. Design, measurement, and analytical considerations for testing hypotheses relative to condom effectiveness against non-viral STIs. Sex Transm Infect 2002; 78:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/34\">",
"      Devine OJ, Aral SO. The impact of inaccurate reporting of condom use and imperfect diagnosis of sexually transmitted disease infection in studies of condom effectiveness: a simulation-based assessment. Sex Transm Dis 2004; 31:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/35\">",
"      Steiner MJ, Feldblum PJ, Padian N. Invited commentary: condom effectiveness-will prostate-specific antigen shed new light on this perplexing problem? Am J Epidemiol 2003; 157:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/36\">",
"      Warner L, Clay-Warner J, Boles J, Williamson J. Assessing condom use practices. Implications for evaluating method and user effectiveness. Sex Transm Dis 1998; 25:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/37\">",
"      Warner L, Macaluso M, Austin HD, et al. Application of the case-crossover design to reduce unmeasured confounding in studies of condom effectiveness. Am J Epidemiol 2005; 161:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/38\">",
"      Warner L, Newman DR, Austin HD, et al. Condom effectiveness for reducing transmission of gonorrhea and chlamydia: the importance of assessing partner infection status. Am J Epidemiol 2004; 159:242.",
"     </a>",
"    </li>",
"    <li>",
"     Warner, L, Macaluso, M, Newman, DR, et al. Re: Condom effectiveness for prevention of chlamydia trachomatis infection. Sex Transm Inf (In press).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/40\">",
"      Zenilman JM, Weisman CS, Rompalo AM, et al. Condom use to prevent incident STDs: the validity of self-reported condom use. Sex Transm Dis 1995; 22:15.",
"     </a>",
"    </li>",
"    <li>",
"     Winer, RL, Hughes, JP, Feng, Q, et al. The effect of consistent condom use on the risk of genital HPV infection among newly sexually active young women. International Society for STI Research, Abstract Nr. MP-120, Amsterdam, July 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/42\">",
"      Casper C, Wald A. Condom use and the prevention of genital herpes acquisition. Herpes 2002; 9:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/43\">",
"      Wald A, Langenberg AG, Krantz E, et al. The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med 2005; 143:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/44\">",
"      Wald A, Langenberg AG, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001; 285:3100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/45\">",
"      Barlow D. The condom and gonorrhoea. Lancet 1977; 2:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/46\">",
"      Ramstedt K, Forssman L, Giesecke J, Granath F. Risk factors for Chlamydia trachomatis infection in 6810 young women attending family planning clinics. Int J STD AIDS 1992; 3:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/47\">",
"      Upchurch DM, Brady WE, Reichart CA, Hook EW 3rd. Behavioral contributions to acquisition of gonorrhea in patients attending an inner city sexually transmitted disease clinic. J Infect Dis 1990; 161:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/48\">",
"      Fennema JS, van Ameijden EJ, Coutinho RA, Van den Hoek A. Clinical sexually transmitted diseases among human immunodeficiency virus-infected and noninfected drug-using prostitutes. Associated factors and interpretation of trends, 1986 to 1994. Sex Transm Dis 1997; 24:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/49\">",
"      Levine WC, Revollo R, Kaune V, et al. Decline in sexually transmitted disease prevalence in female Bolivian sex workers: impact of an HIV prevention project. AIDS 1998; 12:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/50\">",
"      Hooper RR, Reynolds GH, Jones OG, et al. Cohort study of venereal disease. I: the risk of gonorrhea transmission from infected women to men. Am J Epidemiol 1978; 108:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/51\">",
"      Baeten JM, Nyange PM, Richardson BA, et al. Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol 2001; 185:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/52\">",
"      Cates WC Jr, Holmes KK. Re: Condom efficacy against gonorrhea and nongonococcal urethritis. Am J Epidemiol 1996; 143:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/53\">",
"      S&aacute;nchez J, Gotuzzo E, Escamilla J, et al. Sexually transmitted infections in female sex workers: reduced by condom use but not by a limited periodic examination program. Sex Transm Dis 1998; 25:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/54\">",
"      Schwartz MA, Lafferty WE, Hughes JP, Handsfield HH. Risk factors for urethritis in heterosexual men. The role of fellatio and other sexual practices. Sex Transm Dis 1997; 24:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/55\">",
"      Hogewoning CJ, Bleeker MC, van den Brule AJ, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer 2003; 107:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/56\">",
"      Bleeker MC, Hogewoning CJ, Voorhorst FJ, et al. Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia. Int J Cancer 2003; 107:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/57\">",
"      Alfonsi, GA, Shlay, J. The effectiveness of condoms for the prevention of sexually transmitted diseases. Current Women's Health Reviews 2005; 1:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/58\">",
"      Koss CA, Dunne EF, Warner L. A systematic review of epidemiologic studies assessing condom use and risk of syphilis. Sex Transm Dis 2009; 36:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/59\">",
"      Richens J, Imrie J, Copas A. Condoms and seat belts: the parallels and the lessons. Lancet 2000; 355:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/60\">",
"      Cassell MM, Halperin DT, Shelton JD, Stanton D. Risk compensation: the Achilles' heel of innovations in HIV prevention? BMJ 2006; 332:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/61\">",
"      Kajubi P, Kamya MR, Kamya S, et al. Increasing condom use without reducing HIV risk: results of a controlled community trial in Uganda. J Acquir Immune Defic Syndr 2005; 40:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/62\">",
"      Imrie J, Stephenson JM, Cowan FM, et al. A cognitive behavioural intervention to reduce sexually transmitted infections among gay men: randomised trial. BMJ 2001; 322:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/63\">",
"      Smoak ND, Scott-Sheldon LA, Johnson BT, Carey MP. Sexual risk reduction interventions do not inadvertently increase the overall frequency of sexual behavior: a meta-analysis of 174 studies with 116,735 participants. J Acquir Immune Defic Syndr 2006; 41:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/64\">",
"      Cecil M, Nelson AL, Trussell J, Hatcher R. If the condom doesn't fit, you must resize it. Contraception 2010; 82:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/65\">",
"      Reece M, Herbenick D, Dodge B. Penile dimensions and men's perceptions of condom fit and feel. Sex Transm Infect 2009; 85:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/66\">",
"      Smith AM, Jolley D, Hocking J, et al. Factors affecting men's liking of condoms they have used. Int J STD AIDS 1999; 10:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/67\">",
"      Rotz LD, Dotson DA, Damon IK, et al. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm Rep 2001; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/68\">",
"      Zaza S, Reeder JM, Charles LE, Jarvis WR. Latex sensitivity among perioperative nurses. AORN J 1994; 60:806.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Occupational Safety and Health. Preventing allergic reactions to natural rubber latex in the workplace [NIOSH alert]. National Institute for Occupational Safety and Health, June 1997 [DHHS (NIOSH) publication No. 97-135].",
"    </li>",
"    <li>",
"     Food and Drug Administration. Allergic reactions to latex-containing medical devices [press release]. Rockville MD; Food and Drug Administration, March 29, 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/71\">",
"      Yassin MS, Lierl MB, Fischer TJ, et al. Latex allergy in hospital employees. Ann Allergy 1994; 72:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/72\">",
"      Hamann CP, Kick SA. Update: immediate and delayed hypersensitivity to natural rubber latex. Cutis 1993; 52:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/73\">",
"      Steiner MJ, Cates W Jr, Warner L. The real problem with male condoms is nonuse. Sex Transm Dis 1999; 26:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/74\">",
"      Cates W Jr, Steiner MJ. Dual protection against unintended pregnancy and sexually transmitted infections: what is the best contraceptive approach? Sex Transm Dis 2002; 29:168.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines. NNWR 2006; 55(RR-11).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/76\">",
"      Steiner M, Piedrahita C, Glover L, Joanis C. Can condom users likely to experience condom failure be identified? Fam Plann Perspect 1993; 25:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/77\">",
"      Norris AE, Ford K. Associations between condom experiences and beliefs, intentions, and use in a sample of urban, low-income, African-American and Hispanic youth. AIDS Educ Prev 1994; 6:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/78\">",
"      Paz-Bailey G, Koumans EH, Sternberg M, et al. The effect of correct and consistent condom use on chlamydial and gonococcal infection among urban adolescents. Arch Pediatr Adolesc Med 2005; 159:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/79\">",
"      Fishbein M, Pequegnat W. Evaluating AIDS prevention interventions using behavioral and biological outcome measures. Sex Transm Dis 2000; 27:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/80\">",
"      Calzavara L, Burchell AN, Remis RS, et al. Delayed application of condoms is a risk factor for human immunodeficiency virus infection among homosexual and bisexual men. Am J Epidemiol 2003; 157:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/81\">",
"      Crosby RA, Sanders SA, Yarber WL, et al. Condom use errors and problems among college men. Sex Transm Dis 2002; 29:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/82\">",
"      Albert AE, Warner DL, Hatcher RA, et al. Condom use among female commercial sex workers in Nevada's legal brothels. Am J Public Health 1995; 85:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/83\">",
"      Cook L, Nanda K, Taylor D. Randomized crossover trial comparing the eZ.on plastic condom and a latex condom. Contraception 2001; 63:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/84\">",
"      Valappil T, Kelaghan J, Macaluso M, et al. Female condom and male condom failure among women at high risk of sexually transmitted diseases. Sex Transm Dis 2005; 32:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/85\">",
"      Macaluso M, Kelaghan J, Artz L, et al. Mechanical failure of the latex condom in a cohort of women at high STD risk. Sex Transm Dis 1999; 26:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/86\">",
"      Walsh TL, Frezieres RG, Peacock K, et al. Effectiveness of the male latex condom: combined results for three popular condom brands used as controls in randomized clinical trials. Contraception 2004; 70:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/87\">",
"      Russell-Brown P, Piedrahita C, Foldesy R, et al. Comparison of condom breakage during human use with performance in laboratory testing. Contraception 1992; 45:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/88\">",
"      Mukenge-Tshibaka L, Alary M, Geraldo N, Lowndes CM. Incorrect condom use and frequent breakage among female sex workers and their clients. Int J STD AIDS 2005; 16:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/89\">",
"      Silverman BG, Gross TP. Use and effectiveness of condoms during anal intercourse. A review. Sex Transm Dis 1997; 24:11.",
"     </a>",
"    </li>",
"    <li>",
"     Richters, J, Kippax, S. Condoms for anal sex. In: Condoms, 1st ed, Mindel, A (Ed), BMJ Publishing Group, London 2000. p. 132.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30696/abstract/91\">",
"      Voeller B, Coulson AH, Bernstein GS, Nakamura RM. Mineral oil lubricants cause rapid deterioration of latex condoms. Contraception 1989; 39:95.",
"     </a>",
"    </li>",
"    <li>",
"     Personal communication from Eli Carter.",
"    </li>",
"    <li>",
"     World Health Organization Department of Reproductive Health and Research and Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs, INFO Project. Family Planning: A Global Handbook for Providers. Baltimore and Geneva: CCP and WHO, 2007.",
"    </li>",
"    <li>",
"     Glasser, G, Hatcher, RA. The effect on condom integrity of carrying a condom in a wallet for three months [abstract]. Proceedings of the American College of Obstetricians and Gynecologists District IV Conference, November 1992. San Juan PR.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5463 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-211.167.112.17-380DEE3FB3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_62_30696=[""].join("\n");
var outline_f29_62_30696=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF CONDOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Material",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Spermicidal condoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Quality control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Protection from STIs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - HIV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Other STIs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Condom promotion for STI prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ADVANTAGES AND DISADVANTAGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Advantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Disadvantages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      General",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Latex sensitivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      STRATEGIES FOR PROMOTING EFFECTIVE CONDOM USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Effective use of condoms depends heavily on the skill level and experience of the user",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Emphasize that condoms should be used with every coital act",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Instruct the client on use and supervise practice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Inform the client to use the condom during the entire sexual act",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Provide condoms at low or no cost to encourage use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Discuss what to do if a condom slips or breaks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Discuss use of lubricants and medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      INSTRUCTIONS FOR USE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      STORAGE AND EXPIRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5463\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5463|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/46/32488\" title=\"figure 1\">",
"      Comparison of effectiveness of contraceptive methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5463|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/56/13197\" title=\"table 1\">",
"      Pregnancy rate during first year of contraception",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/5/31833?source=related_link\">",
"      Emergency contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/2/22563?source=related_link\">",
"      Patient information: Barrier methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=related_link\">",
"      Prevention of sexually transmitted infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_62_30697="Evaluation of the living kidney donor and risk of donor nephrectomy";
var content_f29_62_30697=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the living kidney donor and risk of donor nephrectomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/62/30697/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/62/30697/contributors\">",
"     Emilio Ramos, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/62/30697/contributors\">",
"     Anitha Vijayan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/62/30697/contributors\">",
"     John Vella, MD, FACP, FRCP, FASN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/62/30697/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/62/30697/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/62/30697/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/62/30697/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/62/30697/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of patients awaiting renal transplantation in the United States steadily has increased over time, with the gap between allograft supply and demand continuing to widen. An increase in the number of living donors (including living-unrelated donors) may ameliorate this trend [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/1-6\">",
"     1-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recipients of living-related allografts enjoy a significant graft survival advantage over those who receive deceased donor grafts. In addition, living donor transplants have the advantage of being performed with minimal delay, thereby permitting preemptive transplantation (transplantation prior to dialysis). There is also increasing evidence that patients who undergo preemptive transplantation have improved graft survival compared to those who undergo a period of dialysis before transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14170?source=see_link\">",
"     \"Risk factors for graft failure in kidney transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11224?source=see_link\">",
"     \"Dialysis issues prior to and after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Previously, only individuals who were genetically related to the recipient were considered possible candidates for kidney donation. However, kidneys from unrelated living donors are increasingly being used since recipients of living-unrelated kidneys also have a graft survival advantage when compared to those who receive deceased donor kidneys. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31925?source=see_link\">",
"     \"Living unrelated donors in renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Within the United States, CMS (Centers for Medicare and Medicaid Services) has regulated the participation of an \"independent living donor advocate\" (ILDA) into the evaluation of all living donors, whether related, unrelated or altruistic. One of the primary roles of the ILDA is to ensure the potential donor is free of coercion from the potential recipient or other involved individuals.",
"   </p>",
"   <p>",
"    The evaluation of a potential renal allograft living donor is presented here, although most is relevant to the deceased donor as well. The evaluation of the renal transplant recipient is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=see_link\">",
"     \"Evaluation of the potential renal transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DONOR EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The workup of a potential living kidney donor generally starts with an assessment of the donor and recipient blood groups and a crossmatch between the individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/4\">",
"     4",
"    </a>",
"    ]. Issues surrounding ABO incompatibility and HLA sensitization are discussed separately, with some programs offering transplantation across such barriers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31925?source=see_link\">",
"     \"Living unrelated donors in renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=see_link\">",
"     \"HLA and ABO sensitization and desensitization in renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As rhesus antigens are not expressed on kidney tissue cell surfaces, this antigen system does not play a major role in allograft rejection. As a result, matching for rhesus antigens is not relevant in most settings, although some (but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/7\">",
"     7",
"    </a>",
"    ]) evidence suggests that rhesus antigen mismatching may be associated with decreased allograft survival [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, female Rh negative recipients of child-bearing age are at risk for sensitization when the donor is Rh positive and should receive a dose of anti-Rh immunoglobulin (Rhogam) at the time of transplantation.",
"   </p>",
"   <p>",
"    In some centers, HLA typing is not even performed for most donors because of the current availability of markedly improved immunosuppressive regimens and outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/4,9\">",
"     4,9",
"    </a>",
"    ]. As an example, allograft survival with an unrelated living donor is similar to that from a one-haplotype matched living donor [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A thorough medical, surgical, and psychosocial evaluation of the prospective donor is performed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/10\">",
"     10",
"    </a>",
"    ]. The overall purpose is to ensure that the potential donor is in good health, has normal kidney function and structure, and is not a risk to the recipient with respect to transmission of viral or other infections.",
"   </p>",
"   <p>",
"    In men, a detailed physical examination should include a testicular examination, and in those over the age of 50, a measurement of prostate specific antigen and a digital rectal examination. Women should undergo breast examination, mammography (if over the age of 40), pelvic examination, and Papanicolaou smear. All potential donors over 50 years of age should undergo colon cancer screening, preferably with a colonoscopy. Younger donors with family history of breast cancer and colon cancer should undergo screening as per American Cancer Society guidelines.",
"   </p>",
"   <p>",
"    The following clinical tests are also usually performed as part of the donor evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/9,11-13\">",
"     9,11-13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count, blood urea nitrogen, serum creatinine, electrolytes, fasting blood glucose, cholesterol, triglycerides, calcium, phosphorous, and albumin, liver function tests, prothrombin time, and partial thromboplastin time, glycosylated hemoglobin (HbA1C)",
"     </li>",
"     <li>",
"      ABO blood type",
"     </li>",
"     <li>",
"      HLA assay",
"     </li>",
"     <li>",
"      Urinalysis with microscopy and urine culture",
"     </li>",
"     <li>",
"      24 hour urine for protein excretion or early morning spot urine for protein or microalbumin to creatinine ratio",
"     </li>",
"     <li>",
"      Urine collection for creatinine clearance or estimation of glomerular filtration rate (GFR) via estimation equations",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      measurement via isotopic estimation [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/9,14\">",
"       9,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Viral testing includes HIV, HTLV, cytomegalovirus, herpes simplex virus, Epstein Barr virus, Varicella Zoster, and hepatitis B and C [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/13,15,16\">",
"       13,15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chest x-ray",
"     </li>",
"     <li>",
"      Electrocardiogram",
"     </li>",
"     <li>",
"      Rapid plasma reagin (RPR) or VDRL, and (possibly) toxoplasma testing and Chagas antibody (for donors from Central or South America or Mexico)",
"     </li>",
"     <li>",
"      Renal imaging (Helical CT, CT angiogram, or MR angiogram) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/17-20\">",
"       17-20",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some patients, further evaluation may include echocardiography, stress test, colonoscopy, endoscopy, cystoscopy, renal biopsy, oral glucose tolerance test, and other tests [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/11\">",
"     11",
"    </a>",
"    ]. Possible future recommendations for screening may include West Nile virus and HHV-8 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of some of the issues related to the evaluation and workup of the potential living donor is presented in a few tables from an international forum titled \"Care of the Live Kidney Donor\" [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/9\">",
"     9",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef72684 \" href=\"UTD.htm?1/57/1949\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef53735 \" href=\"UTD.htm?9/4/9293\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef65502 \" href=\"UTD.htm?26/13/26844\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EXCLUSIONARY CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon this evaluation, a potential kidney donor may be accepted, excluded, or require additional assessment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Absolute contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is substantial variability in the criteria used to exclude potential donors, generally accepted absolute contraindications include the presence of one or more of the following clinical characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/10,11,15,21\">",
"     10,11,15,21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Proteinuria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hematuria (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Renal function'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Impaired renal function (defined as GFR &lt;80",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Renal function'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Markedly abnormal urologic and renal vascular abnormalities",
"     </li>",
"     <li>",
"      Active infection",
"     </li>",
"     <li>",
"      Chronic active viral infection (HIV, HTLV, Hepatitis B and C virus)",
"     </li>",
"     <li>",
"      Active malignancy",
"     </li>",
"     <li>",
"      History of malignancy, arising from lung, breast, renal or urologic, gastrointestinal, or hematologic organs and melanoma",
"     </li>",
"     <li>",
"      Chronic illness, particularly pulmonary, liver, autoimmune, neurologic, or cardiac disease",
"     </li>",
"     <li>",
"      Clinically significant hypertension (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Hypertension'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Nephrocalcinosis, bilateral kidney stones, or recurrent nephrolithiasis (see",
"      <a class=\"local\" href=\"#H10\">",
"       'History of nephrolithiasis'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Poorly controlled psychosis",
"     </li>",
"     <li>",
"      Active substance abuse",
"     </li>",
"     <li>",
"      Pregnancy",
"     </li>",
"     <li>",
"      Disorders requiring anticoagulation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Some relative contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following section relates to some relative contraindications to kidney donation, which include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Active peptic ulcer disease",
"     </li>",
"     <li>",
"      History of nephrolithiasis",
"     </li>",
"     <li>",
"      Urological abnormalities (eg, multiple renal vessels)",
"     </li>",
"     <li>",
"      Morbid obesity, most commonly defined as body mass index greater than 35 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/9,14\">",
"       9,14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Age greater than 65 or less than 18 years",
"     </li>",
"     <li>",
"      Strong family history of diabetes mellitus or hypertension",
"     </li>",
"     <li>",
"      Family history of renal cell cancer",
"     </li>",
"     <li>",
"      ABO or HLA incompatibility, which may allow for desensitization (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=see_link\">",
"       \"HLA and ABO sensitization and desensitization in renal transplantation\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is substantial inter-center variability concerning exclusion criteria for living kidney donation. In some centers, for example, potential donors who may be excluded include those of older age; those with borderline-to-mild hypertension, and those with borderline low glomerular filtration rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Increased risk of diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential donors with a family history of diabetes should be evaluated for this disorder. Some centers also evaluate those with an elevated fasting glucose or a history of gestational diabetes.",
"   </p>",
"   <p>",
"    Exclusion criteria based upon the fasting plasma glucose or oral glucose tolerance test varies by transplant center. One study, for example, found that patients with fasting glucose values greater than 100, 110, and 120",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    are excluded in 37, 7, and 5 percent of centers, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/14\">",
"     14",
"    </a>",
"    ]; in addition, 61 and 64 percent of centers exclude those with a two-hour value in an oral glucose tolerance test above 140",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or with type 2 diabetes mellitus, respectively.",
"   </p>",
"   <p>",
"    Obtaining a hemoglobin A1C or a formal glucose tolerance test may also be used to assess the presence or risk for diabetes (",
"    <a class=\"graphic graphic_algorithm graphicRef75300 \" href=\"UTD.htm?23/28/24015\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previously, older donors, such as those over 50 years of age, were not considered suitable. However, the kidneys from such donors are now commonly used if these individuals are in good physical and mental condition and have adequate kidney function.",
"   </p>",
"   <p>",
"    A review of 219 living kidney donors over the age of 70 demonstrated donor survival of 99.5, 95.8 and 90.0 percent at 1, 5, and 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/22\">",
"     22",
"    </a>",
"    ]. Donor survival was higher than that of a matched cohort from the NHANES-III (hazard ratio of 0.37, 95% CI 0.21-0.65). However, the graft survival in the recipients was only comparable to deceased donors aged 50 to 59 years and significantly lower compared with allografts from living donors aged 50 to 59 years.",
"   </p>",
"   <p>",
"    In addition, patients older than 60 years are more likely to have a GFR below 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    after donation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. This was best demonstrated in a retrospective study that compared outcomes of 422 donors younger than 60 years with those of 117 donors 60 years or older [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/24\">",
"     24",
"    </a>",
"    ]. At a median follow-up of 5.5 years, significantly more elderly donors had an estimated GFR &lt;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    compared with younger donors (80 versus 31 percent). However, there was no difference between groups in the mean maximal decline in GFR (38 &plusmn; 9 percent) in both groups that remained stable out to 13 years, but the starting GFR was lower among elderly patients (80 versus 96",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 among younger individuals). Thus, although age over 60 should not be an exclusion criteria for donation, such candidates should be carefully evaluated and perhaps should be required to have a higher minimum GFR in order to be accepted for donation.",
"   </p>",
"   <p>",
"    The increased use of older donors was reflected in a 2007 survey of kidney transplant centers in the United States in which almost 60 percent of centers had no upper age limit for kidney donors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/14\">",
"     14",
"    </a>",
"    ]. Among the remaining centers, an age limit of 75, 70, 65, 60, and 55 years was reported in 4, 5, 21, 7, and 1 percent, respectively.",
"   </p>",
"   <p>",
"    With respect to a lower age limit, most centers report that an age less than 18 years is an absolute exclusion criterion. In the 2007 survey, for example, 77 percent of centers excluded prospective donors less than 18 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most centers require that donors have a glomerular filtration rate (GFR) of at least 80",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    If renal function is evaluated via a creatinine clearance, the adequacy of the 24 hour urine collection should be carefully assessed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35190?source=see_link\">",
"     \"Calculation of the creatinine clearance\"",
"    </a>",
"    .) Furthermore, the dietary intake of protein should be at least 1 g of protein per",
"    <span class=\"nowrap\">",
"     kg/body",
"    </span>",
"    weight, since a low protein diet may decrease creatinine clearance by as much as 10",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Difficulties inherent to the accurate measurement of the creatinine clearance, including variability in urine collections, may cause spurious results. Some centers therefore advocate the use of estimated GFR calculations such as the MDRD equation for the initial screen. Among those with a glomerular filtration rate &lt;80",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    by initial estimation, isotopic studies are subsequently performed to measure renal function more accurately. The MDRD-epi may estimate GFR more accurately than the MDRD equation among those with a true GFR greater than 60",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, estimation equations are frequently inaccurate when used for potential kidney donors. One study, for example, attempted to define the normal range of renal clearance from 365 potential kidney donors as determined by non-radiolabeled iothalamate, which was then used to assess the accuracy of creatinine-based GFR estimates [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/26\">",
"     26",
"    </a>",
"    ]. Men at the age of 20 years had a mean GFR of 129",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    that declined by 4.6",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per decade, and women at the age of 20 years had a mean GFR of 123",
"    <span class=\"nowrap\">",
"     mL/min/decade",
"    </span>",
"    that declined by 7.1",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per decade. There was no difference between the sexes when GFR was corrected for body surface area. Correlation with both the MDRD and Cockcroft-Gault estimation equations was poor. Unfortunately, the study did not include a comparison with measured creatinine clearance. The MDRD equation also has to be used with caution in very thin females since it has not been validated in these individuals.",
"   </p>",
"   <p>",
"    Ideally, protein excretion should also be measured on the 24 hour urine collection. However, some centers use a spot urine protein to creatinine ratio or microalbumin to creatinine ratio. Most transplant centers exclude patients with proteinuria that exceeds 300",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    while others use a lower threshold of greater than 150",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The definition of hematuria appears to vary by transplant center. In the United States, some centers define hematuria as at least 10 red blood cells per high powered field",
"    <span class=\"nowrap\">",
"     (RBC/hpf),",
"    </span>",
"    while others use 3",
"    <span class=\"nowrap\">",
"     RBC/hpf",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/14\">",
"     14",
"    </a>",
"    ]. In one study, living kidney donors who had hematuria defined as the presence of more than three red blood cells per high power field developed a progressive decline in kidney function [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/27\">",
"     27",
"    </a>",
"    ]. Some centers exclude everyone with greater than 10",
"    <span class=\"nowrap\">",
"     RBC/hpf",
"    </span>",
"    as a possible transplant donor. Others will only accept a donor with hematuria if the urologic evaluation and kidney biopsy are negative. Any donor with persistent hematuria should have a thorough urological evaluation and a kidney biopsy, if deemed necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although florid hypertension is clearly a contraindication for kidney donation, the precise risk to donors who have borderline elevations in blood pressure and those with a family history of hypertension is less clear. Larger transplant centers tend to use such donors with greater frequency than those with smaller programs, but few data have been published to date that specifically examine the outcome of such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/4,28\">",
"     4,28",
"    </a>",
"    ]. In a 2007 survey of kidney transplant centers in the United States, 47 and 41 percent of centers excluded patients taking any antihypertensive medication or taking more than one medication, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Long-term risk'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Detection of hypertension is principally performed by measuring blood pressure in the clinic. The use of ambulatory blood pressure monitoring may help identify those with white coat hypertension or masked hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/29\">",
"     29",
"    </a>",
"    ]. Whether this technique increases the accuracy of risk assessment in such patients requires further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     History of nephrolithiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the majority of transplant centers will accept a donor with a history of nephrolithiasis if the evaluation reveals the absence of stones and metabolic studies are normal [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/14\">",
"     14",
"    </a>",
"    ]. By comparison, approximately 20 percent exclude all patients with a history of nephrolithiasis, while another 20 percent will accept those with a history of stones if stones are not present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RISK OF DONOR NEPHRECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complications from kidney donation can be divided into those arising immediately from the operation, and those which may emerge many years after the kidney was donated [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Immediate risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important perioperative risks due to donor nephrectomy include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Atelectasis",
"     </li>",
"     <li>",
"      Pneumothorax",
"     </li>",
"     <li>",
"      Pneumonia",
"     </li>",
"     <li>",
"      Urinary tract infection",
"     </li>",
"     <li>",
"      Wound complication",
"     </li>",
"     <li>",
"      Deep vein thrombosis with or without pulmonary embolism",
"     </li>",
"     <li>",
"      Death",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surgical mortality with live kidney donation is extremely low. In one study of over 80,000 live kidney donors, surgical mortality was 3.1 per 10,000 donors, a rate that has been unchanged over the last 15 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To reduce the risk for perioperative thromboembolism, women are required to discontinue hormonal contraception or hormone replacement therapy six weeks prior to donor nephrectomy. Estrogen containing intra-uterine devices and vaginal rings should be removed six weeks prior to surgery, since they also carry a risk of thromboembolism. Low-dose progesterone only (less than 30 mcg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    ) medications or intra-uterine devices may be continued, since there is very little data to support an increased risk for thrombosis with these agents.",
"   </p>",
"   <p>",
"    Most operations on living donors are performed laparoscopically versus an open approach. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/56/16262?source=see_link\">",
"     \"Benefits and complications of laparoscopic donor nephrectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Long-term risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall long-term survival after donor nephrectomy is the same as similar matched individuals who did not undergo surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/23,31-33\">",
"     23,31-33",
"    </a>",
"    ]. As an example, in one long-term study of over 80,000 live kidney donors, the risk of death after a median period of 6.3 years was the same for kidney donors and age and comorbidity-matched NHANES III participants [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although 50 percent of the functioning renal mass is removed after unilateral nephrectomy, compensatory hypertrophy in the remaining normal kidney returns the glomerular filtration rate to approximately 70 percent of baseline at 10 to 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/34\">",
"     34",
"    </a>",
"    ] and approximately 75 to 85 percent of baseline at long-term follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. In addition, long-term follow-up studies have not shown a progressive loss of glomerular filtration over time [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/35-42\">",
"     35-42",
"    </a>",
"    ]. The long-term renal outcomes after unilateral nephrectomy can be illustrated by the observations in a few different studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/23,37,40,41,43\">",
"     23,37,40,41,43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis of living kidney donors in the US between 1994 and 2003 (identified using the Organ Procurement and Transplantation Network and the Center for Medicare and Medicaid Services) demonstrated a rate of end-stage renal disease (ESRD) among living donors of 0.134 per 1000 years at risk over an average follow-up period of 9.8 years [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/43\">",
"       43",
"      </a>",
"      ]. The incidence of ESRD was 0.22 percent (126 cases of ESRD among 56,458 living donors) which was not statistically higher than that of the general population. The median time to ESRD from donation was 10 years and 55 percent of donors reached ESRD in less than 10 years post donation. The donors who developed ESRD were slightly younger than donors in general (median age of 36 versus 38 years) and were more likely to have donated to a full sibling (51 versus 40 percent), implying a genetic component to the development of ESRD, but this has not been validated. The causes of ESRD included diabetes mellitus, hypertension, and glomerulonephritis. In 49 percent of the cases where recipient data was available, 50 percent of the donors had the same cause of ESRD as the recipient.",
"     </li>",
"     <li>",
"      In another long-term study, overall survival, renal outcomes, and risk of ESRD were examined in 3698 individuals who donated a kidney during the period from 1963 to 2007 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/23\">",
"       23",
"      </a>",
"      ]. As of the end of 2007, donor survival was similar to that of the general control population matched for age, sex, and race or ethnic group, while the rate of ESRD was significantly lower than the rate in the general population (180 versus 268 per million per year).",
"      <br/>",
"      <br/>",
"      In addition, at a mean period of 12 years after donation among the subgroup of 255 donors (99 percent white, 60 percent women, average age of 41 years at donation) in whom the GFR, blood pressure, and proteinuria could be assessed, 86, 32, and 13 percent had a GFR &ge;60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2, hypertension, and albuminuria, respectively. Overall, donors had a decreased estimated GFR, systolic blood pressure, and urinary albumin excretion rate compared with matched controls. The subgroup of 255 donors was young and almost all white; it is not known if the above findings would apply to non-white ethnic groups and older individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a literature review, the long-term effects were examined among 3124 patients with reduced renal mass, almost all of whom had undergone unilateral nephrectomy (mostly for transplant donation) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/37\">",
"       37",
"      </a>",
"      ]. When compared to controls, there was no evidence that nephrectomy was associated with an increased prevalence of renal dysfunction or hypertension, but there was a small increase in mild proteinuria and in the systolic blood pressure (2.4 mmHg initially and a further 1.1 mmHg per decade).",
"     </li>",
"     <li>",
"      Another report evaluated the outcomes 45 years after removal of one kidney due to trauma during World War II among 62 men [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/40\">",
"       40",
"      </a>",
"      ]. Examination of renal tissue at autopsy in 10 patients showed only minimal glomerular scarring that was not different from age-matched controls [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar findings were noted in a single center study of 152 donors followed for approximately 11 years [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/41\">",
"       41",
"      </a>",
"      ]. The small changes that were noted included an increase in blood pressure (from",
"      <span class=\"nowrap\">",
"       125/79",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       134/81",
"      </span>",
"      mmHg) but no hypertension, albuminuria in 10 percent, and a reduction in GFR of approximately 25 percent. The changes in blood pressure and albuminuria were largely attributed to aging, while the decline in glomerular filtration rate reflected the effect of unilateral nephrectomy (as noted above) and perhaps aging.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The specific risk of increased blood pressure over time after kidney donation was best evaluated in a meta-analysis of 48 studies that enrolled 5149 donors, with only six reports being controlled [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/45\">",
"     45",
"    </a>",
"    ]. Analysis of the controlled studies with at least five year follow-up found that, compared with control participants, systolic and diastolic pressures were 6 and 4 mmHg higher in kidney donors, respectively. Given these limited data, further study is required to better understand the possible risk of increased blood pressure with kidney donation.",
"   </p>",
"   <p>",
"    The effect of the modest decrease in GFR on the development of metabolic bone disease among kidney donors is not clear. One study showed that kidney donors had higher serum concentrations of fibroblast growth factor (FGF)-23 and greater fractional excretion of inorganic phosphate compared with non-donor controls [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/46\">",
"     46",
"    </a>",
"    ]. However a matched cohort study showed no increase in the risk of non-trauma-related upper or lower extremity fractures, and no difference in the proportion of adults receiving prescriptions for bisphosphonates among 2015 kidney donors compared with matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall risk of developing cancer does not appear to be increased among donors. In one study that utilized data provided by a private health insurer and was linked to the Organ Procurement and Transplantation Network (OPTN) database, the frequency of non-skin cancer was lower among donors compared with non-donor individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/48\">",
"     48",
"    </a>",
"    ]. This observation likely reflects the selective effect of pre-donation screening since it was limited to donors who enrolled in the insurance plan within 4.9 years of donating the kidney. However, this study also showed an increase in incidence of prostate cancer among donors compared with non-donors that was not explained by disproportionate selection of donors with prostate cancer-risk factors or by increased prostate screening among donors. Further study of the incidence of cancer and of prostate cancer in particular is warranted.",
"   </p>",
"   <p>",
"    Depression is generally lower among kidney donors compared with the general population but may be increased among unrelated donors in the setting of recipient death or graft failure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Racial differences in medical outcomes post-nephrectomy appear to occur among living kidney donors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      This was shown in an analysis of 4650 individuals who had donated a kidney between October 1987 through July 2007; of the donors, 76, 13, 8, and 2 percent were white, black, Hispanic, and another race or ethnic group, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/50\">",
"       50",
"      </a>",
"      ]. Information concerning post-nephrectomy medical conditions was determined via medical insurance billing claims, with the median time from donation to the end of insurance benefits being 7.7 years.",
"      <br/>",
"      <br/>",
"      Compared with white donors, black donors had an increased risk of hypertension (adjusted hazard ratio 1.52, 95% CI 1.28-1.88), diabetes mellitus that needed medical therapy (adjusted hazard ratio 2.31, 95% CI 1.33-3.98), and chronic kidney disease (adjusted hazard ratio 2.32, 95% CI 1.48-3.62). Hispanic donors had similar medical outcomes as black donors.",
"      <br/>",
"      <br/>",
"      However, comparisons to NHANES data suggest that the increased risk of these morbidities is not greater than that associated with black individuals in the general population. There are no definitive studies that have shown that donor nephrectomy increases the risk of diabetes, hypertension and chronic kidney disease associated with black race [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the largest published series on African-American donors (single center study), the incidence of hypertension was 41 percent at follow-up (average seven years); there was also a 29 relative decline in GFR compared to baseline, with a decline that was even higher in donors with BMI greater than 35 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study that compared long-term outcomes between 33 African-Americans and 11 Caucasians showed no difference between groups in GFR or albumin excretion at a follow-up of 5 to 23 years after kidney donation [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/53\">",
"       53",
"      </a>",
"      ]. Among African-Americans, older age at the time of kidney donation was associated with a lower GFR when compared with younger ages.",
"     </li>",
"     <li>",
"      In the study cited above of living kidney donors in the US between 1994 and 2003, African-Americans comprised only 13 percent of the total number of living donors, but accounted for 47 percent of the donors who developed ESRD [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/43\">",
"       43",
"      </a>",
"      ]. African-American donors were five times more likely than Caucasians to develop ESRD, although this was not different compared with the general population.",
"      <br/>",
"      <br/>",
"      African American donors were younger than Caucasian counterparts at the time of donation (median age 34 versus 40 years) and the age discrepancy was even greater among those who developed ESRD (31 versus 47 years). The median age at ESRD was 47 years for all donors, but African American donors were much younger at the onset of ESRD compared with Caucasians (42 versus 57 years).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The racial disparity in outcomes may be due, in part, to genetic factors. Polymorphisms in the MYH9 and APOL1 genes that confer increased to ESRD are disproportionately represented among African-Americans. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/32/521?source=see_link&amp;anchor=H1626413#H1626413\">",
"     \"Epidemiology of chronic kidney disease\", section on 'APOL1 in African Americans'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link&amp;anchor=H9804961#H9804961\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'FSGS in African Americans'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some have suggested that potential donors that self-identify as African-Americans be screened for the APOL1 risk allele: the presence of two risk alleles may be a prudent relative contraindication to donation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multicenter donor registry is essential for long-term follow up of all donors to fully understand the risk of unilateral nephrectomy across race, age and sex. At this point, African-American and Hispanic donors should be counseled regarding these findings by the living donor advocate. In addition, among potential donors of African-American or Hispanic ethnicity, we recommend utilizing the most conservative assessment of the GFR, 24-hour ambulatory blood pressure monitoring, and glucose tolerance testing. Until more data are available, we recommend not screening for the APOL1 risk allele unless there is a strong family history of ESRD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H607613486\">",
"    <span class=\"h3\">",
"     Monitoring renal function after kidney donation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the good long-term renal outcomes in almost patients who have undergone unilateral nephrectomy, there have been occasional reports of patients who developed end-stage renal disease after donation, possibly due in some to hereditary factors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/36,55,56\">",
"     36,55,56",
"    </a>",
"    ]. As a result, some have suggested that living donors should undergo an annual assessment of renal function, including screening for proteinuria. It remains unclear who should perform such testing and how such post donation evaluations should be funded. Most transplant programs recommend that living donors follow-up with their primary care doctors at periodic intervals after donation. At present, there is no mechanism in place whereby donors are systematically observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Maternal and fetal outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important issue for women of child-bearing age is whether donor nephrectomy may have an adverse effect upon future pregnancies. There is a paucity of data that has examined this issue. Evidence is mostly derived from observational studies in the nondonor general population and case series in female donors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/57-62\">",
"     57-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, it appears that the risk of some disorders of pregnancy is higher after kidney donation compared with pregnancies prior to kidney donation. However, the risk of such disorders after",
"    <strong>",
"     donor",
"    </strong>",
"    nephrectomy is generally the same as that observed in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations were best described in the following two large studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest study, pregnancy and birth outcomes after kidney donation from 1967 to 2002 (106 pregnancies) were compared with control groups consisting of kidney donors prior to donation (620 pregnancies) and a random sample from the Medical Birth Registry of Norway (21,511 pregnancies) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/61\">",
"       61",
"      </a>",
"      ]. Compared with pregnancy before donation, pregnancy after donation was associated with a significantly increased risk of preeclampsia (5.7 versus 2.6 percent) and a nonsignificant increase in stillbirth (2.8 versus 1.1 percent). However, there were no differences in adverse pregnancy outcomes between kidney donors and the general population.",
"     </li>",
"     <li>",
"      A single center survey evaluated pregnancy outcomes in 1085 kidney donors who reported 3213 pregnancies [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/62\">",
"       62",
"      </a>",
"      ]. Postdonation pregnancies, versus predonation pregnancies, were associated with a significantly higher risk of fetal loss (19 versus 11 percent), gestational diabetes (2.7 versus 0.7 percent), gestational hypertension (5.7 versus 0.6 percent), and preeclampsia (5.5 versus 0.8 percent). However, rates of complications with postdonation pregnancies were similar to those reported in the general population.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, there is an increased risk for fetal loss, gestational diabetes, gestational hypertension, and preeclampsia with pregnancy after kidney donation, compared to pregnancy prior to kidney donation. Given this, we recommend that women should have completed planned child-bearing prior to considering kidney donation. Nevertheless, the generally good outcomes should NOT exclude donors who have not completed child-bearing; potential donors, however, must be aware of the increased risks with pregnancy after kidney donation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Psychologic consequences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up evaluations of those who have donated kidneys have found that the vast majority of individuals had overall positive experiences, including an improved sense of well-being and enhanced self-esteem. As an example, nearly 1000 patients who donated kidneys at the University of Minnesota from 1984 to 1996 were mailed a 36-item health survey questionnaire (SF-36) addressing their current quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/64\">",
"     64",
"    </a>",
"    ]. Compared to the healthy population of the United States, donors had superior scores in seven of eight general categories. However, a small number of donors had an adverse outcome; these individuals were more likely to have been more distantly related to the recipient, have donated to an individual who died within one year of surgery, have had perioperative complications, or be female.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Economic considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The financial costs incurred by kidney donation primarily consist of those arising from the pretransplant evaluation, tissue typing, organ procurement, and hospitalization. Although these costs are largely absorbed by Medicare in the United States, some donors experience some degree of financial hardship as a consequence of organ donation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Financial concerns may be minimized by coordinating the timing of pretransplant evaluation with the time required for work to minimize the number of lost work days. An earlier return to work may be facilitated by the use of laparoscopic donor nephrectomy, a technique available in some transplant centers [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/67-69\">",
"     67-69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Living organ donors may encounter difficulties with insurance after donation. This was shown in a systematic review of 23 studies consisting of 2076 living organ donors, 385 potential donors, and 239 responses from insurance companies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/70\">",
"     70",
"    </a>",
"    ]. Three to 11 percent of donors stated that they had problems obtaining insurance.",
"   </p>",
"   <p>",
"    To address this problem, term life insurance in the amount of one million United States dollars for a year post donation and long term health insurance for all donors have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/71\">",
"     71",
"    </a>",
"    ]. However, this proposal has been considered controversial and no legislation has been enacted thus far [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30697/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A thorough medical, surgical, and psychosocial evaluation of the prospective donor is performed. Within the United States, it is also mandated that patients meet with an &ldquo;Independent Living Donor Advocate&rdquo; who is separate from the program. This is a person with a clear understanding of transplantation whose sole purpose is to promote the best interest of the potential living donor, advocate for the rights of the potential living donor and assist the potential living donor in obtaining and understanding information regarding the consent and evaluation processes, the surgical procedure. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The overall purpose of the evaluation is to ensure that the potential donor is in good health, has normal kidney function and structure, and is not a risk to the recipient with respect to transmission of viral or other infections. As a result, a large number of clinical tests are also usually performed as part of the donor evaluation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Donor evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Based upon this evaluation, a potential kidney donor may be accepted, excluded, or require additional assessment. There are a significant number of generally accepted absolute contraindications. There is also substantial inter-center variability concerning relative exclusion criteria for living kidney donation. The decision-making process is a nuanced one and also incorporates donor autonomy. Donor autonomy is determined by the donor&rsquo;s understanding of the risk, their relationship to the recipient, and benefit that they may accrue by donation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Exclusionary criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The complications from kidney donation can be divided into those arising immediately from the operation, and those which may emerge many years after the kidney was donated. Immediate risks from kidney donation largely involve those due to the surgery itself. Studies evaluating long-term term risks with nephrectomy have found that patient and renal outcomes are generally excellent. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Risk of donor nephrectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since black and Hispanic donors are more likely to develop chronic kidney disease (CKD), hypertension and diabetes after donation compared with white donors, African-American and Hispanic donors should be counseled regarding these findings by the living donor advocate. In addition, among potential donors of African-American or Hispanic ethnicity, we recommend utilizing the most conservative assessment of the glomerular filtration rate (GFR), 24-hour ambulatory blood pressure monitoring, and glucose tolerance testing. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Long-term risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An important issue for women of child-bearing age is whether donor nephrectomy may have an adverse effect upon future pregnancies. There is an increased risk for fetal loss, gestational diabetes, gestational hypertension, and preeclampsia with pregnancy after kidney donation, compared to pregnancy prior to kidney donation. Given this, we recommend that women should have completed planned child-bearing prior to considering kidney donation. Nevertheless, the generally good outcomes should not exclude donors who have not completed child-bearing. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Maternal and fetal outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Cecka, JM. The UNOS scientific renal transplant registry. In: Clinical Transplants 2002, Cecka, JM, Terasaki, PI (Eds), UCLA Immunogenetics Center. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/2\">",
"      Hou S. Expanding the kidney donor pool: ethical and medical considerations. Kidney Int 2000; 58:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/3\">",
"      Ellison MD, McBride MA, Taranto SE, et al. Living kidney donors in need of kidney transplants: a report from the organ procurement and transplantation network. Transplantation 2002; 74:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/4\">",
"      Davis CL. Evaluation of the living kidney donor: current perspectives. Am J Kidney Dis 2004; 43:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/5\">",
"      Port FK, Dykstra DM, Merion RM, Wolfe RA. Trends and results for organ donation and transplantation in the United States, 2004. Am J Transplant 2005; 5:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/6\">",
"      Delmonico FL, Sheehy E, Marks WH, et al. Organ donation and utilization in the United States, 2004. Am J Transplant 2005; 5:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/7\">",
"      Osman Y, El-Husseini A, Sheashaa H, et al. Impact of Rh(D) blood group system on graft function and survival in live-donor kidney transplantation: a single-institution experience. Transplantation 2004; 78:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/8\">",
"      Bryan CF, Mitchell SI, Lin HM, et al. Influence of the Rh (D) blood group system on graft survival in renal transplantation. Transplantation 1998; 65:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/9\">",
"      Delmonico F, Council of the Transplantation Society. A Report of the Amsterdam Forum On the Care of the Live Kidney Donor: Data and Medical Guidelines. Transplantation 2005; 79:S53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/10\">",
"      Kasiske BL, Ravenscraft M, Ramos EL, et al. The evaluation of living renal transplant donors: clinical practice guidelines. Ad Hoc Clinical Practice Guidelines Subcommittee of the Patient Care and Education Committee of the American Society of Transplant Physicians. J Am Soc Nephrol 1996; 7:2288.",
"     </a>",
"    </li>",
"    <li>",
"     Handbook of Kidney Transplantation 2005, Fourth Edition. Chapter 5, Medical and surgical aspects of kidney donation. Danovitch, GM (editor). Lippincott Williams and Wilkins, Philadelphia, PA.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/12\">",
"      Davis CL, Delmonico FL. Living-donor kidney transplantation: a review of the current practices for the live donor. J Am Soc Nephrol 2005; 16:2098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/13\">",
"      The American Society of Transplantation Infectious Disease Guidelines. Am J Transplant 2009; 9(Suppl 4):S8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/14\">",
"      Mandelbrot DA, Pavlakis M, Danovitch GM, et al. The medical evaluation of living kidney donors: a survey of US transplant centers. Am J Transplant 2007; 7:2333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/15\">",
"      Screening of donor and recipient prior to solid organ transplantation. Am J Transplant 2004; 4 Suppl 10:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/16\">",
"      Kotton CN, Fishman JA. Viral infection in the renal transplant recipient. J Am Soc Nephrol 2005; 16:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/17\">",
"      Bakker J, Ligtenberg G, Beek FJ, et al. Preoperative evaluation of living renal donors with gadolinium-enhanced magnetic resonance angiography. Transplantation 1999; 67:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/18\">",
"      Rubin GD, Alfrey EJ, Dake MD, et al. Assessment of living renal donors with spiral CT. Radiology 1995; 195:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/19\">",
"      Neville C, House AA, Nguan CY, et al. Prospective comparison of magnetic resonance angiography with selective renal angiography for living kidney donor assessment. Urology 2008; 71:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/20\">",
"      Gluecker TM, Mayr M, Schwarz J, et al. Comparison of CT angiography with MR angiography in the preoperative assessment of living kidney donors. Transplantation 2008; 86:1249.",
"     </a>",
"    </li>",
"    <li>",
"     McKay, DB, Milford, EL, Sayegh, MH. Clinical aspects of renal transplantation. In: Brenner, BM, Rector, FC (Eds), The Kidney, 5th ed, Saunders, Philadelphia, 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/22\">",
"      Berger JC, Muzaale AD, James N, et al. Living kidney donors ages 70 and older: recipient and donor outcomes. Clin J Am Soc Nephrol 2011; 6:2887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/23\">",
"      Ibrahim HN, Foley R, Tan L, et al. Long-term consequences of kidney donation. N Engl J Med 2009; 360:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/24\">",
"      Dols LF, Kok NF, Roodnat JI, et al. Living kidney donors: impact of age on long-term safety. Am J Transplant 2011; 11:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/25\">",
"      PULLMAN TN, ALVING AS, DERN RJ, LANDOWNE M. The influence of dietary protein intake on specific renal functions in normal man. J Lab Clin Med 1954; 44:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/26\">",
"      Rule AD, Bergstralh EJ, Slezak JM, et al. Glomerular filtration rate estimated by cystatin C among different clinical presentations. Kidney Int 2006; 69:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/27\">",
"      Kido R, Shibagaki Y, Iwadoh K, et al. Persistent glomerular hematuria in living kidney donors confers a risk of progressive kidney disease in donors after heminephrectomy. Am J Transplant 2010; 10:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/28\">",
"      Bia MJ, Ramos EL, Danovitch GM, et al. Evaluation of living renal donors. The current practice of US transplant centers. Transplantation 1995; 60:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/29\">",
"      Ommen ES, Schr&ouml;ppel B, Kim JY, et al. Routine use of ambulatory blood pressure monitoring in potential living kidney donors. Clin J Am Soc Nephrol 2007; 2:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/30\">",
"      Hartmann A, Fauchald P, Westlie L, et al. The risk of living kidney donation. Nephrol Dial Transplant 2003; 18:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/31\">",
"      Segev DL, Muzaale AD, Caffo BS, et al. Perioperative mortality and long-term survival following live kidney donation. JAMA 2010; 303:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/32\">",
"      Delanaye P, Weekers L, Dubois BE, et al. Outcome of the living kidney donor. Nephrol Dial Transplant 2012; 27:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/33\">",
"      Garg AX, Meirambayeva A, Huang A, et al. Cardiovascular disease in kidney donors: matched cohort study. BMJ 2012; 344:e1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/34\">",
"      Pabico RC, McKenna BA, Freeman RB. Renal function before and after unilateral nephrectomy in renal donors. Kidney Int 1975; 8:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/35\">",
"      Edgren J, Laasonen L, Kock B, et al. Kidney function and compensatory growth of the kidney in living kidney donors. Scand J Urol Nephrol 1976; 10:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/36\">",
"      Fehrman-Ekholm I, Dun&eacute;r F, Brink B, et al. No evidence of accelerated loss of kidney function in living kidney donors: results from a cross-sectional follow-up. Transplantation 2001; 72:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/37\">",
"      Kasiske BL, Ma JZ, Louis TA, Swan SK. Long-term effects of reduced renal mass in humans. Kidney Int 1995; 48:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/38\">",
"      Davison JM, Uldall PR, Walls J. Renal function studies after nephrectomy in renal donors. Br Med J 1976; 1:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/39\">",
"      Najarian JS, Chavers BM, McHugh LE, Matas AJ. 20 years or more of follow-up of living kidney donors. Lancet 1992; 340:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/40\">",
"      Narkun-Burgess DM, Nolan CR, Norman JE, et al. Forty-five year follow-up after uninephrectomy. Kidney Int 1993; 43:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/41\">",
"      Gossmann J, Wilhelm A, Kachel HG, et al. Long-term consequences of live kidney donation follow-up in 93% of living kidney donors in a single transplant center. Am J Transplant 2005; 5:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/42\">",
"      Anderson CF, Velosa JA, Frohnert PP, et al. The risks of unilateral nephrectomy: status of kidney donors 10 to 20 years postoperatively. Mayo Clin Proc 1985; 60:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/43\">",
"      Cherikh WS, Young CJ, Kramer BF, et al. Ethnic and gender related differences in the risk of end-stage renal disease after living kidney donation. Am J Transplant 2011; 11:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/44\">",
"      Tan JC, Chertow GM. Cautious optimism concerning long-term safety of kidney donation. N Engl J Med 2009; 360:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/45\">",
"      Boudville N, Prasad GV, Knoll G, et al. Meta-analysis: risk for hypertension in living kidney donors. Ann Intern Med 2006; 145:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/46\">",
"      Young A, Hodsman AB, Boudville N, et al. Bone and mineral metabolism and fibroblast growth factor 23 levels after kidney donation. Am J Kidney Dis 2012; 59:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/47\">",
"      Garg AX, Pouget J, Young A, et al. Fracture risk in living kidney donors: a matched cohort study. Am J Kidney Dis 2012; 59:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/48\">",
"      Lentine KL, Vijayan A, Xiao H, et al. Cancer diagnoses after living kidney donation: linking U.S. Registry data and administrative claims. Transplantation 2012; 94:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/49\">",
"      Lentine KL, Schnitzler MA, Xiao H, et al. Depression diagnoses after living kidney donation: linking U.S. Registry data and administrative claims. Transplantation 2012; 94:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/50\">",
"      Lentine KL, Schnitzler MA, Xiao H, et al. Racial variation in medical outcomes among living kidney donors. N Engl J Med 2010; 363:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/51\">",
"      Gaston RS, Young CJ. Living donor nephrectomy: understanding long-term risk in minority populations. Am J Transplant 2010; 10:2574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/52\">",
"      Nogueira JM, Weir MR, Jacobs S, et al. A study of renal outcomes in African American living kidney donors. Transplantation 2009; 88:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/53\">",
"      Budisavljevic MN, Nietert PJ, Zhai Y, et al. Long-term effects of kidney donation on renal function and blood pressure in African Americans. Clin J Am Soc Nephrol 2011; 6:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/54\">",
"      Cohen DM, Mittalhenkle A, Scott DL, et al. African American living-kidney donors should be screened for APOL1 risk alleles. Transplantation 2011; 92:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/55\">",
"      Ladefoged J. Renal failure 22 years after kidney donation. Lancet 1992; 339:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/56\">",
"      al Shohaib S. Chronic renal failure following living-related kidney donation. Nephron 1995; 71:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/57\">",
"      Hawkins JL, Birnbach DJ. Maternal mortality in the United States: where are we going and how will we get there? Anesth Analg 2001; 93:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/58\">",
"      Buszta C, Steinmuller DR, Novick AC, et al. Pregnancy after donor nephrectomy. Transplantation 1985; 40:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/59\">",
"      Jones JW, Acton RD, Elick B, et al. Pregnancy following kidney donation. Transplant Proc 1993; 25:3082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/60\">",
"      Wrenshall LE, McHugh L, Felton P, et al. Pregnancy after donor nephrectomy. Transplantation 1996; 62:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/61\">",
"      Reisaeter AV, R&oslash;islien J, Henriksen T, et al. Pregnancy and birth after kidney donation: the Norwegian experience. Am J Transplant 2009; 9:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/62\">",
"      Ibrahim HN, Akkina SK, Leister E, et al. Pregnancy outcomes after kidney donation. Am J Transplant 2009; 9:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/63\">",
"      Nevis IF, Garg AX, Donor Nephrectomy Outcomes Research (DONOR) Network. Maternal and fetal outcomes after living kidney donation. Am J Transplant 2009; 9:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/64\">",
"      Johnson EM, Anderson JK, Jacobs C, et al. Long-term follow-up of living kidney donors: quality of life after donation. Transplantation 1999; 67:717.",
"     </a>",
"    </li>",
"    <li>",
"     Committee for the study of Medicare end-stage renal disease program. Medicare ESRD payment policy. In: Rettig, RA, Levinsky, NG, (Eds) Kidney failure and the federal government. National Academy Press, Washington, DC 1991. p. 191.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/66\">",
"      Smith MD, Kappell DF, Province MA, et al. Living-related kidney donors: a multicenter study of donor education, socioeconomic adjustment, and rehabilitation. Am J Kidney Dis 1986; 8:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/67\">",
"      Ratner LE, Kavoussi LR, Sroka M, et al. Laparoscopic assisted live donor nephrectomy--a comparison with the open approach. Transplantation 1997; 63:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/68\">",
"      Suzuki K, Ushiyama T, Ishikawa A, et al. Retroperitoneoscopy assisted live donor nephrectomy: the initial 2 cases. J Urol 1997; 158:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/69\">",
"      Kavoussi LR. Laparoscopic donor nephrectomy. Kidney Int 2000; 57:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/70\">",
"      Yang RC, Thiessen-Philbrook H, Klarenbach S, et al. Insurability of living organ donors: a systematic review. Am J Transplant 2007; 7:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/71\">",
"      Gaston RS, Danovitch GM, Epstein RA, et al. Limiting financial disincentives in live organ donation: a rational solution to the kidney shortage. Am J Transplant 2006; 6:2548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30697/abstract/72\">",
"      Fox MD. The price is wrong: the moral cost of living donor inducements. Am J Transplant 2006; 6:2529.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7315 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-168C04E0CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_62_30697=[""].join("\n");
var outline_f29_62_30697=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DONOR EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EXCLUSIONARY CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Absolute contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Some relative contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Increased risk of diabetes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Renal function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - History of nephrolithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RISK OF DONOR NEPHRECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Immediate risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Long-term risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H607613486\">",
"      - Monitoring renal function after kidney donation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Maternal and fetal outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Psychologic consequences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Economic considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7315\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7315|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?23/28/24015\" title=\"algorithm 1\">",
"      DM testing living donors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7315|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/57/1949\" title=\"table 1\">",
"      Amsterdam Forum Guide A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/4/9293\" title=\"table 2\">",
"      Amsterdam Forum Guide B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/13/26844\" title=\"table 3\">",
"      Amsterdam Forum Guide C",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/56/16262?source=related_link\">",
"      Benefits and complications of laparoscopic donor nephrectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35190?source=related_link\">",
"      Calculation of the creatinine clearance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11224?source=related_link\">",
"      Dialysis issues prior to and after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/32/521?source=related_link\">",
"      Epidemiology of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=related_link\">",
"      Evaluation of the potential renal transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=related_link\">",
"      HLA and ABO sensitization and desensitization in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31925?source=related_link\">",
"      Living unrelated donors in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14170?source=related_link\">",
"      Risk factors for graft failure in kidney transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_62_30698="Creutzfeldt-Jakob disease";
var content_f29_62_30698=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Creutzfeldt-Jakob disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/62/30698/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/62/30698/contributors\">",
"     Henry G Brown, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/62/30698/contributors\">",
"     John M Lee, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/62/30698/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/62/30698/contributors\">",
"     Steven T DeKosky, MD, FAAN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/62/30698/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/62/30698/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/62/30698/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prion diseases are neurodegenerative diseases that have long incubation periods and progress inexorably once clinical symptoms appear. Five human prion diseases are currently recognized: kuru, Creutzfeldt-Jakob disease (CJD), variant Creutzfeldt-Jakob disease (vCJD), Gerstmann-Str&auml;ussler-Scheinker syndrome (GSS), and fatal familial insomnia (FFI). CJD accounts for more than 90 percent of sporadic prion disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These human prion diseases share certain common neuropathologic features including neuronal loss, proliferation of glial cells, absence of an inflammatory response, and the presence of small vacuoles within the neuropil, which produces a spongiform appearance.",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of Creutzfeldt-Jakob disease will be reviewed here. Variant Creutzfeldt-Jakob disease, Kuru, GSS, and FFI, and the biology of prions and the genetics of prion diseases are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40728?source=see_link\">",
"     \"Variant Creutzfeldt-Jakob disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31176?source=see_link\">",
"     \"Diseases of the central nervous system caused by prions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7017?source=see_link\">",
"     \"Biology and genetics of prions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Creutzfeldt-Jakob disease (CJD) is the most frequent of the human prion diseases, although it is still rare. Sporadic (sCJD), familial (fCJD), iatrogenic (iCJD), and variant forms of CJD (vCJD) are all recognized. The vast majority of CJD cases are sporadic (85 to 95 percent), while 5 to 15 percent are due to fCJD; iCJD generally accounts for less than 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately one case of sporadic CJD occurs per 1,000,000 population per year with a worldwide distribution. The mean age for the onset of disease is between 57 and 62 years, although rare cases in young adults and those over 80 years of age have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. Patients with vCJD and iCJD tend to be much younger, which led to an early appreciation that the mode of transmission might be different. fCJD patients have only a slightly younger age of onset compared with sCJD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/8\">",
"     8",
"    </a>",
"    ]. There is no gender predilection for CJD. In the United States, the incidence of CJD appears to be less in African Americans, American Indians, and Alaska natives compared with the white population, however this observation may have resulted from ascertainment bias [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of CJD is increased 30 to 100-fold in certain geographic regions including areas of North Africa, Israel, Italy, and Slovakia, due primarily to clusters of fCJD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Sporadic CJD",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of epidemiologic studies have attempted to identify potential risk factors for sCJD. In one reappraisal of three case-control studies, family history of CJD (adjusted odds ratio [OR] 19.1) or medical history of psychosis (OR 9.9) were the only significant factors associated with disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/11\">",
"     11",
"    </a>",
"    ]. A second study in Australia found that a history of multiple surgical procedures and residence for more than 10 years on a farm were significant risk factors for sCJD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/12\">",
"     12",
"    </a>",
"    ]. This latter report used community rather than hospital-based controls. Neither study documented an increased risk of sCJD with receipt of blood products.",
"   </p>",
"   <p>",
"    Small clusters of sCJD cases have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. A retrospective case-control study of all sCJD cases from 1990 to 1998 in the United Kingdom concluded that sCJD cases lived closer together than might be expected in the absence of a disease-clustering mechanism; the results suggested that some sCJD cases may result from exposure to a common external factor [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/16\">",
"     16",
"    </a>",
"    ]. However, the significance of these possible clusters remains unclear. The results of one statistical analysis have suggested that these apparent clusters may result from higher intensity of surveillance in localized geographic regions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Variant CJD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variant CJD (vCJD) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40728?source=see_link\">",
"     \"Variant Creutzfeldt-Jakob disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Familial CJD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, fCJD contributes to less than 15 percent of CJD cases. Familial CJD is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7017?source=see_link&amp;anchor=H11#H11\">",
"     \"Biology and genetics of prions\", section on 'Familial CJD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Iatrogenic CJD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iatrogenic CJD (iCJD) has followed administration of cadaveric human pituitary hormones (growth hormone and gonadotrophin) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/18-20\">",
"     18-20",
"    </a>",
"    ], dural graft transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/21-23\">",
"     21-23",
"    </a>",
"    ], use of dural mater in radiographic embolization procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/24\">",
"     24",
"    </a>",
"    ], corneal transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/25,26\">",
"     25,26",
"    </a>",
"    ], liver transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/27\">",
"     27",
"    </a>",
"    ], and the use of contaminated neurosurgical instruments or stereotactic depth electrodes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/28\">",
"     28",
"    </a>",
"    ]. Dural graft transplants and use of cadaveric pituitary hormones account for the vast majority of cases of iCJD.",
"   </p>",
"   <p>",
"    It is possible that other surgical procedures also play a role in the transmission of CJD. In a case control study, the risk of sporadic CJD was increased among individuals who had ever undergone surgery (OR 2.0; 95% CI:1.3-2.1) with highest rates in the category called \"other surgery\" which included skin stitches,",
"    <span class=\"nowrap\">",
"     nose/throat",
"    </span>",
"    operations and removal of",
"    <span class=\"nowrap\">",
"     growths/cysts/moles",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/29\">",
"     29",
"    </a>",
"    ]. This is consistent with two other case control studies that also found an association between CJD and prior surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/12,30,31\">",
"     12,30,31",
"    </a>",
"    ]. In one of these studies, latency from surgery to clinical disease onset was shorter with surgeries involving the central nervous system or eye and longer for systemic surgeries [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/31\">",
"     31",
"    </a>",
"    ]. In another study, three or more procedures was associated with a higher risk than fewer procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/12\">",
"     12",
"    </a>",
"    ]. It is possible that recall bias plays a role in this apparent association.",
"   </p>",
"   <p>",
"    Because prions are resistant to conventional physical decontamination methods, disinfection and sterilization of prion-contaminated medical instruments requires specific procedures. It is important to keep the instruments moist after use (either by immersion in water or a prionicidal detergent), because sterilization does not appear to be as effective on dried tissue. Prior to sterilization the instruments should be decontaminated in an automated dishwasher. Options for sterilization that appear to be effective include [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Autoclave at 134&ordm;C for 18 minutes in a prevacuum sterilizer",
"     </li>",
"     <li>",
"      Autoclave at 132&ordm;C for 1 hour in a gravity displacement sterilizer",
"     </li>",
"     <li>",
"      Immerse in 1 N NaOH for 1 hour; remove and rinse in water then transfer to an open pan and autoclave for 1 hour at 121&ordm;C in a gravity displacement sterilizer or at 134*C in a porous or prevacuum sterilizer",
"     </li>",
"     <li>",
"      Immerse in 1 N NaOH for 1 hour; then heat in a gravity displacement sterilizer at 121*C for 30 minutes, then clean and subject to routine sterilization",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the instrument is not fully accessible to the actions of the steam sterilizant, it should be discarded. It should also be noted that the combination of NaOH and steam sterilization can be harmful to surgical instruments. Flash sterilization or low temperature methods for sterilization should not be used.",
"   </p>",
"   <p>",
"    Proven surgical routes for transmission have now been largely eliminated following changes in procedures used to prepare dural grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/33\">",
"     33",
"    </a>",
"    ] and use of recombinant-derived hormones rather than hormones derived from cadaveric pituitary pools. An international CJD surveillance team reported that, in 2000, all incident cases of iatrogenic CJD were due to long incubation periods from infections acquired before 1985 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/34\">",
"     34",
"    </a>",
"    ]. An exception may be the use of Lyodura dural grafts; those manufactured before 1987 (before new procedures were instituted) were not recalled internationally, and continued to be used until 1993 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/35\">",
"     35",
"    </a>",
"    ]. Cases of CJD related to these grafts continue to accrue, in some cases 25 years after surgery. In addition, there are four reported cases of transfusion-associated variant CJD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40728?source=see_link&amp;anchor=H5#H5\">",
"     \"Variant Creutzfeldt-Jakob disease\", section on 'Transfusion-related vCJD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incubation period for iCJD is unknown and probably depends upon the mode of transmission. One study estimated a mean time of 9 to 10 years based upon mathematical models of the incubation time for iCJD acquired after administration of human growth hormone in a population of 1361 recipients, 55 of whom had developed iCJD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/36\">",
"     36",
"    </a>",
"    ]. A similar mean incubation period has been reported for dural graft transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/33\">",
"     33",
"    </a>",
"    ]. However, incubation periods as short as five years and as long as 30 years have been reported in other patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Transfusion-related CJD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available epidemiologic studies suggest that a history of preceding transfusion does not increase the risk of developing sCJD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. However, human-to-human transmission of prion diseases can occur under special circumstances, and low levels of infectivity have been noted when whole blood, serum, or buffy coat derived from patients with sCJD is inoculated into animals.",
"   </p>",
"   <p>",
"    No definite cases of transfusion-associated iCJD are known to have occurred. One study reviewed 436 recipients of 36 blood donors who subsequently developed CJD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/41\">",
"     41",
"    </a>",
"    ]. After 2096 person years of follow-up, no recipient had developed CJD; 144 recipients survived more than five years after transfusion; 68 of these had received blood donated less than 60 months before the donor developed CJD. There is one report of development of sCJD in a patient 8 to 10 months after albumin infusions during coronary artery bypass surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/42\">",
"     42",
"    </a>",
"    ]; however, this is likely to represent a de novo rather than transfusion-acquired case of sCJD. Transfusion-associated vCJD has been reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40728?source=see_link&amp;anchor=H5#H5\">",
"     \"Variant Creutzfeldt-Jakob disease\", section on 'Transfusion-related vCJD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Beginning in November, 1999, leukocyte depletion of all blood components was mandated in the United Kingdom in order to reduce the concentration of transmissible agents [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/43\">",
"     43",
"    </a>",
"    ]. Other risk-reduction measures are in development [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/44-48\">",
"     44-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15451900\">",
"    <span class=\"h3\">",
"     Infections in health care workers",
"    </span>",
"    &nbsp;&mdash;&nbsp;CJD infection in health care workers is extremely rare [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/49\">",
"     49",
"    </a>",
"    ]. A 1993 publication reports a CJD infection in a sixth physician (neurosurgeons, pathologists) and 24th health care worker (including laboratory technicians, nurses) to date [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/50\">",
"     50",
"    </a>",
"    ]. Several cases have since been reported, but such reports have not been systematically collected [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. Not all cases were biopsy-proven. In most cases, a link to a prior exposure is difficult to establish given the long incubation period and the dependence on the recall of relatives",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    coworkers. Case-control studies have not found a significant association between CJD and health care profession [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/53-55\">",
"     53-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physical contact with CJD patients entails no risk of transmission and special precautions are not required in their care. However, special precautions should be employed in the handling of cerebrospinal fluid as well as biopsy tissue; all materials and instruments used must be decontaminated according to established protocols [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. Routine sterilization measures are not adequate for decontamination of CJD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link\">",
"     \"General principles of infection control\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Possible animal origins of sCJD",
"    </span>",
"    &nbsp;&mdash;&nbsp;All available evidence suggests that a single bovine prion strain responsible for BSE has infected humans to cause vCJD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40728?source=see_link&amp;anchor=H3#H3\">",
"     \"Variant Creutzfeldt-Jakob disease\", section on 'Relationship with BSE'",
"    </a>",
"    .) However, additional bovine prion strains have now been reported to cause spongiform encephalopathy in cattle [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. One of these strains is associated with atypical amyloid deposition, a neuropathological feature not found in typical BSE [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/61\">",
"     61",
"    </a>",
"    ]. The PrPSc molecular signature of this amyloidotic form of BSE (called BASE) is similar to that of sCJD subtype MV2. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Molecular subtypes of sCJD'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The significance of this PrPSc molecular similarity is unclear. One explanation is that some cases of sCJD with the PrPSc MV2 pattern might be the result of exposure to BASE. However, it is important to recognize that glycosylation and migration patterns of PrPSc may not be a reliable indicator of prion protein origin. Until further evidence accumulates, the role, if any, of BASE exposure as a source of sCJD should be considered speculative [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     NEUROPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;On gross examination, most cases show some atrophy. However, some, even those associated with long clinical histories, appear normal in this respect. Atrophic brains usually show ventricular enlargement. The atrophy may include the deep gray structures: the caudate, putamen, and thalamus. In contrast to Alzheimer disease, the hippocampus is spared. The cerebellum may also show atrophy of the folia, usually due to loss of gray matter.",
"   </p>",
"   <p>",
"    The main histologic features of prion disease are (",
"    <a class=\"graphic graphic_picture graphicRef80949 \" href=\"UTD.htm?21/8/21638\">",
"     picture 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Spongiform change",
"     </li>",
"     <li>",
"      Neuronal loss (particularly of cortical layers III-V) without inflammation",
"     </li>",
"     <li>",
"      Accumulation of the abnormal prion protein",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Spongiform change",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vacuoles that create the spongiform change in CJD are round and between 20 to 50 microns in diameter (",
"    <a class=\"graphic graphic_picture graphicRef70414 \" href=\"UTD.htm?40/59/41908\">",
"     picture 2",
"    </a>",
"    ). Electron microscopy has revealed that the vacuolization is an intraneuronal process, and that synaptic loss is another common ultrastructural feature.",
"   </p>",
"   <p>",
"    Spongiform vacuolation can occur in other diseases. Neurodegenerative diseases associated with severe neuronal loss produce status spongiosus as a common feature in end stages. This is a coarse microvacuolization with astrocytosis. The vacuoles are usually larger and more irregular than those seen in CJD, and they are usually concentrated in the upper layers (I-III) of the cerebral cortex. Microvacuolization in frontotemporal dementias is usually restricted to the upper cortical layers and to the frontal and temporal lobes. Transcortical vacuolization in dementia with Lewy bodies is usually restricted to the medial temporal lobe. Acute hypoxic ischemic and other metabolic encephalopathies can also give this microscopic appearance. Finally, inadequate tissue fixation or poor processing can cause artifactual changes that resemble prion vacuoles. The clinical history along with prion protein immunohistochemistry generally clearly distinguishes among these entities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prion protein immunohistochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accumulation of the prion protein is detected by immunohistochemical techniques (",
"    <a class=\"graphic graphic_picture graphicRef50744 \" href=\"UTD.htm?29/28/30149\">",
"     picture 3",
"    </a>",
"    ). The prion protein can be distributed in several patterns, such as a perivacuolar distribution, a diffuse synaptic distribution, or in plaques.",
"   </p>",
"   <p>",
"    The plaque type can be associated with specific prion protein diseases, such as kuru, Gerstmann-Str&auml;ussler-Scheinker syndrome, or vCJD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40728?source=see_link\">",
"     \"Variant Creutzfeldt-Jakob disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31176?source=see_link&amp;anchor=H11#H11\">",
"     \"Diseases of the central nervous system caused by prions\", section on 'Neuropathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pattern and distribution of prion protein deposition may be specific to the subtype of sCJD. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Molecular subtypes of sCJD'",
"    </a>",
"    below.) As examples, MM1 and MV1 subtypes have been associated with the synaptic pattern of PrP immunostaining, MV2 and VV2 with plaque formation, especially prominent in the deep gray structures and cerebellum, and MM2 with perivacuolar and loose plaque-like formations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/63\">",
"     63",
"    </a>",
"    ]. Iatrogenic CJD related to dura mater grafts has also been associated with plaque formation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapidly progressive mental deterioration and myoclonus are the two cardinal clinical manifestations of sCJD. Death usually occurs within one year of symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mental deterioration may be manifest as dementia, behavioral abnormalities, and deficits involving higher cortical function. Concentration, memory, and judgment difficulties are frequent early signs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/66\">",
"     66",
"    </a>",
"    ]. Mood changes such as apathy and depression are common; euphoria, emotional lability, and anxiety occur less frequently. Sleep disturbances, particularly hypersomnia, but also insomnia, are also common, and may be a presenting sign [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. With disease progression, dementia becomes dominant in most patients and can advance rapidly.",
"   </p>",
"   <p>",
"    Myoclonus, especially provoked by startle, is present in more than 90 percent of patients at some point during the illness but may be absent at presentation, even when dementia is profound. sCJD should always be considered in a patient with the combination of a rapidly progressive dementia and myoclonus.",
"   </p>",
"   <p>",
"    Extrapyramidal signs such as hypokinesia and cerebellar manifestations, including nystagmus and ataxia, occur in approximately two-thirds of patients and are the presenting symptoms in 20 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/66\">",
"     66",
"    </a>",
"    ]. In particular, iatrogenic CJD related to human gonadotrophin and growth hormone treatment as well as to dura mater grafts has a propensity to manifest as a largely isolated cerebellar syndrome early in the disease course [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/20,64,69\">",
"     20,64,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Signs of corticospinal tract involvement develop in 40 to 80 percent of patients, including such findings as hyperreflexia, extensor plantar responses (Babinski sign), and spasticity.",
"   </p>",
"   <p>",
"    Younger patients with sCJD have clinical features that are somewhat distinct from the more typical older patient. In one case series of 52 patients younger than 50 years, psychiatric symptoms were more prominent and the clinical course more prolonged than in older patients, features that may suggest variant CJD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40728?source=see_link\">",
"     \"Variant Creutzfeldt-Jakob disease\"",
"    </a>",
"    .) However, test results, CSF protein markers, and neuroimaging, are consistent with sCJD.",
"   </p>",
"   <p>",
"    Some clinical findings, although compatible with CJD, should raise the suspicion of an alternative diagnosis, especially if they are among the more prominent features of the illness. These include cranial nerve abnormalities, sensory abnormalities, and involvement of the peripheral nervous system. Disturbances of pupillary responses, extraocular movements, trigeminal neuropathy, and vestibulocochlear dysfunction have all been reported in isolated cases but are not characteristic. Sensory signs and symptoms are common in vCJD but are otherwise extremely atypical in human prion diseases.",
"   </p>",
"   <p>",
"    However, a number of variants or subtypes of disease have been defined based upon focal neurologic findings reflecting predominant involvement of individual brain regions. Examples of these include forms with mainly visual (Heidenhain variant), cerebellar (Oppenheimer-Brownell variant), thalamic, and striatal features [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Variants of sCJD have also been classified based according to the genotype of the prion protein gene (PRNP) and the molecular properties of the pathological prion protein (PrPSc) as will be discussed next.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Molecular subtypes of sCJD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical phenotypes of sporadic CJD have been associated with molecular subtypes determined by the PRNP gene codon 129 genotype and the pathologic prion protein (PrPSc) type. The PRNP genotype is homozygous or heterozygous for methionine (M) or valine (V) at codon 129. The PrPSc type is determined by Western blot analysis and classified in the",
"    <span class=\"nowrap\">",
"     Parchi/Gambetti",
"    </span>",
"    nomenclature as type 1 or type 2 depending on the size and electrophoretic mobility of the protease resistant core fragment (PrPres) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using this molecular classification, six clinical phenotypes of sCJD have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. The frequency and duration of illness are based on a series of 300 cases in North America and Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/74\">",
"     74",
"    </a>",
"    ] and an additional 2451 patients were analyzed for diagnostic test characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/76\">",
"     76",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MM1 and MV1 (myoclonic, Heidenhain variant) account for about 70 percent of cases and correlate with the \"classic CJD\" phenotype of advanced age at onset, a rapidly progressive dementia with early and prominent myoclonus, and a short duration of illness (mean 3.9 months). The MM1 phenotype is the one most commonly associated with periodic sharp wave complexes (PSWC) on electroencephalogram (EEG).",
"     </li>",
"     <li>",
"      VV2 (ataxic variant) accounts for 15 percent or less of sCJD and presents with ataxia at onset, often as an isolated feature, late dementia, and a longer duration of illness (mean 7 to 9 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      MV2 (Kuru plaque variant) accounts for 9 percent and presents with ataxia, progressive dementia with prominent psychiatric features, and longer duration (mean 17.1 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/78\">",
"       78",
"      </a>",
"      ]. The 14-3-3 protein in the CSF is a relatively insensitive marker for the MV2 variant (about 70 percent), and PSWC are only infrequently seen on EEG [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/76,78-80\">",
"       76,78-80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      MM2 can present as either a thalamic variant or a cortical variant. Some, but not all, patients have a young age at onset, and the disease course is typically long, with a median disease duration of 14 months in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/81\">",
"       81",
"      </a>",
"      ]. The 14-3-3 protein has been reported to be present in 61 to 91 percent of patients with MM2, and periodic sharp wave complexes (PSWCs) on EEG are more often absent than in other MM and MV subtypes [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/74,76,79-81\">",
"       74,76,79-81",
"      </a>",
"      ]. The clinical features of MM2 type sCJD may resemble those of variant CJD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40728?source=see_link&amp;anchor=H6#H6\">",
"       \"Variant Creutzfeldt-Jakob disease\", section on 'Clinical features'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The thalamic MM2 variant accounts for 2 percent of cases, and mean disease duration is 15.6 months. Insomnia, psychomotor hyperactivity, ataxia, and cognitive impairment are the predominate manifestations, and this phenotype resembles that of fatal familial insomnia (FFI) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/82\">",
"       82",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31176?source=see_link&amp;anchor=H12#H12\">",
"       \"Diseases of the central nervous system caused by prions\", section on 'Fatal familial insomnia'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The cortical MM2 variant accounts for 2 percent of cases, with a mean disease duration of 15.7 months. Dementia is the predominate manifestation, while cerebellar and visual signs are rarely described at presentation [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      VV1 accounts for 1 percent of cases and is notable for progressive dementia and longer duration (mean 15.3 months). A case series of nine patients with this subtype confirmed the slower, more prolonged course (median 21 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/84\">",
"       84",
"      </a>",
"      ]. All patients had elevated CSF levels of the 14-3-3 protein, but none had PSWCs on EEG, and cortical rather than basal ganglia abnormalities were more common on MRI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The classification for PrPSc is complicated by the existence of at least two nomenclatures, although the Parchi and Gambetti nomenclature for PrPSc [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/73,74\">",
"     73,74",
"    </a>",
"    ] described above may be the most widely used. The alternate Collinge nomenclature distinguishes four rather than two PrPSc subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/85-87\">",
"     85-87",
"    </a>",
"    ]. The Collinge PrPSc types 1 and 2 are thought to correspond with Parchi and Gambetti PrPSc type 1, and Collinge types 3 and 4 with Parchi and Gambetti type 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These molecular subtypes have also been associated with distinctive patterns of cerebral gene expression in CJD involving upregulation of genes involved in immune and stress responses and in cell death and downregulation of genes involved in synaptic function [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/89\">",
"     89",
"    </a>",
"    ]. Another study found that more than one molecular subtype may be present in 20 percent of individuals with sCJD and that PrPSc type might be influenced by both genetic and brain region-specific factors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ongoing identification of rare molecular subtypes of CJD that are not included in these classification schemes may require their subsequent modification [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/91\">",
"     91",
"    </a>",
"    ]. As an example, it has been increasingly recognized that some patients with CJD have both type 1 and type 2 PrPSc, and that patients who have both types have a distinct clinical and pathologic phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/92\">",
"     92",
"    </a>",
"    ]. In a series of 34 patients with the MM genotype, 20 individuals had both types (MM1+2) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/93\">",
"     93",
"    </a>",
"    ]. These patients had histopathologic features that were intermediate between patients with the MM1 and MM2 subtypes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Creutzfeldt-Jakob disease (CJD) must be distinguished from other dementias. Occasionally Alzheimer disease (AD) and frontotemporal dementia is associated with myoclonus and a more rapidly progressive course than is typical and is therefore mistaken for CJD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/94\">",
"     94",
"    </a>",
"    ]. Prominent ataxia or parkinsonism when present may suggest dementia with Lewy bodies, progressive supranuclear palsy, or multiple systems atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/94-96\">",
"     94-96",
"    </a>",
"    ]. However, even when more rapidly progressive than is usual, the neurodegenerative dementias virtually never have a disease course that progresses to death within 12 months, a time-frame that is typical for CJD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other entities that have been mistaken for CJD include [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/94,96,98-104\">",
"     94,96,98-104",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Autoimmune disorders, including paraneoplastic syndromes, demyelinating disease, sarcoidosis, and Hashimoto's encephalopathy",
"     </li>",
"     <li>",
"      Infections, including viral and postviral encephalitis, fungal and tubercular meningitis, and HIV",
"     </li>",
"     <li>",
"      Malignancy, including lymphoma, gliomatosis cerebri, and paraneoplastic syndromes",
"     </li>",
"     <li>",
"      Toxic and metabolic encephalopathies, including alcoholic cerebral degeneration, and methylmalonic acidemia,",
"     </li>",
"     <li>",
"      Cerebrovascular disease, including cerebral amyloid angiopathy, MELAS, and CADISIL",
"     </li>",
"     <li>",
"      Psychiatric disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain biopsy remains the gold standard diagnostic test for Creutzfeldt-Jakob disease (CJD). However, a number of tests can be helpful in providing clinical support for the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     MR imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the available neuroimaging modalities, magnetic resonance imaging (MRI) is the most helpful in the diagnosis of CJD (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56359 \" href=\"UTD.htm?41/13/42196\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58441 \" href=\"UTD.htm?23/18/23840\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommended MR imaging protocol for assessment of patients with suspected CJD include T2 and proton density axial images with 3 mm slice thickness, FLAIR axial and sagittal images at 3 mm slice thickness, T1 images, and diffusion-weighted images (DWI) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the data are limited to small studies and case reports, the following observations have been made regarding MRI in the evaluation of CJD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormally increased T2 and FLAIR signal intensity in the putamen and head of the caudate are the most common finding on conventional MRI sequences in patients with CJD [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/106-110\">",
"       106-110",
"      </a>",
"      ]. Less commonly, areas of T2 and FLAIR signal hyperintensity are seen in the globus pallidus, thalamus, cerebral and cerebellar cortex, and white matter. Laminar lesions in the cerebral cortex and cerebellum may be observed.",
"     </li>",
"     <li>",
"      Proton density and DWI are more sensitive than T2-weighted MRI and FLAIR for the detection of CJD-related lesions. DWI is the most sensitive technique, especially for cortical changes. This is also the most sensitive test in the early stages of disease, showing abnormalities before the onset of characteristic clinical findings such as myoclonus and periodic sharp wave complexes seen on electroencephalogram (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Electroencephalogram'",
"      </a>",
"      below) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/111-115\">",
"       111-115",
"      </a>",
"      ]. In autopsy studies, decreased apparent diffusion coefficient (ADC) correlates with areas of spongiform change with gliosis and neuronal loss [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/116\">",
"       116",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      These findings are not entirely specific for CJD and may be confused with stroke, vasculitis, or reversible posterior leukoencephalopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/117,118\">",
"       117,118",
"      </a>",
"      ]. However, one study found that a pattern of",
"      <span class=\"nowrap\">",
"       FLAIR/DWI",
"      </span>",
"      hyperintensity and restricted diffusion could reliably distinguish CJD from other causes of rapidly progressive dementia, with a high degree of sensitivity [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/119\">",
"       119",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      MRI abnormalities may vary with the clinical syndrome and molecular subtype. Patients with suspected sCJD and increased T2 signal in the caudate and putamen are more likely to have early dementia, shorter survival, and VV2, MV2, or MM1 codon 129 genotypes than those without high basal ganglia signal [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/67,120\">",
"       67,120",
"      </a>",
"      ]. Thalamic hyperintensities occur most often in VV2 and MV2 subtypes, and wide cortical signal increase is most common in the VV1 and MV1 subtypes [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/120\">",
"       120",
"      </a>",
"      ]. Patients with the MM2 thalamic form of sCJD (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Molecular subtypes of sCJD'",
"      </a>",
"      above) may have nearly normal brain by MRI and DWI, or show only late atrophy or white matter change [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/121\">",
"       121",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The MRI features of vCJD differ from those of sCJD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40728?source=see_link\">",
"       \"Variant Creutzfeldt-Jakob disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Diagnostic utility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Independent interpretation of MRI films in 193 patients with CJD by three radiologists were associated with 82 to 86 percent agreement as to whether findings were typical or atypical for CJD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/122\">",
"     122",
"    </a>",
"    ]. High degrees of interrater reliability have been found in other studies as well [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An analysis of 1036 patients accrued between 1992 and 2002 with pathologically confirmed CJD found that MRI studies had an overall sensitivity of 46 percent when obtained at least six months after disease onset [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/76\">",
"     76",
"    </a>",
"    ]. This finding is consistent with an earlier, smaller study of conventional MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/107\">",
"     107",
"    </a>",
"    ]. However, this study found a high specificity of MRI findings of 93 percent.",
"   </p>",
"   <p>",
"    DWI increases the sensitivity of MRI, particularly for cortical changes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/112-114,123\">",
"     112-114,123",
"    </a>",
"    ]. DWI abnormalities can appear early in the course of CJD, and in some cases (with familial CJD) even before the onset of clinical signs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/112,124\">",
"     112,124",
"    </a>",
"    ]. In studies that used patients with other causes of rapidly progressive dementia as controls, MRI with DWI had sensitivities that ranged between 83 to 92 percent, higher than for EEG abnormalities and similar to 14-3-3 protein in the CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/112,113,123\">",
"     112,113,123",
"    </a>",
"    ]. Specificities in these studies ranged from 87 to 95 percent, requiring some caution in MRI interpretation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/125\">",
"     125",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Evolution of MRI abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appears to be a characteristic progression of MRI signal change from early to late disease in sCJD and iCJD. Although the data are limited to small observational studies, the following MRI patterns have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/106,115,117,126\">",
"     106,115,117,126",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early CJD is characterized by increased DWI signal in cortex or deep gray matter (particularly the caudate nucleus and anterior putamen) or both. The abnormal signal may be unilateral or bilateral, focal, multifocal or diffuse, and asymmetrical or symmetrical. The corresponding apparent diffusion coefficient (ADC) values are decreased, suggesting restricted diffusion and tissue injury.",
"     </li>",
"     <li>",
"      Intermediate CJD is characterized on DWI by progression of",
"      <span class=\"nowrap\">",
"       unilateral/asymmetrical",
"      </span>",
"      lesions to greater",
"      <span class=\"nowrap\">",
"       contralateral/symmetrical",
"      </span>",
"      involvement and progression of caudate lesions to involve the putamen (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56359 \" href=\"UTD.htm?41/13/42196\">",
"       image 1",
"      </a>",
"      ). FLAIR images are very likely to show high signal abnormalities, but with less prominence than DWI. Generalized atrophy and ventricular dilatation may be apparent on all sequences.",
"     </li>",
"     <li>",
"      Late or terminal CJD is characterized by prominent generalized atrophy and ventricular dilatation. Limited data suggest that loss of abnormal cortical and basal ganglionic DWI high signal may occur in some but not all cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the early and intermediate stages of CJD, FLAIR appears to be more sensitive than T2 imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/127\">",
"     127",
"    </a>",
"    ], but sensitivity and conspicuity are best with DWI (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56359 \" href=\"UTD.htm?41/13/42196\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58441 \" href=\"UTD.htm?23/18/23840\">",
"     image 2",
"    </a>",
"    ). The relative sensitivities of these methods in late CJD are unclear. While a positive scan can bolster the diagnosis, a negative MRI should not be interpreted to exclude CJD in a compatible clinical case, particularly if DWI is not performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other neuroimaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is better than computed tomography (CT) in detecting abnormalities in patients with sCJD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. A head CT scan is generally normal and serves mainly to exclude other diagnoses. However, serial CT scans performed over several months may show rapid ventricular enlargement and progressive cortical atrophy in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormal positron emission tomography (PET), single photon emission computed tomography (SPECT), and MRI spectroscopy have also been described in patients with sCJD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/129-131\">",
"     129-131",
"    </a>",
"    ]. As an example, thalamic hypometabolism on PET scan or hypoperfusion on cerebral blood flow SPECT have been reported with the MM2 thalamic variant (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Molecular subtypes of sCJD'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/121\">",
"     121",
"    </a>",
"    ]. However, these tests have not been evaluated sufficiently to assess their clinical utility [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Electroencephalogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;An electroencephalogram (EEG) can provide supportive but not definitive evidence for CJD. A characteristic EEG pattern of periodic synchronous bi- or triphasic sharp wave complexes (PSWC) is observed in 67 to 95 percent of patients with sCJD at some time during the course of the illness.",
"   </p>",
"   <p>",
"    PSWCs have a very high specificity for the diagnosis of sCJD. Objective diagnostic EEG criteria proposed in 1996 were found to have a sensitivity and specificity of 67 and 86 percent, respectively for the diagnosis of CJD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/132\">",
"     132",
"    </a>",
"    ]. In addition, interobserver variability was very low. The PSWCs typical of sCJD were characterized by the following features [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/132\">",
"     132",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Strictly periodic cerebral potentials, the majority with a duration of 100 to 600 milliseconds and an intercomplex interval of 500 to 2000 milliseconds",
"     </li>",
"     <li>",
"      Generalized and lateralized complexes permitted",
"     </li>",
"     <li>",
"      At least five repetitive intervals with a duration difference of &lt;500 milliseconds required to exclude semiperiodic activity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a subsequent report from the same investigators, a much larger series of autopsy confirmed (n=150) or autopsy excluded (n=56) cases of CJD were studied [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/133\">",
"     133",
"    </a>",
"    ]. Objective EEG criteria for sCJD showed a sensitivity and specificity of 64 and 91 percent, respectively, and positive and negative predictive values were 95 and 49 percent. In this study, there were five false-positive EEG results; four had Alzheimer disease, and one had vascular dementia. However, applying combined EEG criteria with clinical criteria yielded an overall specificity of 98 percent and resulted in only one false-positive case among the 56 excluded from CJD by autopsy.",
"   </p>",
"   <p>",
"    The mechanism of PSWCs is speculative, but attention has been called to the similarity of PSWCs in sCJD to the EEG pattern seen in preterm newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/133-135\">",
"     133-135",
"    </a>",
"    ]; cortical degeneration due to sCJD may erode the normal physiologic sleep architecture, which is replaced by activity driven from an underlying midline pacemaker, possibly thalamic, and involved with the ascending reticulothalamocortical activating system [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PSWCs are helpful in the differentiation of sCJD from other prion disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/133\">",
"     133",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PSWCs are occasionally found in patients with fCJD, although PSWCs are found more commonly in patients with fCJD who have the codon 200 mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/137\">",
"       137",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      PSWCs are not found in patients with new variant CJD (vCJD). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40728?source=see_link\">",
"       \"Variant Creutzfeldt-Jakob disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      PSWCs are also not found in patients with kuru, Gerstmann-Str&auml;ussler-Scheinker syndrome, or fatal familial insomnia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31176?source=see_link&amp;anchor=H8#H8\">",
"       \"Diseases of the central nervous system caused by prions\", section on 'Gerstmann-Str&auml;ussler-Scheinker Syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31176?source=see_link&amp;anchor=H2#H2\">",
"       \"Diseases of the central nervous system caused by prions\", section on 'Kuru'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other factors may contribute to the sensitivity of the PSWC finding.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Molecular subtype. In particular, PSWCs may be more commonly absent in the thalamic variant of MM2 sCJD, as well as the MV2 and VV2 subtypes [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/76,78,138\">",
"       76,78,138",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Disease duration. PSWCs may not be recorded in the initial stages of the illness. The probability of recording PSWCs corresponds to the amount of neuronal loss, and serial EEG recording may be useful in patients suspected of having sCJD when initial EEG recordings are negative [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/134\">",
"       134",
"      </a>",
"      ]. PSWCs typically disappear in later stages of sCJD, which is characterized by low voltage activity followed by electrocerebral inactivity [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/76,139\">",
"       76,139",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Age. One analysis of 2083 patients with pathologically confirmed CJD found that the presence of PSWCs steadily increased with age, from 22 percent in individuals &lt;50 years old to 67 percent in those &gt;70 years [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Drugs such as barbiturates and benzodiazepines can mask PSWCs.",
"     </li>",
"     <li>",
"      Iatrogenic CJD may also be less likely to be associated with PSWCs [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Protein markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports have suggested that abnormal CSF proteins may serve as a marker of this illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     14-3-3 protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;One abnormal protein, the 14-3-3 protein, has been advanced as a sensitive and specific diagnostic test for sCJD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/140,141\">",
"     140,141",
"    </a>",
"    ]. In one study, a modified western blot technique for CSF 14-3-3 protein had a positive predictive value of 95 percent for patients with pathologically definite and probable sCJD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/141\">",
"     141",
"    </a>",
"    ]. However, subsequent reports have found somewhat lower sensitivities and specificities of 53 to 88 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/76,142-144\">",
"     76,142-144",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, \"false positive\" elevations in CSF 14-3-3 have been noted in patients with a variety of neurologic diseases including herpes simplex encephalitis, hypoxic encephalopathy, cerebral metastases, paraneoplastic disease, and metabolic encephalopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/80,141,145,146\">",
"     80,141,145,146",
"    </a>",
"    ]. False-positive results are less likely in neurodegenerative disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/80\">",
"     80",
"    </a>",
"    ]. Another report examined expression of this protein in cell cultures of neural and nonneural tissues and found the protein in all cell types, suggesting that the protein may be a marker of brain cell death rather than CJD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/146\">",
"     146",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seven distinct isoforms of the 14-3-3 protein, with two phosphorylated subtypes, have been found in neurons. It has been suggested that CSF assays for one or more of the specific isoforms may have improved specificity for distinguishing sCJD from other dementias compared with the standard commercial 14-3-3 assay [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/147,148\">",
"     147,148",
"    </a>",
"    ]. However, elevated CSF levels of most 14-3-3 isoforms are described in a variety of other conditions including Alzheimer disease, vascular dementia, metabolic and viral encephalopathies, and paraneoplastic syndromes, indicating that none of these is clearly diagnostic of prion disease.",
"   </p>",
"   <p>",
"    The test characteristics of 14-3-3 protein test may be influenced by several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one preliminary report, based on the NIH experience, the sensitivity was significantly lower (62 percent) in patients with fCJD. Based upon this report, caution should be used in interpreting negative 14-3-3 test results in patients with possible fCJD.",
"     </li>",
"     <li>",
"      The clinical and molecular heterogeneity of sCJD may also affect the results of 14-3-3 protein testing. Studies in patients with sCJD have found that the sensitivity of CSF 14-3-3 protein was high in the classical subtypes MMI and MV1 (91 to 100 percent) and relatively low in most of the nonclassical subtypes, especially MM2 and MV2 (57 to 68 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/76,78-80\">",
"       76,78-80",
"      </a>",
"      ]. These results suggest that the CSF 14-3-3 protein test may be helpful for diagnosis of the classical subtypes of sCJD but may be falsely negative for the nonclassical subtypes. Small numbers of patients for most of the nonclassical subtypes in this study limit the strength of these findings. In one study, a second lumbar puncture (LP) at later stages of the disease improved the sensitivity of this test [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one analysis of 1032 assays for the 14-3-3 protein, a positive result was significantly less likely when obtained more than 12 months after disease onset, compared with earlier in the disease (72 versus 92 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these studies suggest that detection of CSF 14-3-3 protein in CSF should be considered an adjunctive rather than absolute test for the diagnosis of prion diseases. A negative test does not exclude the diagnosis, especially in cases of possible fCJD or nonclassical sCJD, and a positive result can occur in nonprion diseases. However, a positive test increases the probability of CJD when other clinical features are suggestive but not diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/149\">",
"     149",
"    </a>",
"    ]. Pathological studies of brain material to detect protease resistant PrPSc remain the gold standard for the diagnosis of prion diseases (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7017?source=see_link&amp;anchor=H9#H9\">",
"     \"Biology and genetics of prions\", section on 'Demonstration of PrPSc'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The National Prion Disease Pathology Surveillance Center (",
"    <a class=\"external\" href=\"file://www.cjdsurveillance.com/\">",
"     www.cjdsurveillance.com",
"    </a>",
"    ) based at Case Western Reserve University is the only laboratory in the United States that tests for the 14-3-3 protein. This center helps to monitor and diagnose cases of CJD, as well as act as a reporting center to the CDC. Testing done at the center is free of charge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other CSF diagnostic tests have been reported in small series, including the S100 protein [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/81\">",
"     81",
"    </a>",
"    ], neuron specific enolase [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/150\">",
"     150",
"    </a>",
"    ], thymosin &beta;4 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/151\">",
"     151",
"    </a>",
"    ], and tau protein [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/148,152-154\">",
"     148,152-154",
"    </a>",
"    ]. In one large case series, tau had superior accuracy and specificity when compared to 14-3-3 protein as a diagnostic test for CJD, although both tests produced a significant number of false negative and false positive results [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/153\">",
"     153",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Prion protein diagnostic assays performed on blood samples, are in development [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/155,156\">",
"     155,156",
"    </a>",
"    ], and in one case series, elevated plasma levels of several acute phase reactants were noted in patients with CJD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/157\">",
"     157",
"    </a>",
"    ]. All of these tests are of unproven diagnostic utility at present.",
"   </p>",
"   <p>",
"    Studies are also examining the diagnostic utility of CSF test combinations in detecting CJD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/80,144,154\">",
"     80,144,154",
"    </a>",
"    ]. The presence of any of the following markers: 14-3-3, tau, S100, and neuron specific enolase was associated with high sensitivity of CSF analysis for detecting CJD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/80\">",
"     80",
"    </a>",
"    ]. However, the sensitivity still remained low (50 to 85 percent) for the nonclassical MV2 subtype of CJD, and overall specificity was also modest (57 to 88 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Routine tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory studies are normal in CJD with the occasional exception of liver function tests [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/158\">",
"     158",
"    </a>",
"    ]. The CSF contains no cells and usually has normal glucose. An elevated CSF protein may occur in about 40 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Extraneural PrPSc",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishing the diagnosis of prion diseases by detecting abnormal prions outside of the CNS remains a major research goal. Although a number of methods have been reported, none have been validated as diagnostic tests in human prion diseases.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study reported that protease-resistant prion protein isoform was detected in the urine of hamsters, cattle, and humans affected with prion disease [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/159\">",
"       159",
"      </a>",
"      ]. However, a subsequent study failed to confirm the presence of PrPSc by Western blot analysis in urine from patients with sporadic, familial, or variant CJD [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/160\">",
"       160",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In nine patients with sCJD, PrPSc was detected at autopsy in the olfactory mucosa and cilia, but not in the respiratory mucosa and not in olfactory tissue from control patients or those with other neurodegenerative conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/161\">",
"       161",
"      </a>",
"      ]. This small study raises the possibility that a nasal biopsy might provide tissue for diagnosis.",
"     </li>",
"     <li>",
"      Another report, using differential precipitation to concentrate PrPSc prior to performing a Western blot, found evidence of this protein in spleen and skeletal muscle specimens in approximately one-third of 36 patients with known sCJD; all patients had positive tests for PrPSc in brain tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/162\">",
"       162",
"      </a>",
"      ]. Patients with PrPSc detectable in spleen, muscle, or both specimens had a longer history of the disease and were more likely to have uncommon molecular variants.",
"     </li>",
"     <li>",
"      PrPSc deposits were detected at autopsy in dorsal root ganglia and superficial peroneal nerve from one of three patients with sCJD [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/163\">",
"       163",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The development of a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"       streptomycin",
"      </a>",
"      precipitation protocol holds promise in its ability to improve the rapid detection of PrPSc in extraneural tissue; as yet, this has only been demonstrated in cerebral tissues [",
"      <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/164\">",
"       164",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to recognize that none of the assays described above have yet been subjected to anything but the most rudimentary evaluation on human material, and no information exists about their sensitivity or specificity, even in non-human prion diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of criteria for the diagnosis of sCJD have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/2,165-167\">",
"     2,165-167",
"    </a>",
"    ]. Appropriate clinical and laboratory features generally are sufficient for a \"probable\" diagnosis of sCJD.",
"   </p>",
"   <p>",
"    The Centers for Disease Control and Prevention (CDC) outline the following criteria for probable sporadic CJD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/168\">",
"     168",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progressive dementia and",
"     </li>",
"     <li>",
"      At least two out of the following four clinical features: myoclonus; visual or cerebellar disturbance;",
"      <span class=\"nowrap\">",
"       pyramidal/extrapyramidal",
"      </span>",
"      dysfunction; akinetic mutism and",
"     </li>",
"     <li>",
"      Atypical electroencephalogram (EEG) during an illness of any duration,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a positive 14-3-3 cerebrospinal fluid (CSF) assay with a clinical duration to death less than two years,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      magnetic resonance imaging (MRI) high signal abnormalities in caudate nucleus",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      putamen on diffusion-weighted imaging (DWI) or fluid attenuated inversion recovery (FLAIR) and",
"     </li>",
"     <li>",
"      Routine investigations should not suggest an alternative diagnosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, a definitive diagnosis requires these features in combination with one or more of the following neuropathologic findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loss of neurons, gliosis, spongiform degeneration, or plaques positive for PrPSc on histopathology of brain tissue",
"     </li>",
"     <li>",
"      Positive PrPSc staining following pretreatment of brain tissue with proteinase K to destroy PrPC reactivity",
"     </li>",
"     <li>",
"      Positive histoblotting of brain tissue extracts for PrPSc after treatment with proteinase to destroy PrPC reactivity",
"     </li>",
"     <li>",
"      Transmission of characteristic neurodegenerative disease to experimental animals",
"     </li>",
"     <li>",
"      Demonstration of PRNP gene mutations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immunohistochemistry techniques such as ELISA and conformation-dependent immunoassay (CDI) can detect the presence and levels of disease-causing PrPSc in human brain tissue at autopsy or in biopsy samples. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7017?source=see_link&amp;anchor=H9#H9\">",
"     \"Biology and genetics of prions\", section on 'Demonstration of PrPSc'",
"    </a>",
"    .) The CDI method appears to have a much higher sensitivity for the diagnosis of sCJD disease compared with routine neuropathologic examination and immunohistochemistry [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/169\">",
"     169",
"    </a>",
"    ], but its specificity remains to be established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     TREATMENT AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no effective treatment for CJD which is uniformly fatal. Death usually occurs within one year of symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?29/62/30698/abstract/65\">",
"     65",
"    </a>",
"    ]. An overview of past and ongoing efforts to find a treatment for CJD and other prion diseases is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31176?source=see_link&amp;anchor=H18#H18\">",
"     \"Diseases of the central nervous system caused by prions\", section on 'Treatment of prion diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/50/25378?source=see_link\">",
"       \"Patient information: Creutzfeldt-Jakob disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9729802\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Creutzfeldt-Jakob disease (CJD) is the most frequent of the human prion diseases, although it is still rare. Approximately one case of sporadic CJD occurs per 1,000,000 population per year. The mean age of onset is between 57 and 62 years. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Iatrogenic CJD has followed administration of cadaveric human pituitary hormones, dural graft transplants, use of dural mater in radiographic embolization procedures, corneal transplants, liver transplants, and the use of contaminated neurosurgical instruments or stereotactic depth electrodes. No definite cases of transfusion-associated CJD are known to have occurred; although transfusion-related variant CJD has been described. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Iatrogenic CJD'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40728?source=see_link&amp;anchor=H5#H5\">",
"       \"Variant Creutzfeldt-Jakob disease\", section on 'Transfusion-related vCJD'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The main histologic features of prion disease are spongiform change, neuronal loss (particularly of cortical layers III-V) without inflammation, and accumulation of the abnormal prion protein. Accumulation of the prion protein is detected by immunohistochemical techniques. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Neuropathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rapidly progressive mental deterioration, often with behavioral abnormalities, and myoclonus are the two cardinal clinical manifestations of sCJD. Extrapyramidal signs such as hypokinesia and cerebellar manifestations are also common. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical phenotypes of sporadic CJD have been associated with molecular subtypes determined by the PRNP gene codon 129 genotype and the pathologic prion protein (PrPSc) type. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Molecular subtypes of sCJD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CJD is distinguished from more common causes of dementia by its rapidly progressive course with prominent myoclonus and gait disturbance. Other autoimmune, infectious, malignant, and toxic-metabolic etiologies should be considered in the differential diagnosis. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While brain biopsy is the gold standard test for diagnosis, it is often unnecessary. A typical clinical presentation with corroborating findings on magnetic resonance imaging, electroencephalography, and cerebrospinal fluid are in most cases sufficient to exclude other causes and establish CJD as the probable diagnosis. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      MRI should be performed according to a suggested protocol and in typically shows abnormal signal in the putamen and head of the caudate. Sensitivity and specificity for typical MRI findings range between 83 to 92 percent and 87 to 95 percent respectively. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'MR imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A finding of periodic sharp wave complexes on EEG has a high specificity for the diagnosis of CJD, but a low sensitivity. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Electroencephalogram'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The 14-3-3 protein test in cerebrospinal fluid is a specific test finding for CJD, but its sensitivity can be low, particularly in some molecular subtypes. (See",
"      <a class=\"local\" href=\"#H24\">",
"       '14-3-3 protein'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no effective treatment for CJD which is uniformly fatal. Death usually occurs within one year of symptom onset",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/1\">",
"      Puoti G, Bizzi A, Forloni G, et al. Sporadic human prion diseases: molecular insights and diagnosis. Lancet Neurol 2012; 11:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/2\">",
"      Masters CL, Harris JO, Gajdusek DC, et al. Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol 1979; 5:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/3\">",
"      Ladogana A, Puopolo M, Croes EA, et al. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology 2005; 64:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/4\">",
"      Brown P, Cathala F, Raubertas RF, et al. The epidemiology of Creutzfeldt-Jakob disease: conclusion of a 15-year investigation in France and review of the world literature. Neurology 1987; 37:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/5\">",
"      Monreal J, Collins GH, Masters CL, et al. Creutzfeldt-Jakob disease in an adolescent. J Neurol Sci 1981; 52:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/6\">",
"      de Silva R, Findlay C, Awad I, et al. Creutzfeldt-Jakob disease in the elderly. Postgrad Med J 1997; 73:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/7\">",
"      Johnson RT, Gonzalez RG, Frosch MP. Case records of the Massachusetts General Hospital. Case 27-2005. An 80-year-old man with fatigue, unsteady gait, and confusion. N Engl J Med 2005; 353:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/8\">",
"      Ladogana A, Puopolo M, Poleggi A, et al. High incidence of genetic human transmissible spongiform encephalopathies in Italy. Neurology 2005; 64:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/9\">",
"      Maddox RA, Holman RC, Belay ED, et al. Creutzfeldt-Jakob disease among American Indians and Alaska Natives in the United States. Neurology 2006; 66:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/10\">",
"      Gibbons RV, Holman RC, Belay ED, Schonberger LB. Creutzfeldt-Jakob disease in the United States: 1979-1998. JAMA 2000; 284:2322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/11\">",
"      Wientjens DP, Davanipour Z, Hofman A, et al. Risk factors for Creutzfeldt-Jakob disease: a reanalysis of case-control studies. Neurology 1996; 46:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/12\">",
"      Collins S, Law MG, Fletcher A, et al. Surgical treatment and risk of sporadic Creutzfeldt-Jakob disease: a case-control study. Lancet 1999; 353:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/13\">",
"      Farmer PM, Kane WC, Hollenberg-Sher J. Incidence of Creutzfeldt-Jakob disease in Brooklyn and Staten Island. N Engl J Med 1978; 298:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/14\">",
"      Will RG, Matthews WB. Evidence for case-to-case transmission of Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 1982; 45:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/15\">",
"      Collins S, Boyd A, Fletcher A, et al. Creutzfeldt-Jakob disease cluster in an Australian rural city. Ann Neurol 2002; 52:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/16\">",
"      Linsell L, Cousens SN, Smith PG, et al. A case-control study of sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of clustering. Neurology 2004; 63:2077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/17\">",
"      Klug GM, Wand H, Boyd A, et al. Enhanced geographically restricted surveillance simulates sporadic Creutzfeldt-Jakob disease cluster. Brain 2009; 132:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/18\">",
"      Brown P, Preece MA, Will RG. \"Friendly fire\" in medicine: hormones, homografts, and Creutzfeldt-Jakob disease. Lancet 1992; 340:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/19\">",
"      Frasier SD. The not-so-good old days: working with pituitary growth hormone in North America, 1956 to 1985. J Pediatr 1997; 131:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/20\">",
"      Lewis AM, Yu M, DeArmond SJ, et al. Human growth hormone-related iatrogenic Creutzfeldt-Jakob disease with abnormal imaging. Arch Neurol 2006; 63:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/21\">",
"      Centers for Disease Control and Prevention (CDC). Creutzfeldt-Jakob disease associated with cadaveric dura mater grafts -- Japan, January 1979-May 1996. MMWR Morb Mortal Wkly Rep 1997; 46:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/22\">",
"      Centers for Disease Control and Prevention (CDC). Update: Creutzfeldt-Jakob disease associated with cadaveric dura mater grafts--Japan, 1979-2003. MMWR Morb Mortal Wkly Rep 2003; 52:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/23\">",
"      Preusser M, Str&ouml;bel T, Gelpi E, et al. Alzheimer-type neuropathology in a 28 year old patient with iatrogenic Creutzfeldt-Jakob disease after dural grafting. J Neurol Neurosurg Psychiatry 2006; 77:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/24\">",
"      Defebvre L, Dest&eacute;e A, Caron J, et al. Creutzfeldt-Jakob disease after an embolization of intercostal arteries with cadaveric dura mater suggesting a systemic transmission of the prion agent. Neurology 1997; 48:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/25\">",
"      Allan B, Tuft S. Transmission of Creutzfeldt-Jakob disease in corneal grafts. BMJ 1997; 315:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/26\">",
"      Heckmann JG, Lang CJ, Petruch F, et al. Transmission of Creutzfeldt-Jakob disease via a corneal transplant. J Neurol Neurosurg Psychiatry 1997; 63:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/27\">",
"      Cr&eacute;ange A, Gray F, Cesaro P, et al. Creutzfeldt-Jakob disease after liver transplantation. Ann Neurol 1995; 38:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/28\">",
"      Johnson RT, Gibbs CJ Jr. Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. N Engl J Med 1998; 339:1994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/29\">",
"      Ward HJ, Everington D, Cousens SN, et al. Risk factors for sporadic Creutzfeldt-Jakob disease. Ann Neurol 2008; 63:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/30\">",
"      Ward HJ, Everington D, Croes EA, et al. Sporadic Creutzfeldt-Jakob disease and surgery: a case-control study using community controls. Neurology 2002; 59:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/31\">",
"      de Pedro-Cuesta J, Mahillo-Fern&aacute;ndez I, R&aacute;bano A, et al. Nosocomial transmission of sporadic Creutzfeldt-Jakob disease: results from a risk-based assessment of surgical interventions. J Neurol Neurosurg Psychiatry 2011; 82:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/32\">",
"      Rutala WA, Weber DJ, Society for Healthcare Epidemiology of America. Guideline for disinfection and sterilization of prion-contaminated medical instruments. Infect Control Hosp Epidemiol 2010; 31:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/33\">",
"      Heath CA, Barker RA, Esmonde TF, et al. Dura mater-associated Creutzfeldt-Jakob disease: experience from surveillance in the UK. J Neurol Neurosurg Psychiatry 2006; 77:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/34\">",
"      Brown P, Brandel JP, Preece M, et al. Iatrogenic Creutzfeldt-Jakob disease: the waning of an era. Neurology 2006; 67:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/35\">",
"      Centers for Disease Control and Prevention (CDC). Update: Creutzfeldt-Jakob disease associated with cadaveric dura mater grafts--Japan, 1978-2008. MMWR Morb Mortal Wkly Rep 2008; 57:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/36\">",
"      Huillard d'Aignaux J, Costagliola D, Maccario J, et al. Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France. Neurology 1999; 53:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/37\">",
"      Furtner M, Gelpi E, Kiechl S, et al. Iatrogenic Creutzfeldt-Jakob disease 22 years after human growth hormone therapy: clinical and radiological features. J Neurol Neurosurg Psychiatry 2008; 79:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/38\">",
"      Swerdlow AJ, Higgins CD, Adlard P, et al. Creutzfeldt-Jakob disease in United Kingdom patients treated with human pituitary growth hormone. Neurology 2003; 61:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/39\">",
"      Ricketts MN, Cashman NR, Stratton EE, ElSaadany S. Is Creutzfeldt-Jakob disease transmitted in blood? Emerg Infect Dis 1997; 3:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/40\">",
"      Brown P. Can Creutzfeldt-Jakob disease be transmitted by transfusion? Curr Opin Hematol 1995; 2:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/41\">",
"      Dorsey K, Zou S, Schonberger LB, et al. Lack of evidence of transfusion transmission of Creutzfeldt-Jakob disease in a US surveillance study. Transfusion 2009; 49:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/42\">",
"      Patry D, Curry B, Easton D, et al. Creutzfeldt-Jakob disease (CJD) after blood product transfusion from a donor with CJD. Neurology 1998; 50:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/43\">",
"      Williamson LM. Leucocyte depletion of the blood supply - how will patients benefit? Br J Haematol 2000; 110:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/44\">",
"      Ludlam CA, Turner ML. Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products. Br J Haematol 2006; 132:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/45\">",
"      Gregori L, Gurgel PV, Lathrop JT, et al. Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins. Lancet 2006; 368:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/46\">",
"      Wiltshire M, Thomas S, Scott J, et al. Prion reduction of red blood cells: impact on component quality. Transfusion 2010; 50:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/47\">",
"      Sowemimo-Coker SO, Demczyk CA, Andrade F, Baker CA. Evaluation of removal of prion infectivity from red blood cells with prion reduction filters using a new rapid and highly sensitive cell culture-based infectivity assay. Transfusion 2010; 50:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/48\">",
"      Guntz P, Walter C, Schosseler P, et al. Feasibility study of a screening assay that identifies the abnormal prion protein PrPTSE in plasma: initial results with 20,000 samples. Transfusion 2010; 50:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/49\">",
"      Tarantola A, Abiteboul D, Rachline A. Infection risks following accidental exposure to blood or body fluids in health care workers: a review of pathogens transmitted in published cases. Am J Infect Control 2006; 34:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/50\">",
"      Berger JR, David NJ. Creutzfeldt-Jakob disease in a physician: a review of the disorder in health care workers. Neurology 1993; 43:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/51\">",
"      Matthews WB. CJD in health care workers. Neurology 1993; 43:2421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/52\">",
"      Mitrov&aacute; E, Belay G. Creutzfeldt-Jakob disease in health professionals in Slovakia. Eur J Epidemiol 2000; 16:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/53\">",
"      Hillier CE, Salmon RL. Is there evidence for exogenous risk factors in the aetiology and spread of Creutzfeldt-Jakob disease? QJM 2000; 93:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/54\">",
"      van Duijn CM, Delasnerie-Laupr&ecirc;tre N, Masullo C, et al. Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95. European Union (EU) Collaborative Study Group of Creutzfeldt-Jakob disease (CJD). Lancet 1998; 351:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/55\">",
"      Harries-Jones R, Knight R, Will RG, et al. Creutzfeldt-Jakob disease in England and Wales, 1980-1984: a case-control study of potential risk factors. J Neurol Neurosurg Psychiatry 1988; 51:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/56\">",
"      Ena J. Prions: who should worry about them? Arch Med Res 2005; 36:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/57\">",
"      Taylor DM. Preventing accidental transmission of human transmissible spongifom encephalopathies. Br Med Bull 2003; 66:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/58\">",
"      Bl&auml;ttler T. Implications of prion diseases for neurosurgery. Neurosurg Rev 2002; 25:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/59\">",
"      Yamakawa Y, Hagiwara K, Nohtomi K, et al. Atypical proteinase K-resistant prion protein (PrPres) observed in an apparently healthy 23-month-old Holstein steer. Jpn J Infect Dis 2003; 56:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/60\">",
"      Biacabe AG, Laplanche JL, Ryder S, Baron T. Distinct molecular phenotypes in bovine prion diseases. EMBO Rep 2004; 5:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/61\">",
"      Casalone C, Zanusso G, Acutis P, et al. Identification of a second bovine amyloidotic spongiform encephalopathy: molecular similarities with sporadic Creutzfeldt-Jakob disease. Proc Natl Acad Sci U S A 2004; 101:3065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/62\">",
"      Priola SA, Vorberg I. Identification of possible animal origins of prion disease in human beings. Lancet 2004; 363:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/63\">",
"      Gambetti P, Kong Q, Zou W, et al. Sporadic and familial CJD: classification and characterisation. Br Med Bull 2003; 66:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/64\">",
"      Noguchi-Shinohara M, Hamaguchi T, Kitamoto T, et al. Clinical features and diagnosis of dura mater graft associated Creutzfeldt Jakob disease. Neurology 2007; 69:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/65\">",
"      Haywood AM. Transmissible spongiform encephalopathies. N Engl J Med 1997; 337:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/66\">",
"      Rabinovici GD, Wang PN, Levin J, et al. First symptom in sporadic Creutzfeldt-Jakob disease. Neurology 2006; 66:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/67\">",
"      Meissner B, K&ouml;rtner K, Bartl M, et al. Sporadic Creutzfeldt-Jakob disease: magnetic resonance imaging and clinical findings. Neurology 2004; 63:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/68\">",
"      Landolt HP, Glatzel M, Bl&auml;ttler T, et al. Sleep-wake disturbances in sporadic Creutzfeldt-Jakob disease. Neurology 2006; 66:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/69\">",
"      Will RG. Acquired prion disease: iatrogenic CJD, variant CJD, kuru. Br Med Bull 2003; 66:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/70\">",
"      Boesenberg C, Schulz-Schaeffer WJ, Meissner B, et al. Clinical course in young patients with sporadic Creutzfeldt-Jakob disease. Ann Neurol 2005; 58:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/71\">",
"      Appleby BS, Appleby KK, Crain BJ, et al. Characteristics of established and proposed sporadic Creutzfeldt-Jakob disease variants. Arch Neurol 2009; 66:208.",
"     </a>",
"    </li>",
"    <li>",
"     Kirschbaum WR. Jakob-Creutzfeldt disease. Elsevier, New York 1968.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/73\">",
"      Parchi P, Castellani R, Capellari S, et al. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol 1996; 39:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/74\">",
"      Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999; 46:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/75\">",
"      Lewis V, Hill AF, Klug GM, et al. Australian sporadic CJD analysis supports endogenous determinants of molecular-clinical profiles. Neurology 2005; 65:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/76\">",
"      Collins SJ, Sanchez-Juan P, Masters CL, et al. Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain 2006; 129:2278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/77\">",
"      Cooper SA, Murray KL, Heath CA, et al. Sporadic Creutzfeldt-Jakob disease with cerebellar ataxia at onset in the UK. J Neurol Neurosurg Psychiatry 2006; 77:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/78\">",
"      Krasnianski A, Schulz-Schaeffer WJ, Kallenberg K, et al. Clinical findings and diagnostic tests in the MV2 subtype of sporadic CJD. Brain 2006; 129:2288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/79\">",
"      Castellani RJ, Colucci M, Xie Z, et al. Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease. Neurology 2004; 63:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/80\">",
"      Sanchez-Juan P, Green A, Ladogana A, et al. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2006; 67:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/81\">",
"      Krasnianski A, Meissner B, Schulz-Schaeffer W, et al. Clinical features and diagnosis of the MM2 cortical subtype of sporadic Creutzfeldt-Jakob disease. Arch Neurol 2006; 63:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/82\">",
"      Parchi P, Capellari S, Chin S, et al. A subtype of sporadic prion disease mimicking fatal familial insomnia. Neurology 1999; 52:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/83\">",
"      Nozaki I, Hamaguchi T, Noguchi-Shinohara M, et al. The MM2-cortical form of sporadic Creutzfeldt-Jakob disease presenting with visual disturbance. Neurology 2006; 67:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/84\">",
"      Meissner B, Westner IM, Kallenberg K, et al. Sporadic Creutzfeldt-Jakob disease: clinical and diagnostic characteristics of the rare VV1 type. Neurology 2005; 65:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/85\">",
"      Collinge J, Sidle KC, Meads J, et al. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature 1996; 383:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/86\">",
"      Wadsworth JD, Jackson GS, Hill AF, Collinge J. Molecular biology of prion propagation. Curr Opin Genet Dev 1999; 9:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/87\">",
"      Hill AF, Joiner S, Wadsworth JD, et al. Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain 2003; 126:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/88\">",
"      Head MW, Bunn TJ, Bishop MT, et al. Prion protein heterogeneity in sporadic but not variant Creutzfeldt-Jakob disease: UK cases 1991-2002. Ann Neurol 2004; 55:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/89\">",
"      Xiang W, Windl O, Westner IM, et al. Cerebral gene expression profiles in sporadic Creutzfeldt-Jakob disease. Ann Neurol 2005; 58:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/90\">",
"      Schoch G, Seeger H, Bogousslavsky J, et al. Analysis of prion strains by PrPSc profiling in sporadic Creutzfeldt-Jakob disease. PLoS Med 2006; 3:e14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/91\">",
"      Giaccone G, Di Fede G, Mangieri M, et al. A novel phenotype of sporadic Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2007; 78:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/92\">",
"      Head MW, Ironside JW. Sporadic Creutzfeldt-Jakob disease: discrete subtypes or a spectrum of disease? Brain 2009; 132:2627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/93\">",
"      Cali I, Castellani R, Alshekhlee A, et al. Co-existence of scrapie prion protein types 1 and 2 in sporadic Creutzfeldt-Jakob disease: its effect on the phenotype and prion-type characteristics. Brain 2009; 132:2643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/94\">",
"      Tschampa HJ, Neumann M, Zerr I, et al. Patients with Alzheimer's disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2001; 71:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/95\">",
"      Josephs KA, Tsuboi Y, Dickson DW. Creutzfeldt-Jakob disease presenting as progressive supranuclear palsy. Eur J Neurol 2004; 11:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/96\">",
"      Heinemann U, Krasnianski A, Meissner B, et al. Creutzfeldt-Jakob disease in Germany: a prospective 12-year surveillance. Brain 2007; 130:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/97\">",
"      Josephs KA, Ahlskog JE, Parisi JE, et al. Rapidly progressive neurodegenerative dementias. Arch Neurol 2009; 66:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/98\">",
"      Seipelt M, Zerr I, Nau R, et al. Hashimoto's encephalitis as a differential diagnosis of Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 1999; 66:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/99\">",
"      Poser S, Mollenhauer B, Kraubeta A, et al. How to improve the clinical diagnosis of Creutzfeldt-Jakob disease. Brain 1999; 122 ( Pt 12):2345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/100\">",
"      Slee M, Pretorius P, Ansorge O, et al. Parkinsonism and dementia due to gliomatosis cerebri mimicking sporadic Creutzfeldt-Jakob disease (CJD). J Neurol Neurosurg Psychiatry 2006; 77:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/101\">",
"      Geschwind MD, Shu H, Haman A, et al. Rapidly progressive dementia. Ann Neurol 2008; 64:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/102\">",
"      Geschwind MD, Tan KM, Lennon VA, et al. Voltage-gated potassium channel autoimmunity mimicking creutzfeldt-jakob disease. Arch Neurol 2008; 65:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/103\">",
"      Chitravas N, Jung RS, Kofskey DM, et al. Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease. Ann Neurol 2011; 70:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/104\">",
"      Weiss D, Brockmann K, N&auml;gele T, et al. Rapid emergence of temporal and pulvinar lesions in MELAS mimicking Creutzfeldt-Jakob disease. Neurology 2011; 77:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/105\">",
"      Macfarlane RG, Wroe SJ, Collinge J, et al. Neuroimaging findings in human prion disease. J Neurol Neurosurg Psychiatry 2007; 78:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/106\">",
"      Collie DA, Sellar RJ, Zeidler M, et al. MRI of Creutzfeldt-Jakob disease: imaging features and recommended MRI protocol. Clin Radiol 2001; 56:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/107\">",
"      Schr&ouml;ter A, Zerr I, Henkel K, et al. Magnetic resonance imaging in the clinical diagnosis of Creutzfeldt-Jakob disease. Arch Neurol 2000; 57:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/108\">",
"      de Priester JA, Jansen GH, de Kruijk JR, Wilmink JT. New MRI findings in Creutzfeldt-Jakob disease: high signal in the globus pallidus on T1-weighted images. Neuroradiology 1999; 41:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/109\">",
"      Zeidler M, Sellar RJ, Collie DA, et al. The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet 2000; 355:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/110\">",
"      Finkenstaedt M, Szudra A, Zerr I, et al. MR imaging of Creutzfeldt-Jakob disease. Radiology 1996; 199:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/111\">",
"      Demaerel P, Heiner L, Robberecht W, et al. Diffusion-weighted MRI in sporadic Creutzfeldt-Jakob disease. Neurology 1999; 52:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/112\">",
"      Shiga Y, Miyazawa K, Sato S, et al. Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt-Jakob disease. Neurology 2004; 63:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/113\">",
"      Young GS, Geschwind MD, Fischbein NJ, et al. Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: high sensitivity and specificity for diagnosis. AJNR Am J Neuroradiol 2005; 26:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/114\">",
"      Kallenberg K, Schulz-Schaeffer WJ, Jastrow U, et al. Creutzfeldt-Jakob disease: comparative analysis of MR imaging sequences. AJNR Am J Neuroradiol 2006; 27:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/115\">",
"      Ukisu R, Kushihashi T, Kitanosono T, et al. Serial diffusion-weighted MRI of Creutzfeldt-Jakob disease. AJR Am J Roentgenol 2005; 184:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/116\">",
"      Manners DN, Parchi P, Tonon C, et al. Pathologic correlates of diffusion MRI changes in Creutzfeldt-Jakob disease. Neurology 2009; 72:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/117\">",
"      Bavis J, Reynolds P, Tegeler C, Clark P. Asymmetric neuroimaging in Creutzfeldt-Jakob disease: a ruse. J Neuroimaging 2003; 13:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/118\">",
"      Sibon I, Foubert A, Menegon P, et al. Creutzfeldt-Jakob disease mimicking radiologic posterior reversible leukoencephalopathy. Neurology 2005; 65:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/119\">",
"      Vitali P, Maccagnano E, Caverzasi E, et al. Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias. Neurology 2011; 76:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/120\">",
"      Meissner B, Kallenberg K, Sanchez-Juan P, et al. MRI lesion profiles in sporadic Creutzfeldt-Jakob disease. Neurology 2009; 72:1994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/121\">",
"      Hamaguchi T, Kitamoto T, Sato T, et al. Clinical diagnosis of MM2-type sporadic Creutzfeldt-Jakob disease. Neurology 2005; 64:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/122\">",
"      Tschampa HJ, Kallenberg K, Urbach H, et al. MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease: a study on inter-observer agreement. Brain 2005; 128:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/123\">",
"      Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain 2009; 132:2659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/124\">",
"      Lee H, Rosenmann H, Chapman J, et al. Thalamo-striatal diffusion reductions precede disease onset in prion mutation carriers. Brain 2009; 132:2680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/125\">",
"      Zeidler M, Green A. Advances in diagnosing Creutzfeldt-Jakob disease with MRI and CSF 14-3-3 protein analysis. Neurology 2004; 63:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/126\">",
"      Murata T, Shiga Y, Higano S, et al. Conspicuity and evolution of lesions in Creutzfeldt-Jakob disease at diffusion-weighted imaging. AJNR Am J Neuroradiol 2002; 23:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/127\">",
"      Schwaninger M, Winter R, Hacke W, et al. Magnetic resonance imaging in Creutzfeldt-Jakob disease: evidence of focal involvement of the cortex. J Neurol Neurosurg Psychiatry 1997; 63:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/128\">",
"      Hayashi R, Hanyu N, Kuwabara T, Moriyama S. Serial computed tomographic and electroencephalographic studies in Creutzfeldt-Jakob disease. Acta Neurol Scand 1992; 85:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/129\">",
"      Itoh Y, Amano T, Shimizu T, et al. Single-photon emission computed tomography image of benzodiazepine receptors in a patient with Creutzfeldt-Jakob disease. Intern Med 1998; 37:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/130\">",
"      Villemagne VL, McLean CA, Reardon K, et al. 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2009; 80:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/131\">",
"      Lodi R, Parchi P, Tonon C, et al. Magnetic resonance diagnostic markers in clinically sporadic prion disease: a combined brain magnetic resonance imaging and spectroscopy study. Brain 2009; 132:2669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/132\">",
"      Steinhoff BJ, R&auml;cker S, Herrendorf G, et al. Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease. Arch Neurol 1996; 53:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/133\">",
"      Steinhoff BJ, Zerr I, Glatting M, et al. Diagnostic value of periodic complexes in Creutzfeldt-Jakob disease. Ann Neurol 2004; 56:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/134\">",
"      Bortone E, Bettoni L, Giorgi C, et al. Reliability of EEG in the diagnosis of Creutzfeldt-Jakob disease. Electroencephalogr Clin Neurophysiol 1994; 90:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/135\">",
"      Goto K, Umezaki H, Suetsugu M. Electroencephalographic and clinicopathological studies on Creutzfeldt-Jakob syndrome. J Neurol Neurosurg Psychiatry 1976; 39:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/136\">",
"      NELSON JR, LEFFMAN H. The human diffusely projecting system. Evoked potentials and interactions. Arch Neurol 1963; 8:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/137\">",
"      Brown P, Gibbs CJ Jr, Rodgers-Johnson P, et al. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol 1994; 35:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/138\">",
"      Zerr I, Schulz-Schaeffer WJ, Giese A, et al. Current clinical diagnosis in Creutzfeldt-Jakob disease: identification of uncommon variants. Ann Neurol 2000; 48:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/139\">",
"      Lee RG, Blair RD. Evolution of EEG and visual evoked response changes in Jakob-Creutzfeldt disease. Electroencephalogr Clin Neurophysiol 1973; 35:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/140\">",
"      Hsich G, Kenney K, Gibbs CJ, et al. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 1996; 335:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/141\">",
"      Zerr I, Bodemer M, Gefeller O, et al. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol 1998; 43:32.",
"     </a>",
"    </li>",
"    <li>",
"     Kenney, K, Hsich, G, Brechtel, C, Gibbs, CJ,. The cerebrospinal fluid 14-3-3- assay's diagnostic utility among clinically suspected Creutzfeldt-Jakob disease patients: the NIH experience. Neurol 2002; 58(Suppl 3); A250 (abstract).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/143\">",
"      Geschwind MD, Martindale J, Miller D, et al. Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. Arch Neurol 2003; 60:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/144\">",
"      Chohan G, Pennington C, Mackenzie JM, et al. The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year review. J Neurol Neurosurg Psychiatry 2010; 81:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/145\">",
"      Chapman T, McKeel DW Jr, Morris JC. Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000; 55:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/146\">",
"      Satoh J, Kurohara K, Yukitake M, Kuroda Y. The 14-3-3 protein detectable in the cerebrospinal fluid of patients with prion-unrelated neurological diseases is expressed constitutively in neurons and glial cells in culture. Eur Neurol 1999; 41:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/147\">",
"      Van Everbroeck BR, Boons J, Cras P. 14-3-3 {gamma}-isoform detection distinguishes sporadic Creutzfeldt-Jakob disease from other dementias. J Neurol Neurosurg Psychiatry 2005; 76:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/148\">",
"      Zanusso G, Fiorini M, Farinazzo A, et al. Phosphorylated 14-3-3zeta protein in the CSF of neuroleptic-treated patients. Neurology 2005; 64:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/149\">",
"      Muayqil T, Gronseth G, Camicioli R. Evidence-based guideline: diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 2012; 79:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/150\">",
"      Zerr I, Bodemer M, Otto M, et al. Diagnosis of Creutzfeldt-Jakob disease by two-dimensional gel electrophoresis of cerebrospinal fluid. Lancet 1996; 348:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/151\">",
"      Le Pera M, Urso E, Sprovieri T, et al. Contribution of cerebrospinal fluid thymosin &beta;4 levels to the clinical differentiation of Creutzfeldt-Jakob disease. Arch Neurol 2012; 69:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/152\">",
"      Otto M, Wiltfang J, Cepek L, et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2002; 58:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/153\">",
"      Hamlin C, Puoti G, Berri S, et al. A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease. Neurology 2012; 79:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/154\">",
"      Nilsson-Helander K, Silbernagel KG, Thome&eacute; R, et al. Acute achilles tendon rupture: a randomized, controlled study comparing surgical and nonsurgical treatments using validated outcome measures. Am J Sports Med 2010; 38:2186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/155\">",
"      Pan T, Sethi J, Nelsen C, et al. Detection of misfolded prion protein in blood with conformationally sensitive peptides. Transfusion 2007; 47:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/156\">",
"      McGuire LI, Peden AH, Orr&uacute; CD, et al. Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease. Ann Neurol 2012; 72:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/157\">",
"      Fratini F, Principe S, Puopolo M, et al. Increased levels of acute-phase inflammatory proteins in plasma of patients with sporadic CJD. Neurology 2012; 79:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/158\">",
"      Tanaka M, Iizuka O, Yuasa T. Hepatic dysfunction in Creutzfeldt-Jakob disease. Neurology 1992; 42:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/159\">",
"      Shaked GM, Shaked Y, Kariv-Inbal Z, et al. A protease-resistant prion protein isoform is present in urine of animals and humans affected with prion diseases. J Biol Chem 2001; 276:31479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/160\">",
"      Head MW, Kouverianou E, Taylor L, et al. Evaluation of urinary PrPSc as a diagnostic test for sporadic, variant, and familial CJD. Neurology 2005; 64:1794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/161\">",
"      Zanusso G, Ferrari S, Cardone F, et al. Detection of pathologic prion protein in the olfactory epithelium in sporadic Creutzfeldt-Jakob disease. N Engl J Med 2003; 348:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/162\">",
"      Glatzel M, Abela E, Maissen M, Aguzzi A. Extraneural pathologic prion protein in sporadic Creutzfeldt-Jakob disease. N Engl J Med 2003; 349:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/163\">",
"      Favereaux A, Quadrio I, Vital C, et al. Pathologic prion protein spreading in the peripheral nervous system of a patient with sporadic Creutzfeldt-Jakob disease. Arch Neurol 2004; 61:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/164\">",
"      Quadrio I, Ugnon-Caf&eacute; S, Dupin M, et al. Rapid diagnosis of human prion disease using streptomycin with tonsil and brain tissues. Lab Invest 2009; 89:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/165\">",
"      Cathala F, Brown P, Castaigne P, Gajdusek DC. [Creutzfeldt-Jacob disease in continental France. Retrospective study from 1968 to 1977]. Rev Neurol (Paris) 1979; 135:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/166\">",
"      Kretzschmar HA, Ironside JW, DeArmond SJ, Tateishi J. Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Arch Neurol 1996; 53:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/167\">",
"      Brandel JP, Delasnerie-Laupr&ecirc;tre N, Laplanche JL, et al. Diagnosis of Creutzfeldt-Jakob disease: effect of clinical criteria on incidence estimates. Neurology 2000; 54:1095.",
"     </a>",
"    </li>",
"    <li>",
"     CDC's Diagnostic Criteria for Creutzfeldt-Jakob Disease (CJD), 2010 file://www.cdc.gov/ncidod/dvrd/cjd/diagnostic_criteria.html (Accessed on June 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/62/30698/abstract/169\">",
"      Safar JG, Geschwind MD, Deering C, et al. Diagnosis of human prion disease. Proc Natl Acad Sci U S A 2005; 102:3501.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5084 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-B1BE4F5CD0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_62_30698=[""].join("\n");
var outline_f29_62_30698=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9729802\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Sporadic CJD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Variant CJD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Familial CJD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Iatrogenic CJD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Transfusion-related CJD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15451900\">",
"      - Infections in health care workers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Possible animal origins of sCJD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      NEUROPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Spongiform change",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prion protein immunohistochemistry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Molecular subtypes of sCJD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MR imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Diagnostic utility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Evolution of MRI abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other neuroimaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Electroencephalogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Protein markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - 14-3-3 protein",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Others",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Routine tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Extraneural PrPSc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      TREATMENT AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9729802\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5084\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5084|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/13/42196\" title=\"diagnostic image 1\">",
"      Serial MRI sCJD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/18/23840\" title=\"diagnostic image 2\">",
"      MRI Heidenhain CJD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5084|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/8/21638\" title=\"picture 1\">",
"      CJD pathology low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/59/41908\" title=\"picture 2\">",
"      CJD pathology high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/28/30149\" title=\"picture 3\">",
"      Prion protein immunoperox prep",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7017?source=related_link\">",
"      Biology and genetics of prions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31176?source=related_link\">",
"      Diseases of the central nervous system caused by prions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/50/25378?source=related_link\">",
"      Patient information: Creutzfeldt-Jakob disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40728?source=related_link\">",
"      Variant Creutzfeldt-Jakob disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_62_30699="Grades salivary gland cancer";
var content_f29_62_30699=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Histologic grades of salivary gland cancers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        High-grade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High-grade mucoepidermoid carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salivary duct carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adenoid cystic carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carcinoma ex-pleomorphic adenoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Squamous cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anaplastic or undifferentiated carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignant mixed carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Low- to intermediate-grade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low-grade mucoepidermoid carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acinic cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polymorphous low-grade adenocarcinoma (PLGA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epithelial-myoepithelial carcinoma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Stenner M, Klussmann JP. Current update on established and novel biomarkers in salivary gland carcinoma pathology and the molecular pathways involved. Eur Arch Otorhinolaryngol 2009; 266:333.",
"      </li>",
"      <li>",
"       Terhaard CH. Salivary glands. In: Principles and Practice of Radiation Oncology, 5th edition, Halperin EC, Perez CA, Brady LW (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2004. p.407.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_62_30699=[""].join("\n");
var outline_f29_62_30699=null;
var title_f29_62_30700="Goldman cardiac risk index";
var content_f29_62_30700=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Goldman cardiac risk index",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Variable",
"       </td>",
"       <td class=\"subtitle1\">",
"        Point score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        History",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Age &gt;70 years",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Preoperative MI within six months",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Physical examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        S3 gallop or increased JVP &gt;12 cm H2O",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Significant valvular aortic stenosis",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        ECG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rhythm other than sinus, or atrial ectopy",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        VPBs &gt;5/minute at any time",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        General medical status - one or more of the following:",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"1\" rowspan=\"5\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PO2 &lt;60 or PCO2 &gt;50 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum K &lt;3.0 or HCO3 &lt;20 meq/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        BUN &gt;50 or creatinine &gt;3.0 mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic liver disease or debilitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Operation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intraperitoneal, intrathoracic, or aortic",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Emergency",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Total possible points",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        53",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"space\" colspan=\"2\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Class I",
"       </td>",
"       <td>",
"        0-5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Class II",
"       </td>",
"       <td>",
"        6-12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Class III",
"       </td>",
"       <td>",
"        13-25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Class IV",
"       </td>",
"       <td>",
"        &gt;25",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Goldman L, Caldera DL, Nussbaum SR, et al. N Engl J Med 1977; 297:845.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_62_30700=[""].join("\n");
var outline_f29_62_30700=null;
var title_f29_62_30701="Laxatives";
var content_f29_62_30701=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Laxatives for treatment of constipation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Laxative",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual adult dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Onset of action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Side effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Bulk-forming laxatives*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Psyllium",
"       </td>",
"       <td>",
"        Up to 1 tablespoon (&cong;3.5 grams fiber) 3 times per day",
"       </td>",
"       <td>",
"        12 to 72 h",
"       </td>",
"       <td rowspan=\"4\">",
"        Impaction above strictures, fluid overload, gas and bloating",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylcellulose",
"       </td>",
"       <td>",
"        Up to 1 tablespoon (&cong;2 grams fiber) or 4 caplets (500 mg fiber per caplet) 3 times per day",
"       </td>",
"       <td>",
"        12 to 72 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Polycarbophil",
"       </td>",
"       <td>",
"        2 to 4 tabs (500 mg fiber per tab) per day",
"       </td>",
"       <td>",
"        24 to 48 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Wheat dextrin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1 to 3 caplets (1 gram fiber per caplet) or 2 teaspoonsful (1.5 gram fiber per teaspoon) up to 3 times per daily",
"       </td>",
"       <td>",
"        24 to 48 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Surfactants (softeners)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Docusate sodium",
"       </td>",
"       <td>",
"        100 mg 2 times per day",
"       </td>",
"       <td>",
"        24 to 72 hours",
"       </td>",
"       <td rowspan=\"2\">",
"        Well tolerated. Use lower dose if administered with another laxative. Contact dermatitis reported.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Docusate calcium",
"       </td>",
"       <td>",
"        240 mg 1 time per day",
"       </td>",
"       <td>",
"        24 to 72 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Osmotic agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Polyethylene glycol (macrogol)",
"       </td>",
"       <td>",
"        8.5 to 34 grams in 240 mL (8 ounces) liquids",
"       </td>",
"       <td>",
"        1 to 4 days",
"       </td>",
"       <td>",
"        Nausea, bloating, cramping",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lactulose",
"       </td>",
"       <td>",
"        10 to 20 grams (15 to 30 mL) every other day. May increase up to 2 times per day.",
"       </td>",
"       <td>",
"        24 to 48 hours",
"       </td>",
"       <td>",
"        Abdominal bloating, flatulence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sorbitol",
"       </td>",
"       <td>",
"        30 grams (120 mL of 25 percent solution) 1 time per day",
"       </td>",
"       <td>",
"        24 to 48 hours",
"       </td>",
"       <td>",
"        Abdominal bloating, flatulence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glycerin (glycerol)",
"       </td>",
"       <td>",
"        One suppository (2 or 3 grams) per rectum for 15 minutes 1 time per day",
"       </td>",
"       <td>",
"        15 to 60 minutes",
"       </td>",
"       <td>",
"        Rectal irritation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Magnesium sulfate",
"       </td>",
"       <td>",
"        One to two teaspoonsful (&cong;5 to 10 grams) dissolved in 240 mL (8 ounces) water 1 time per day",
"       </td>",
"       <td>",
"        0.5 to 3 hours",
"       </td>",
"       <td rowspan=\"2\">",
"        Watery stools and urgency. Caution in renal insufficiency (magnesium toxicity).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Magnesium citrate",
"       </td>",
"       <td>",
"        200 mL (11.6 grams) 1 time per day",
"       </td>",
"       <td>",
"        0.5 to 3 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Stimulant laxatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Bisacodyl",
"       </td>",
"       <td>",
"        10 to 30 mg as enteric coated tabs 1 time per day",
"       </td>",
"       <td>",
"        6 to 10 hours",
"       </td>",
"       <td>",
"        Gastric irritation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10 mg suppository per rectum 1 time per day",
"       </td>",
"       <td>",
"        15 to 60 minutes",
"       </td>",
"       <td>",
"        Rectal irritation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Senna",
"       </td>",
"       <td>",
"        2 to 4 tabs (8.6 mg sennosides per tab) or 1 to 2 tabs (15 mg sennosides per tab) as a single daily dose or divided twice daily",
"       </td>",
"       <td>",
"        6 to 12 hours",
"       </td>",
"       <td>",
"        Melanosis coli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lubiprostone",
"       </td>",
"       <td>",
"        24 micrograms 2 times per day",
"       </td>",
"       <td>",
"        24 to 48 hours",
"       </td>",
"       <td>",
"        Nausea, diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Linaclotide",
"       </td>",
"       <td>",
"        145 micrograms 1 time per day",
"       </td>",
"       <td>",
"        12 to 24 hours",
"       </td>",
"       <td>",
"        Diarrhea, bloating",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    All doses shown are for oral administration unless otherwise noted. Phosphate containing laxatives are not recommended. Mineral oil (enema and oral liquid) laxatives are not generally recommended except as enema following disimpaction (see text).",
"    <div class=\"footnotes\">",
"     * Initiate at one-half or less of dose shown and gradually increase as needed to minimize gas and bloating. Administer with 180 to 360 mL (6 to 12 ounces) water or fruit juice. Do not administer within one hour of other medications. Fiber content per dose may vary. Consult individual product label.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     US trade name Benefiber&reg;.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Arnold Wald, MD. Additional data from: Lexicomp Online. Copyright &copy; 1978-2013 Lexicomp, Inc. All Rights Reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_62_30701=[""].join("\n");
var outline_f29_62_30701=null;
var title_f29_62_30702="Evaluation and initial therapy cirrhosis ascites";
var content_f29_62_30702=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Evaluation and initial therapy of a patient with cirrhosis and ascites",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 396px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_62_30702=[""].join("\n");
var outline_f29_62_30702=null;
var title_f29_62_30703="N telopeptide crosslinks";
var content_f29_62_30703=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F60367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F60367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    N-telopeptide crosslinks and bone collagen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 333px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pyridinoline crosslinks occur in many types of collagen outside of bone. One type of pyridinoline crosslink that is more common in bone collagen is the pyridinoline crosslink in the N-telopeptide region (NTX). These crosslinks joins alpha-1 molecules to alpha-2 molecules (lower right) in bone collagen; in other tissues, these crosslinks join alpha-1 to alpha-1 molecules (upper left).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_62_30703=[""].join("\n");
var outline_f29_62_30703=null;
      